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Tuberculosis (TB) has become the single largest cause of death of any infectious disease 1. 
Today, TB is also one of the top 10 causes of death worldwide. Over the past two hundred 
years it has killed more than a billion lives, more than any other infectious disease in his-
tory 1. The World Health Organization (WHO) estimated that in 2015 TB killed 1.8 million 
people and that there were 10.4 million new TB cases, including one million children 2. 
Globally, three people die as a consequence of TB every minute. To stop this insidious 
disease, the WHO launched the ‘END TB STRATEGY’ in May 2014. To realize the vision 
‘a world free of TB’, targets were set including a 95% reduction in number of TB deaths 
and a 90% reduction in TB incidence rate in 2035 compared to 2015. Therefore, new 
treatment options are urgently needed to attain these targets. The WHO targets are even 
higher when one realizes that an estimated two to three billion people are latently infected 
with Mycobacterium tuberculosis. Of these latently infected people 5 to 15% will develop 
active TB during their life 2. Anyone can get TB, but several factors can increase the risk of 
developing active disease. The main risk factors are health problems affecting the immune 
systems like HIV, but also smoking or substance abuse, living in poverty and diabetes are 
known risk factors 3.
Mycobacterium tuberculosis
The bacterium causing TB is called “Mycobacterium tuberculosis”. This bacterium has been 
with humans for millennia. Descriptions of a TB-like disease can be found in the Vedic 
writings of India (~1500 BC) 4 and in the Old Testament of the Bible (~1300 – 400 BC) 5. In 
Greek the disease was called “phthisis”, meaning “wasting away”. Referring to the symp-
tomatic course of pulmonary TB, which was the basis for the common 19th century name 
“consumption”. The actual tubercle bacillus was discovered by Robert Koch in 1882 6. It 
belongs to the genus of Mycobacteria which also includes Mycobacterium leprae, causing 
leprosy, and Mycobacterium bovis, causing TB in cattle. The genome of Mycobacterium 
tuberculosis is one of the biggest genomes among bacteria, is GC-rich (65%) and encodes 
about 4000 proteins 7. Mycobacterium tuberculosis is classified as Gram-positive and has a 
thick cell wall built of polysaccharides, peptidoglycans and mycolic acid. This thick cell wall 
is impermeable and renders the bacteria acid-fast. This feature can be used to visualize the 
bacteria with a Ziehl-Neelsen staining for microscopy.
Pathogenesis
Mycobacteria causing pulmonary TB enter the body via inhaled aerosols, small droplets 
produced by coughing TB-patients. After entering the airways Mycobacterium tubercu-
losis can be phagocytosed by alveolar macrophages. After infection, a pro-inflammatory 
response is induced and mono nuclear cells and T-lymphocytes are attracted to build a 
granuloma. At this stage of the infection, the immune system of healthy individuals can 
control the pathogen but they remain latently infected. However, the host-pathogen 
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interaction is a delicate balance. On the one hand, Mycobacterium tuberculosis requires 
an immune response that is adequate to establish a granuloma, but not to strong that 
it lead to complete sterilization. On the other hand, inflammation over time should be 
sufficient to promote the eventual breakdown of some granulomas. These granulomas 
can maturate to different states; i.e. solid, necrotic and caseous. In the caseous state, 
Mycobacterium tuberculosis strongly increases in number before the granulomas burst 
open and the mycobacteria will be released into the airways and coughed out and the 
circle of infection is started.
The ‘classic’ clinical symptoms of TB are cough, severe weight loss, night sweats and 
fever, but also weakness, chestpain, loss of appetite and chills are common. When left 
untreated, 70% of smear-positive pulmonary TB-patients are expected to die within ten 
years after infection 8.
TB-drugs
Before the Second World War there was no drug available to treat TB. But in 1944 
streptomycin was isolated from Streptomyces griseus by Schatz and Waksman and para 
aminosalicylic acid (PAS) was discovered and thus the first steps in TB treatment were 
made 9,10. In 1952 isoniazid was discovered and by combining these drugs an effective 
regimen was possible. However, treatment duration was at least 18 months 11, 12. In 1967 
the second cornerstone drug rifampicin was first used for TB. Strikingly, this still forms the 
base for the current drug regimen 13.
The standard treatment recommended by the WHO for drug-susceptible TB consists of a 
2-months intensive phase with at least isoniazid, rifampicin, pyrazinamide and ethambutol, 
followed by a 4-months continuation phase with at least isoniazid and rifampicin. This 
standard treatment, often referred to as the 2HRZE - 4HR regimen can only be used to 
treat drug susceptible mycobacteria and is associated with a 5 to 8% chance of relapse of 
infection 14, 15.
The mycobacterial population in a TB patient is considered not to be homogeneous 16. 
It consists of mycobacteria in various metabolic states i.e. fast-replicating, slow-replicating 
and non-replicating mycobacteria, which can respond differently to antibiotic treatment. 
It is thought that isoniazid is responsible for the elimination of the fast-replicating my-
cobacteria in the first phase of treatment (2 months), whilst for elimination of the slow 
and non-replicating population other drugs are needed 17. For a therapy to be successful, 
the combination of drugs must be active against both the replicating and the persistent 
subpopulation. Persistent bacteria are considered hard to eliminate; they are thought to be 
in a slow-metabolic state possibly due to environmental stress, such as low oxygen levels, 
lack of nutrients or low pH, which makes them less susceptible to killing by drugs 18. What 
is more, they reside inside the thick-walled granulomas where they are almost unreachable 
for antibiotics.
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resistance
Drug-resistant TB poses a major threat to control of TB worldwide 19. Soon after the 
introduction of streptomycin the first single-drug resistant mutants were discovered 20. 
Nowadays, multidrug-resistant (MDR) Mycobacterium tuberculosis strains are frequently 
isolated. MDR is defined as bacteria that are resistant to at least the first-line drugs isonia-
zid and rifampicin. The WHO estimated that nearly half a million cases of MDR-TB have 
occurred in 2015 2. The treatment of MDR-TB is complex due to an extended treatment 
duration of at least 20 months and complexity of administration. Second-line treat-
ment consists of injectables, fluoroquinolones, prothionamide/ethionamide, cyclyserine/
terizidone, ethambutol and/or pyrazinamide. Nevertheless, approximately only 50% of the 
MDR-TB patients respond favourably to treatment 21. Also, it is calculated that in Europe 
the treatment costs for a patient with a drug sensitive TB are €334 (41-1299), whereas the 
treatment of MDR-TB costs €23.272 (2112-77.354) per patient 22.
What is worse, however, that almost 10% of MDR-TB patients were found to have 
been infected with an extensively drug-resistant (XDR) strain 2. XDR-TB is defined as a 
mycobacterial strain being resistant to both isoniazid and rifampicin, to a fluoroquinolone 
and to at least one of the three injectable second-line drugs amikacin, capreomycin or 
kanamycin 23. Its costs are much higher than the costs of MDR-TB treatment, up to mean 
€93.962 (56.028-180.237) in Europe 22. Also the mortality rate is higher compared to 
MDR-TB 24. On top of this, four countries have recently reported strains that are resistant 
to all drugs tested, also known as totally drug-resistant TB (TDR-TB) 25-28.
A major problem with the treatment of drug-resistant TB are the tolerability and toxicity 
of the treatment regimens. Various severe side effects can occur which dramatically reduce 
the quality of life of patients. Side effects were described by patients with MDR-TB as: ”as 
bad as or worse than the illness itself” and “I thought I was going to die because of the 
medicines…it was that bad” 29.
Given all these problems, it will be clear that new drugs and better drug combinations, 
also effective against drug-resistant Mycobacterium tuberculosis are urgently needed. 
Preferably, these new regimens are also affordable, and enabling shortening the treatment 
duration without severe side effects.
Optimize treatment with new TB drugs
The first new TB-drug since the discovery of rifampicin in 1967 was bedaquiline, a 
diarylquinoline 30. Followed by the discovery of delamanid, a nitroimidazooxazole 31. Both 
drugs received FDA approval and are currently used in phase 3 clinical trials to find their 
exact place in the TB treatment. Several other new promising drug candidates, such as 
PBTZ-169, sutezolid, SQ109 and pretomanid, are currently in development, but it might 
take quite some years before all preclinical studies are finished 32.
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Before new compounds can be used on label for TB-patients they must be extensively 
tested in in vitro and ex vivo assays and in vivo animal models, followed by clinical de-
velopment in phase I, phase II and Phase III clinical trials. This preclinical phase can take 
many years 33. Therefore, two major TB-consortia, the European PreDiCT-TB consortium 
and their US counterpart, the “Critical Path to TB Drug Regimens” (CTPR), try to find a 
more rapid though reliable way of identifying the most potent combinations of new drugs 
and hasten their arrival in the clinic. Data from in vitro models, the hollow fiber infection 
model, ex vivo models, various animals models and data from human trials are combined 
using mathematical modelling techniques, to allow comprehensive understanding of the 
translational value of different preclinical models.
Optimize treatment by increasing the efficacy of current drugs
A different strategy in the battle against TB is finding ways to optimize the activity and ef-
ficacy of currently used TB-drugs. Increasing the drug concentrations at the site of infection 
by inhibiting efflux pumps can be an advantageous strategy to enhance the effect of the 
currently used TB-drugs.
Efflux pumps are protein complexes present in the cell membrane that remove drugs 
and toxins from inside the cell, thereby lowering the drug concentrations inside the cell. 
Some pumps are highly specific whereas others can recognize and transport a wide variety 
of structurally diverse compounds 34, 35. There are five different groups of efflux pumps, 
and these can be found in both prokaryotes and eukaryotes. Administered TB-drugs en-
counter the first transporters in the intestines, liver and kidneys, and next at the site of the 
macrophages in which the bacteria can reside. After the macrophage membrane, the final 
barrier is encountered, which is formed by the thick Mycobacterium tuberculosis cell wall 
and the plasma membrane.
Mycobacterium tuberculosis harbours a huge number of transporters involved in the 
extrusion of exogenous compounds; the genes encoding for only the ABC-transporters 
occupy about 2.5% of the genome 36. Efflux pumps can be inactivated by “efflux pump 
inhibitors” 37. Different types of efflux pump inhibitors exhibit different modes of action. 
Some have a broad activity whilst others are specific to one class of efflux pumps 38. 
Blocking or inactivation of efflux pumps may increase the TB-drug exposure at the site of 
infection, without elevating systemic concentrations of the drug associated with adverse 
effects. In addition, higher intrabacterial concentrations may increase the antimycobacte-
rial effect and prevent selection of drug-resistant mutants 39.
Another new approach to achieve higher intrabacterial concentrations of TB-drugs is 
the addition of colistin. Colistin, a member of the polymyxins group, is active against 
Mycobacterium tuberculosis through interaction with the bacterial lipopolysaccharide and 
fatty acids of the bacterial outer membrane 40. As a result, destabilization of the bacterial 
membrane occurs leading to enhanced membrane permeability permitting a higher influx 
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of other TB drugs 41. The first results are promising, as colistin was found to potentiates 
the activity of isoniazid and amikacin against extracellular Mycobacterium tuberculosis 42.
Taken together, promising drugs and novel therapeutic strategies are currently evalu-
ated at different (pre) clinical stages. Still, the predictive value of the various preclinical 
models needs to be further optimized.
In this thesis we focussed on optimizing TB treatment. On the one hand, by increasing 
the efficacy of currently used TB-drugs using efflux pump inhibitors. On the other hand by 
evaluating the bactericidal activity and sterilizing capacity of currently used TB-drugs in our 
mouse TB model, to optimize the predictive value of our mouse TB model.
aim of this thesis
The overall aim of this thesis is to explore and study new therapeutic options to optimize 
TB treatment.
The specific objectives are:
– To assess the therapeutic potential of co-administration of efflux pump inhibitors, i.e. 
thioridazine or SILA-421 with the standard treatment regimen
– To study a moxifloxacin and linezolid combination as a novel treatment regimen for 
MDR-TB and potentiate this combination with efflux pump inhibitors and cell wall 
destabilizing drugs
– To characterize the effect of rifampicin on the transcription profile of a rifampicin-
susceptible and a rifampicin-resistant Mycobacterium tuberculosis strain
– To study the added value of using a Mycobacterium tuberculosis strain of the clinical 
highly relevant Beijing genotype in our mouse TB model
– To compare Colony Forming Units counting, the Time to Positivity assay and the 
Molecular Bacterial Load assay, and explore whether the last assays can detect a myco-
bacterial subpopulation which is unable to grown on solid media
Outline of this thesis
Optimizing TB treatment:
In this thesis we describe different ways to optimize TB therapy, with a special focus on 
efflux pump inhibition. chapter 1 contains a general introduction and short outline of 
this thesis. In chapters 2 & 3 the antimycobacterial effects of the efflux pump inhibitor 
thioridazine and SILA-421 were explored. Both compounds were tested in vitro as single 
drug as well as in combination with isoniazid, rifampicin and pyrazinamide. Both com-
pounds were also studied in our mouse TB model when added to the standard regimen 
of isoniazid, rifampicin and pyrazinamide. In chapter 4 we evaluated the activity of a 
moxifloxacin plus linezolid combination as a novel regimen for MDR-TB treatment. Fur-
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thermore, we explored the effects of the potentiator drugs colistin, verapamil, SQ109 and 
timcodar on the activity of the moxifloxacin plus linezolid regimen. All compounds were 
in vitro tested as single drug, and the potentiator drugs were also studied in combination 
with the moxifloxacin and linezolid combination. In chapters 5 & 6 we described the 
validation of the “Dried Blood Spot” technique for moxifloxacin and linezolid for the use 
in pharmacokinetic and pharmacodynamics (PK/PD) studies in mice. We also defined the 
pharmacokinetic equivalent dose in mice for both drugs.
In chapter 7 we described the effect of rifampicin on the overall transcription pro-
file of Mycobacterium tuberculosis and addressed in particular the differences between 
rifampicin-susceptible and rifampicin-resistant strains. We performed a genome-wide 
transcriptional profile analysis using microarray technology and compared the profiles of 
an isogenic pair of rifampicin-susceptible and rifampicin-resistant strains after exposure to 
rifampicin.
Optimizing our preclinical TB model:
In chapter 8 we described an evaluation of the suitability of our mouse TB model to 
determine therapeutic activity and sterilizing capacity of drug combinations. We assessed 
the bactericidal activity of a broad range of TB drugs and the sterilizing capacity of ten 
rifampicin containing and non-rifampicin containing treatment arms.
To further optimize the way we monitor the mycobacterial load during infection and 
treatment we compared colony forming unit (CFU) counting with time to culture positivity 
and the molecular bacterial load assay. CFU counting is a much used method to monitor 
drug activity and therapeutic efficacy in in vivo studies but may not be the most optimal 
method. Therefore, we explored in chapter 9 whether mycobacterial subpopulations that 
are unable to grow on solid media can be detected using the time to positivity assay or the 
molecular bacterial load assay. chapter 10 provides a summary of results of the studies 
included in this thesis and discusses the main findings. The discussion ends with the recom-
mendations for future research. In chapter 11 the main findings are summarized in Dutch.
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aBsTracT
Objectives: Assessment of the activity of thioridazine towards Mycobacterium tubercu-
losis, in vitro and in vivo as a single drug and in combination with anti-tuberculosis (TB) 
drugs.
methods: The in vitro activity of thioridazine as single drug or in combination with TB 
drugs was assessed in terms of MIC and by use of the time-kill kinetics assay. Various 
Mycobacterium tuberculosis strains among which the Beijing genotype strain BE-1585 
were included.
In vivo, mice with TB induced by BE-1585 were treated with a TB drug regimen with 
thioridazine during 13 weeks. Therapeutic efficacy was assessed by the change in myco-
bacterial load in the lung, spleen and liver during treatment and 13 weeks post-treatment.
results: In vitro, thioridazine showed a concentration-dependent and time-dependent 
bactericidal activity towards both actively-replicating and slowly-replicating Mycobacterium 
tuberculosis. Thioridazine at high concentrations could enhance the activity of isoniazid 
and rifampicin, and in case of isoniazid resulted in elimination of mycobacteria and preven-
tion of isoniazid-resistant mutants. Thioridazine had no added value in combination with 
moxifloxacin or amikacin.
In mice with TB, thioridazine was poorly tolerated, limiting the maximum tolerated dose 
(MTD). The addition of thioridazine at the MTD to an isoniazid-rifampicin-pyrazinamide 
regimen for 13 weeks did not result in enhanced therapeutic efficacy.
conclusions: Thioridazine is bactericidal towards Mycobacterium tuberculosis in vitro, 
irrespective the mycobacterial growth rate and results in enhanced activity of isoniazid or 
rifampicin. The in vitro activity of thioridazine in potentiating isoniazid and rifampicin is not 
reflected by improved therapeutic efficacy in a murine TB-model.
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inTrOducTiOn
Resistance to tuberculosis (TB) drugs is rapidly emerging worldwide with nearly half a 
million cases of multi-drug resistant TB (MDR-TB) recorded annually 1. MDR-TB is caused 
by Mycobacterium tuberculosis strains that are resistant to the two most prominent drugs 
in the treatment of TB; rifampicin and isoniazid. Extensively drug-resistant tuberculosis 
(XDR-TB) is caused by Mycobacterium tuberculosis strains that are resistant to rifampicin, 
isoniazid to any of the fluoroquinolones and to any of the three second-line injectable 
drugs such as amikacin, capreomycin or kanamycin 1. Due to the very poor treatment 
outcome of MDR-TB and XDR-TB 1, more effective treatment is urgently needed.
Acquired drug resistance in other bacterial species is generally mediated through 
horizontal transfer of mobile genetic elements 2. However, in Mycobacterium tuberculosis 
acquired drug resistance is mainly caused by selection of bacteria with spontaneous muta-
tions in chromosomal genes, during sub-optimal treatment 3. In addition, accumulative 
evidence suggests an important role for mycobacterial efflux pumps in the extrusion of 
TB drugs and emergence of drug resistance 4, 5. Analysis of the genome of Mycobacte-
rium tuberculosis reveals that it has one of the largest numbers of putative efflux pumps 
among bacteria compared to its genome size 6. These efflux pumps can extrude several 
compounds and chemicals out of the bacterial cell resulting in decreased intra-cellular drug 
concentrations 7. It has also been demonstrated that antibiotics can serve as inducers by 
regulating the expression of efflux pumps at the level of gene transcription 8.
Phenothiazines are compounds that were previously used as anti-psychotic drugs. 
Additionally, phenothiazines also show a significant inhibitory effect on the growth of 
various clinical Mycobacterium tuberculosis isolates 9. Although, the molecular mecha-
nism of anti-mycobacterial activity of phenothiazines is still unclear, there are several 
hypotheses. Phenothiazines can interact with the DNA metabolism 10, or can disturb the 
Ca2+ -calmodulin signalling 11 and can cause alterations in the bacterial cell membrane 
12. Additionally, there is the alleged ability of phenothiazines to inhibit efflux pumps 5, 13. 
One of the phenothiazines is thioridazine, which is active against intra- and extracellular, 
drug-susceptible and drug-resistant Mycobacterium tuberculosis and is concentrated by 
human macrophages 9, 14, 15.
We hypothesized that combining TB drugs with thioridazine results in increased intra-
cellular drug concentrations and enhancement of the efficacy of the TB drugs.
In the current study, we conducted the in vitro concentration-dependent and time-
dependent killing capacity (time-kill kinetics) of thioridazine towards a Mycobacterium 
tuberculosis strain of the Beijing genotype 16. Furthermore, we investigated whether the 
addition of thioridazine to several TB drugs can enhance the time-kill kinetics of these TB 
drugs towards a Beijing genotype strain.
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Finally, we investigated the therapeutic potential of co-administration of thioridazine to 
a regimen of isoniazid, rifampicin and pyrazinamide in a murine TB-model, induced by a 
Beijing genotype strain 17. Outcome parameters are mycobacterial elimination in infected 
organs and the prevention of emergence of drug resistance and relapse of TB.
maTerials and meThOds
Mycobacterium tuberculosis cultures
Mycobacterium tuberculosis strains H37Rv (ATCC 27294), H37Rv-H526Y, Beijing-1585 (BE-
1585), BE-1585-H526Y and East-African/Indian-1627 (EAI-1627) were used. H37Rv-H526Y 
and BE-1585-H526Y were derived from their respective parental strains by exposure to 64 
mg/L of rifampicin as described before 18. Resistance was due to the His526Tyr mutation in 
codon 526 in the rpoB region. The MIC of rifampicin for the H37Rv strain is 0.5 mg/L, and 
for the BE-1585 strain and the EAI-1627 strain is 0.25 mg/L 16. The MIC of rifampicin for 
both rifampicin-resistant strains is 256 mg/L.
Mycobacterium tuberculosis suspensions were cultured in Middlebrook 7H9 broth (Difco 
Laboratories, Detroit, MI, USA), supplemented with 10% oleic acid-albumin-dextrose-
catalase enrichment (OADC, Baltimore Biological Laboratories, Baltimore, MD, USA), 0.5% 
glycerol (Scharlau Chemie S.A, Sentmenat, Spain) and 0.05% Tween 20 (Sigma Chemical 
Co, St. Louis, MO, USA), under shaking conditions at 96 rpm at 370C. Cultures on solid 
media were grown on Middlebrook 7H10 agar (Difco), supplemented with 10% OADC 
and 0.5% glycerol for 28 days at 37°C with 5% CO2.
TB drugs
Isoniazid (Hospital Pharmacy; Rotterdam, The Netherlands), rifampicin (Rifadin®, Aventis 
Pharma B.V, Hoevelaken, The Netherlands), amikacin (Hospira Benelux BVBA, Brussels, 
Belgium) moxifloxacin (Avelox®, Bayer Schering Pharma A.G, Berlin, Germany) and 
thioridazine (Sigma Chemical Co, St. Louis, MO, USA) were prepared according to the 
recommendations of the manufacturers.
minimal inhibitory concentration (mic)
The MIC of thioridazine for the Mycobacterium tuberculosis strains was determined in 
duplicate using the agar proportion method as described by the CLSI 19. In short, colonies 
grown on solid media were suspended in broth using glass beads and vortexed during 
4 minutes. The suspension was allowed to settle down for 30 minutes, after which the 
supernatant was taken and set to an optical density of McFarland standard 1. Using broth, 
a 1:10 dilution of this Mycobacterium tuberculosis suspension was plated onto solid media 
containing serial two-fold dilution concentrations of TB drug. After incubation the degree 
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of growth was assessed. The MIC was defined as the lowest concentration of TB drug that 
resulted in >99% growth inhibition.
In vitro time-kill kinetics
The concentration-dependent and time-dependent bactericidal activity of thioridazine as 
a single drug were determined as described previously 18. In short, low-density cultures of 
actively replicating BE-1585 or high-density cultures of slowly replicating BE-1585 were 
exposed to two-fold increasing concentrations at 370C. On days 1, 3 and 6 samples (200 
µl) were taken, provided that the mycobacterial suspension did not show visible aggrega-
tion, and were sub-cultured on drug-free solid media for CFU counts after 28 days of 
incubation at 370C with 5% CO2.
The time-kill kinetics of the drug combinations in low-density cultures of actively repli-
cating BE-1585 was determined for thioridazine in combination with isoniazid, rifampicin, 
moxifloxacin and amikacin. The concentrations of TB drugs selected for these experiments 
resulted in a maximum 10-fold change of Mycobacterium tuberculosis numbers after 6 
days of single drug exposure compared to day 0. thioridazine concentrations ranging from 
¼ x MIC to 4x the MIC were added to TB drugs at two-fold increasing concentrations. On 
days 3 and 6 samples (200 µl) were taken, provided that the mycobacterial suspension did 
not show visible aggregation, and were sub-cultured on drug-free and drug-containing 
solid media with 4-fold the critical concentrations of the drug 19, i.e. 0.8 mg/L isoniazid, 4 
mg/L rifampicin, 8 mg/L moxifloxacin or 20 mg/L amikacin to select drug-resistant mutants 
if present. After 28 days of incubation at 370C with 5% CO2 the number of CFU at the 
subculture plates was determined.
Synergistic activity of drugs was determined after 6 days of drug exposure and was 
defined as a ≥ 100-fold (∆log 2) decrease in colony count obtained using the drug combi-
nation compared to the colony count obtained using the most active single agent, or when 
the drug combination resulted in complete mycobacterial elimination while the most active 
single agent did not.
animals
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les Oncins, 
France). At the day of infection, animals were 13-15 weeks old and weighed 20-25 gram. 
Experimental protocols adhered to the rules specified in the Dutch Animal Experimentation 
Act and are in concordance with the EU animal directive 2010/63/EU. The Institutional 
Animal Care and Use Committee of the Erasmus MC approved the present protocol (117-
09-04).
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infection
Mice were infected as described previously 17. In short, mice under anaesthesia were 
infected by intratracheal instillation of a suspension containing 6.4 x 104 CFU of BE-1585, 
followed by proper inhalation.
Treatment with TB drugs
For thioridazine a dose-finding study was performed in BE-1585 infected mice with four 
different thioridazine dose-schedules added to a combination of isoniazid, rifampicin and 
pyrazinamide (HRZ) in human pharmacokinetic-equivalent doses 20. The basic experimental 
scheme is shown in table 1. Briefly, treatment was started 2 weeks after infection and mice 
were randomly divided in five groups in which the thioridazine dosages slowly increased 
every 3 weeks from 3 up to 12 mg/kg/day in group 1, from 6 up to 18 mg/kg/day in group 
2, from 9 up to 27 mg/kg/day in group 3 and from 12 up to 36 mg/kg/day in group 4. 
Group 5 were controls receiving HRZ only. thioridazine in a total volume of 200 µl Aqua 
Destillata (AD) was freshly prepared and daily administered intraperitoneally, HRZ in hu-
man pharmacokinetic-equivalent doses in a total volume of 300 µl was daily administered 
subcutaneously 20. Treatment duration was 13 weeks.
Subsequently, the treatment schedule of thioridazine at the optimal dose obtained in 
the dose-finding study in combination with HRZ was administered to determine therapeu-
tic efficacy.
determination of viable Mycobacterium tuberculosis counts in infected 
organs
At the start of therapy, after 3, 7 and 13 weeks therapy and 13 weeks therapy followed by 
13 weeks relapse assessment mice (n=4 per time point) were sacrificed by CO2 exposure. 
The lung, spleen and liver were removed aseptically and processed as described previously 
20. To prevent carry-over of TB drugs, therapy was stopped 72 hours before sacrificing the 
mice. In addition, tissue homogenate suspensions were centrifuged at 14,000xg for 10 
min, and pellets were re-suspended in Phosphate Buffered Saline (PBS). From the tissue 
Table 1. Basic experimental scheme of the dose finding study
Time (weeks) → 0-2 3-5 6-8 9-15
Treatment group↓
1 Infection THZ 3 mg/kg + HRZ THZ 6 mg/kg + HRZ THZ 12 mg/kg + HRZ
2 Infection THZ 6 mg/kg + HRZ THZ 12 mg/kg + HRZ THZ 18 mg/kg + HRZ
3 Infection THZ 9 mg/kg + HRZ THZ 18 mg/kg + HRZ THZ 27 mg/kg + HRZ
4 Infection THZ 12 mg/kg + HRZ THZ 24 mg/kg + HRZ THZ 36 mg/kg + HRZ
5 Infection HRZ HRZ HRZ
THZ = thioridazine, HRZ = isoniazid + rifampicin + pyrazinamide
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homogenate the 10-fold serial dilutions were performed and samples of 200 µl were cul-
tured on drug-free and drug-containing solid media with 4-fold the critical concentrations 
of the drug 19, i.e. 0.8 mg/L isoniazid or 4 mg/L rifampicin to select drug-resistant mutants 
if present.
assessment of relapse of infection
The number of viable Mycobacterium tuberculosis counts in lung, spleen and liver of mice 
(n=4) was assessed 13 weeks after termination of TB treatment. Relapse was defined as 
Mycobacterium tuberculosis-positive organ cultures, while immediately after termination 
of treatment organs were Mycobacterium tuberculosis culture-negative.
resulTs
In vitro mic
The MICs of thioridazine for the five Mycobacterium tuberculosis strains tested are pre-
sented in table 2. The MIC values for the three susceptible strains as well as the two 
rifampicin-resistant strains proved to be similar, being 4-8 mg/L thioridazine.
In vitro time-kill kinetics
Time–kill kinetic assays were performed for thioridazine as single drug or in combination 
with isoniazid, rifampicin, moxifloxacin and amikacin for the BE-1585 strain. The activity 
of thioridazine against low-density cultures of actively replicating BE-1585 is presented in 
figure 1A. Thioridazine showed a strong concentration- and time-dependent activity in the 
concentration range tested (0.5 up to 128 mg/L). To achieve ≥99% mycobacterial killing, 
16 mg/L thioridazine was needed. To achieve complete mycobacterial elimination 32 mg/L 
thioridazine was required.
Table 2. MIC values of thioridazine for three wild-type Mycobacterium tuberculosis strains (H37Rv, BE-1585 and EAI-1627) 
and two rifampicin-resistant Mycobacterium tuberculosis strains (H37Rv-H526Y and BE-1585-H526Y).
strain mic (mg/l)
H37Rv 4
H37Rv-H526Y 8
BE-1585 8
BE-1585-H526Y 8
EAI-1627 8
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figure 1. Concentration- and time-dependent bactericidal effect of thioridazine towards BE-1585. Low-density cultures 
of actively replicating Mycobacterium tuberculosis (starting at 5.9 x 105 CFU/mL) (a) and high-density cultures of slowly 
replicating Mycobacterium tuberculosis (starting at 6.9 x 106 CFU/mL) (B) were exposed to thioridazine at 2-fold increasing 
concentrations for 6 days at 37°C under shaking conditions. After 1, 3 and 6 days of drug exposure, samples were taken 
and quantitative cultures were performed.
* Due to aggregation of the mycobacteria in the culture, accurate CFU counts could not be performed.
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The activity of thioridazine in high-density cultures of slowly replicating BE-1585 is pre-
sented in figure 1B. Concentrations of 2-8 mg/L thioridazine did not show any activity, 
resulting in mycobacterial aggregation, whereas 16 mg/L thioridazine resulted in >99% 
mycobacterial killing. At a concentration of 32 mg/L thioridazine, complete mycobacterial 
elimination was obtained after three days of exposure.
The results of the time-kill kinetics in low-density cultures of actively replicating BE-
1585 after exposure to the drug combinations are presented in terms of Log10 CFU/mL in 
table 3. In the control BE-1585 cultures CFU counts increased from 5.7 (5.6 – 5.8) to 7.3 
(7.0 – aggregation) within 6 days. Changes in CFU count of the BE-1585 cultures after 
6 days of exposure to thioridazine as single agent were 5.7 (5.6-5.8) to 5.8 (5.1 – 6.5) 
for thioridazine 4 mg/L, 5.7 (5.6 – 5.8) to 4.6 (4.1 – 4.9) for thioridazine 8 mg/L and 5.7 
(5.6 – 5.8) to 1.9 (1.3 – 2.3) for thioridazine 16 mg/L.
Addition of thioridazine at 4, 8 or 16 mg/L to isoniazid (0.063 mg/L) resulted in enhanced 
mycobacterial killing. A synergistic effect of the drug combination was obtained, when 
thioridazine 8 or 16 mg/L was added. Even complete elimination of mycobacteria was 
obtained and emergence of isoniazid resistance was prevented, while single drug exposure 
to isoniazid resulted in selection of isoniazid-resistant mutants (table 3). Addition of thio-
ridazine to rifampicin (0.015 mg/L) also showed enhancement of rifampicin activity, but 
only with the highest concentration of thioridazine (16 mg/L) a clear synergistic activity was 
found. In contrast, addition of thioridazine to moxifloxacin (0.031 mg/L) or amikacin (0.25 
mg/L) resulted in moderate improvement of the activity of moxifloxacin and amikacin, and 
synergistic activity was not obtained.
In vivo therapeutic efficacy
At two weeks after inoculation with the BE-1585 strain, mice had developed a TB infection 
including extra-pulmonary dissemination and treatment with thioridazine was initiated. 
Untreated control animals became moribund by three weeks after infection and were 
euthanized. The highest dose schedule of thioridazine in combination with HRZ (group 
4) resulted in severe toxic events and finally all mice became moribund after 7 weeks of 
treatment. Of the mice from group 3, one mouse died after 4 weeks of treatment and the 
other mice became seriously ill and were euthanized. Mice from group 1 and 2 showed 
abnormal behaviour compared to the controls (group 5) but symptoms disappeared within 
3 weeks. Based upon these results the thioridazine schedule of group 2 (from 6 to 18 mg/
kg/day) was set as the maximum tolerated dosage (MTD) in our mouse model and used to 
assess the therapeutic efficacy (figure 2).
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figure 2. Therapeutic efficacy of treatment with HRZ or a combination of HRZ and thioridazine in mice with TB caused 
by BE-1585, started 2 weeks after inoculation and continued for 13 weeks. Mycobacterium tuberculosis load in infected organs 
in untreated mice (filled grey bars), in HRZ-treated mice (chequered bars) and in mice treated with HRZ + thioridazine 
(striped bars). Results are expressed as median ± range (error bars) of the colony forming units (CFU) per organ, n = 4 per 
time point. Numbers above bars are the numbers of culture-positive mice out of total mice.
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To assess therapeutic efficacy the infected mice were treated for 13 weeks with HRZ or HRZ 
in combination with thioridazine (figure 2). After 13 weeks of treatment, lung, spleen and 
liver were culture-negative in mice receiving HRZ alone. The same results were obtained in 
mice receiving HRZ and thioridazine. Spleens and livers were all culture-negative although 
in one mouse some mycobacteria were found in the lung after 13 weeks of treatment. 
After a 13 weeks post treatment period in the HRZ treated group, relapse of infection 
was observed in the lungs of three out of four mice, and in the spleen and liver of one 
out of four mice (figure 2). All mice treated with HRZ plus thioridazine showed relapse of 
infection in the lungs, whereas three out of four mice were culture-positive in the spleen 
and in one out of four mice the liver was culture-positive.
discussiOn
Back in the 1960’s the first cases were reported in which phenothiazines were used to treat 
TB-patient 21, 22. In 1996 Amaral et al. postulated that thioridazine should be used in newly 
diagnosed TB-patients because it was shown that thioridazine inhibited the respiration 
of a clinical Mycobacterium tuberculosis isolate resistant to the first-line anti TB drugs 15. 
Today, many years later thioridazine is still seldom used in the treatment of (MDR-) TB, 
with the exception of compassionate treatment in patients with XDR-TB 23. The limited 
use of thioridazine might be explained by relatively few studies that evaluated its efficacy 
in preclinical models 24-27, by the variable response to thioridazine in these models, and by 
severe adverse effects that may occur with the use of thioridazine based on its use as a 
neuroleptic 28. However, some promising results were obtained with respect to the activity 
of thioridazine against intracellular mycobacteria regardless the susceptibility status of the 
mycobacteria 14, and this encouraged further investigation of the use of thioridazine as a 
TB drug. Moreover, there is evidence that thioridazine is a potent inhibitor of efflux pumps, 
possibly causing accumulation of drugs inside phagocytic and bacterial cells and as such 
yielding a synergistic effect 5, 13. The present study evaluates the activity of thioridazine, 
as single drug or in combination with TB drugs, towards actively replicating or slowly 
replicating mycobacteria of the Beijing genotype in vitro, and in murine TB caused by the 
same Beijing strain in vivo.
In the present study the in vitro activity of thioridazine in terms of MIC was demonstrat-
ed towards H37Rv, BE-1585 and EAI-1627 strains and two rifampicin-resistant isogenic 
mutants of the H37Rv and BE-1585. We found that thioridazine MIC values were similar 
and conclude that thioridazine is active against extracellular Mycobacterium tuberculosis, 
irrespective their susceptibility or resistance to rifampicin, suggesting that the mechanism 
of action of thioridazine is not influenced by rifampicin resistance.
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Among the in vitro susceptibility assays currently used, the MIC assay provides end-
point data that are obtained after 4 weeks of Mycobacterium tuberculosis exposure to 
TB drugs. With such an assay only inhibition of mycobacterial growth is detected. In the 
present study we also performed the time-kill kinetic assay which is more informative with 
respect to the concentration-dependent and time-dependent activity of the drug (figure 
1A and 1B), and also determines mycobacterial killing. Using this assay, we conclude that 
thioridazine is effective in killing of extra-cellular BE-1585. As a remark, relatively high 
concentrations of thioridazine (≥ 16 mg/L) are needed to achieve mycobacterial killing. It 
is also shown that the bactericidal activity is irrespective of the replicating activity of the 
mycobacteria. The relevance of this observation lies in the fact that the killing capacity of 
thioridazine towards slowly replicating mycobacteria is important from a therapeutic point 
of view, as it is thought that deep-seated Mycobacterium tuberculosis in tissues during the 
dormant state probably exhibit low metabolic activity. It is expected that these low-active 
Mycobacterium tuberculosis are difficult to eliminate because most currently used TB drugs 
are primarily active against actively replicating Mycobacterium tuberculosis.
In the present study also combinations of several common TB drugs and thioridazine 
were tested in low-density cultures of actively replicating BE-1585. In these studies the 
concentrations of TB drugs were selected that resulted in a maximum of 10-fold change 
in CFU counts during 6 days of single drug exposure compared to day 0. The value of 
addition of thioridazine to the TB drugs was most pronounced for isoniazid. With the three 
concentrations of thioridazine tested in combination with isoniazid, a substantial increased 
killing of Mycobacterium tuberculosis was achieved and synergistic activity was obtained. 
Thioridazine 8 and 16 mg/L even resulted in complete elimination of the mycobacteria. 
Furthermore, whereas isoniazid-resistant mutants occurred after exposure of Mycobac-
terium tuberculosis to isoniazid as single drug, the addition of thioridazine at all three 
concentrations prevented selection of isoniazid-resistant mutants. This result expands upon 
a prior study of Dutta et al. in which they presented in an acute murine model that treat-
ment with isoniazid + thioridazine reduced the frequency of isoniazid-resistant mutants 
by 7-fold 24. Machado et al. showed in vitro that isoniazid-resistance can be reduced by 
inhibiting certain mycobacterial efflux pumps by exposure to thioridazine 29. The potential 
of thioridazine in this respect is of high importance in view of the worldwide emerging 
isoniazid resistance.
The enhanced activity of TB drugs following the addition of thioridazine was also 
observed in the combination of thioridazine-rifampicin. This suggests that the activity of 
thioridazine targeting the cell wall may result in an increased cell wall permeability or inhi-
bition of efflux pumps, enabling an increase in intrabacterial concentrations of rifampicin 
30. The synergy found of thioridazine and rifampicin is in concordance with a study of 
Viveiros et al. in which they also demonstrated an enhanced activity of rifampicin following 
addition of thioridazine 31. However, they did not find enhanced activity of isoniazid after 
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addition of thioridazine 31, which might be explained by the use of poly-drug resistant 
Mycobacterium tuberculosis strains or the much lower concentrations of isoniazid applied 
in their experiments.
The in vitro observations of the present study were realized with thioridazine concentra-
tions that are clinically not achievable. However, it is known that accumulation of pheno-
thiazines can occur within alveolar macrophages 32, and this might justify the application 
of thioridazine in potentiating the activity of TB drugs in the treatment of TB in a murine 
model.
Despite the promising results found in vitro in the time-kill kinetics following the addi-
tion of thioridazine to isoniazid or rifampicin, enhancement of therapeutic efficacy of the 
HRZ regimen following co-administration with thioridazine was not found in the treatment 
of TB caused by BE-1585 in mice. Due to severe toxic events following thioridazine admin-
istration, the maximum tolerable dosing schedule of thioridazine escalated the dose up to 
18 mg/kg/day. We did not perform a pharmacokinetic study, but thioridazine was clearly 
absorbed by our mice, considering the dose-limiting adverse effects that we observed. 
Furthermore, the dose of 18 mg/kg/day is close to the 25 mg/kg/day dose that yields 
exposures similar to those in humans after a daily dose of 25 mg, as shown by Dutta 
et al. in the same mice 24. Dutta et al. also showed that thioridazine in this dose range 
concentrates up to 30-fold in murine lung tissue relative to serum in this dose range. 
Therefore, we conclude that addition of thioridazine at the MTD has no additional value 
in the therapeutic efficacy of HRZ treatment in our murine model. These results are in 
concordance with a study of Dutta et al. in which they also showed in their chronic infec-
tion murine model that 2 months treatment with isoniazid + thioridazine or rifampicin + 
thioridazine does not yield to any additive effect on CFU load in the lung. In their acute 
model they showed some additive effect of thioridazine in combination with isoniazid, but 
very limited 24. In 2013, Dutta et al. also demonstrated relatively high mortality when using 
a range of thioridazine dosages in their guinea pig TB model, and no significant decrease 
in mycobacterial load was found when thioridazine as single agent was administered for 
one month with dosages ranging from 2.5 to 80 mg/kg 25.
In contrast to our observations, van Soolingen et al. showed in 2010 enhanced thera-
peutic efficacy in a mouse TB model when thioridazine (32 and 70 mg/kg doses) was added 
to a HRZ treatment 27. After 60 days of treatment the Mycobacterium tuberculosis load in 
the lung was significantly lower in the group receiving HRZ + thioridazine compared to the 
group receiving HRZ only. In spite of the statistical significance achieved, the decrease in 
Mycobacterium tuberculosis load was very limited and lungs still remained culture positive. 
Also in 2007 Martins et al. found a decrease in Mycobacterium tuberculosis load in the 
lung in their murine TB model when mice were treated for 300 days with thioridazine as 
single agent (0.5 mg/day) 26. However, no decrease of Mycobacterium tuberculosis load 
in the spleen and liver were observed. Therefore extra-pulmonary organs could remain 
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a source of Mycobacterium tuberculosis causing re-infection of the lung. This can be an 
explanation for the in vivo results observed in the present study, where relapse occurs 
after 13 weeks therapy followed by a 13 weeks post-treatment period in both the group 
receiving HRZ + thioridazine as well as in the control group receiving only HRZ.
Based on the data from the present study and earlier studies by Martins et al., Dutta 
et al. and from van Soolingen et al. we can conclude that there is a lack of conclusive evi-
dence that proves that thioridazine will be the drug to beat MDR-TB or XDR-TB. However, 
we provide further evidence that an efflux pump inhibitor indeed can be of added value. 
Therefore development of less toxic efflux pump inhibitors is urgently needed.
Summarizing, we conclude that in vitro thioridazine in itself is bactericidal towards a 
Beijing genotype Mycobacterium tuberculosis strain, irrespective the growth rate of the 
mycobacteria. Furthermore, the addition of thioridazine to isoniazid or rifampicin results 
in enhanced activity of both drugs, which is most pronounced for isoniazid. Moreover, 
the addition of thioridazine prevents emergence of isoniazid resistance. The translational 
value of the in vitro observations to the in vivo therapeutic efficacy in the murine TB model 
caused by the same Beijing genotype strain is disappointing. Due to toxicity only limited 
dosages of thioridazine are allowed. At the maximum tolerated dose thioridazine has no 
added value to the therapeutic activity of HRZ in mice.
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aBsTracT
Due to the emergence of multidrug-resistant tuberculosis (TB) and extensively drug-
resistant TB, there is an urgent need for new TB drugs or compounds that improve the 
efficacy of currently used drugs. In this study we performed time-kill kinetics of SILA-421 
as single drug and in combination with isoniazid, rifampicin, moxifloxacin or amikacin 
against Mycobacterium tuberculosis. We also assessed therapeutic efficacy in vivo in our 
mouse TB model. Further in vitro analysis was performed with a rifampicin-susceptible and 
rifampicin-resistant strains of Mycobacterium tuberculosis.
When used as single drug, SILA-421 showed in vitro a concentration-dependent and 
time-dependent bactericidal activity. SILA-421 also enhanced the activity of isoniazid and 
rifampicin, in case of isoniazid resulted in synergy. The emergence of isoniazid-resistance 
after exposure to isoniazid can be prevented by the addition SILA-421. SILA-421 had no 
additional value in combination with moxifloxacin or amikacin. Furthermore, SILA-421 
enhanced the activity of rifampicin towards a rifampicin-resistant strain, and resulted in 
complete elimination of rifampicin-resistant mycobacteria. Unfortunately, in mice with TB, 
induced by a Beijing genotype strain, the addition of SILA-421 to an isoniazid-rifampicin-
pyrazinamide regimen for 13 weeks did not result in enhanced therapeutic efficacy.
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inTrOducTiOn
Tuberculosis (TB) is one of the major life-threatening infectious diseases 1. Most currently 
used TB-drugs being developed more than 50 years ago and due to an increasing amount 
of multi-drug resistant TB (MDR-TB) 1, we must conclude that there is an urge to develop 
new treatment regimens. Despite the fact that several novel compounds with anti TB activ-
ity are in different phases of development, there continues to be a need for new TB-drugs 
or compounds that enhance the therapeutic efficacy of existing TB-drugs 2.
It has been demonstrated that compounds that inhibit efflux pumps can enhance the 
intracellular mycobacterial killing themselves and/or may potentiate the effect of other TB-
drugs 3. It has been previously demonstrated that thioridazine used as TB-drug/efflux pump 
inhibitor (EPI) has in vitro activity. Thioridazine shows a synergistic effect when combined 
with isoniazid and rifampicin 3-7. However, when used in a murine TB-model, thioridazine 
shows toxic effects and enhanced therapeutic efficacy of the standard TB regimen was not 
observed 8. The development of novel EPIs is needed.
The potency of an organosilicon (SILA) compound, SILA-421, to inhibit efflux pumps in 
cancer cells and Escherichia coli has been demonstrated 9, 10. In addition, SILA-421 showed 
in vitro activity against Mycobacterium tuberculosis11, and ex vivo it enhances intracellular 
killing of an extensively drug resistant (XDR) TB isolate inside human macrophages 12.
We hypothesized that combining SILA-421 with TB-drugs of different classes, namely 
isoniazid, rifampicin, moxifloxacin and amikacin could result in enhancement of activity of 
these TB-drugs in vitro, as well as improvement of therapeutic efficacy in our mouse TB 
model.
We studied the time-kill kinetics of SILA-421 towards a Mycobacterium tuberculosis 
strain of the Beijing genotype, and investigated if the addition of SILA-421 to several TB 
drugs would lead to synergy between compounds. We also assessed the time-kill kinet-
ics of SILA-421 in combination with rifampicin towards an isogenic mutant strain of the 
Beijing strain which is resistant to rifampicin. Subsequently, we evaluated the effect of 
the combination of SILA-421 with the standard therapy regimen in a TB model in mice 
infected with Mycobacterium tuberculosis Beijing genotype strain. Outcome parameters 
are mycobacterial elimination in infected organs, the prevention of emergence of drug 
resistance and relapse of TB.
maTerials and meThOds
materials
SILA-421 (1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis{3-1(4-butyl-piperazinyl)-propyl}-
disiloxan tetrahydrochlorid), a patented compound was provided by Dr G. Hajos (Institute 
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for Biomolecular Chemistry, Budapest, Hungary) and prof. L. Amaral (Travel Medicine of 
the Center de Malaria e Doencas Tropicais, Institute of Hygiene and Tropical Medicine, 
Universidade Nova de Lisboa, Lisbon, Portugal) and was dissolved in water.
Isoniazid (Hospital Pharmacy; Rotterdam, The Netherlands), rifampicin (Rifadin®, 
Aventis Pharma B.V, Hoevelaken, The Netherlands), pyrazinamide (Sigma Chemical Co, St. 
Louis, MO, USA), amikacin (Hospira Benelux BVBA, Brussels, Belgium) and moxifloxacin 
(Avelox®, Bayer Schering Pharma A.G, Berlin, Germany) were used according to the rec-
ommendations of the manufacturers.
Mycobacterium tuberculosis suspensions for the in vitro assays were cultured in 
Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI, USA), supplemented with 10% 
oleic acid-albumin-dextrose-catalase enrichment (OADC, Baltimore Biological Laboratories, 
Baltimore, MD, USA), 0.5% glycerol (Scharlau Chemie S.A, Sentmenat, Spain) and 0.02% 
Tween 20 (Sigma Chemical Co, St. Louis, MO, USA), under shaking conditions at 96 rpm at 
370C. All cultures on solid media were grown on Middlebrook 7H10 agar (Difco), supple-
mented with 10% OADC and 0.5% glycerol for 28 days at 37°C with 5% CO2.
Bacterial strains
The Mycobacterium tuberculosis genotype strain Beijing VN 2002-1585 (BE-1585) which 
is susceptible to isoniazid (MIC 0.125 mg/L), rifampicin (MIC 0.25 mg/L), moxifloxacin 
(MIC 0.25 mg/L) and amikacin (MIC 2 mg/L) and the progeny strain BE-1585-H526Y were 
used1 3. The BE-1585-H526Y is resistant to rifampicin (MIC 512 mg/L) due to a mutation 
in the rpoB gene and was derived from the BE-1585 by exposure to 64 mg/L of rifampicin 
as described before 13, 14.
minimal inhibitory concentration assay (mic)
The solid media MIC of SILA-421 for the Beijing strains were determined using the agar 
proportion method as derived from the standards of the CLSI 15.
In vitro time-kill kinetics
The concentration- and time-dependent bactericidal activity of SILA-421 as single drug 
or in combination with TB-drugs were determined in liquid media as described previously 
16. In short, low-density cultures of actively replicating (exponential-phase) BE-1585 were 
exposed to two-fold increasing concentrations of SILA-421 at 370C and 96 rpm. On day 1, 
3 and 6 samples (200 µL) were taken, provided that the mycobacterial suspension did not 
show visible aggregation. Samples were centrifuged at 14.000xg to avoid drug carry-over 
and were sub-cultured on drug-free solid media for CFU counts after 28 days of incubation 
at 370C with 5% CO2. To assess the selection of drug-resistant Mycobacterium tuberculo-
sis, samples were sub-cultured on drug-containing solid media. The drug concentration in 
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the subculture plates were 4-fold the critical concentrations, i.e. 0.8 mg/L isoniazid, 4 mg/L 
rifampicin, 8 mg/L moxifloxacin or 20 mg/L amikacin.
The time-kill kinetics of the drug combinations in low-density Mycobacterium tubercu-
losis cultures of actively replicating BE-1585 were determined for SILA-421 in combination 
with isoniazid, rifampicin, moxifloxacin or amikacin. The concentrations of TB-drugs se-
lected for these experiments were chosen based on the results obtained as single exposure 
where the mycobacterial load on day 6 deviated not more than 1 log compared to day 0. 
SILA-421 concentrations of 1, 2 and 4 mg/L were added to the TB-drugs.
The time-kill kinetics of actively replicating rifampicin-resistant BE-1585-H526Y were 
determined for SILA-421 (2 and 4 mg/L) in combination with rifampicin (64, 128 and 256 
mg/L).
The two endpoints of this experiment were drug synergy and the prevention of the 
emergence of TB-drug resistance. Synergistic activity of a drug combination was de-
termined after 6 days of exposure and was defined as ≥ 100-fold (∆log 2) decrease in 
mycobacterial load in the combination compared to the mycobacterial load in the most 
active single agent, or when the drug combination resulted in complete mycobacterial 
elimination while the most active single agent did not 17. Lower limit of quantification (LLQ) 
was 5 CFU (Log 0.7).
infection model
Mice were infected as described previously 18. In short, mice under anaesthesia were 
infected by intra-tracheal instillation of a suspension (40 µL) containing 3.8 x 104 CFU of 
BE-1585, followed by proper inhalation, to ensure the formation of a bilateral TB infection.
animals
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les Oncins, 
France). At the day of infection, animals were 13-15 weeks old and weighed 20-25 grams. 
Experimental protocols adhered to the rules specified in the Dutch Animal Experimentation 
Act and are in concordance with the EU animal directive 2010/63/EU. The Institutional 
Animal Care and Use Committee of the Erasmus MC approved the present protocols (117-
12-12).
Treatment with TB-drugs
A tolerability study in infected mice was performed using dosages of 5 and 10 mg/kg/
day SILA-421 in combination with isoniazid, rifampicin and pyrazinamide (HRZ) in hu-
man pharmacokinetic-equivalent doses, 25, 10 and 150 mg/kg/day respectively1 9, 20, for 
3 weeks.
In the therapeutic efficacy study in BE-1585 infected mice, treatment was started 2 
weeks after infection and mice were randomly divided in two groups. The first group 
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received HRZ in human pharmacokinetic-equivalent doses 5 days/week, the second group 
received HRZ and 10 mg/kg SILA-421, 5 days/week. HRZ was administered orally in a total 
volume of 0.3 mL, SILA-421 was administered intra-peritoneally in a volume of 0.3 mL. 
Treatment was continued for 13 weeks, followed by a 13 weeks post-treatment period to 
check for relapse of TB infection.
determination of viable Mycobacterium tuberculosis counts in infected 
organs
To assess the therapeutic efficacy and prevention of relapse TB infection, mice were sacri-
ficed by CO2 exposure at several time points: at the start of therapy (n=3), after 8 (n=4) and 
13 weeks therapy (n=4) and at week 26 (13 weeks after termination of therapy) (n=12). To 
prevent carry-over of TB-drugs on subculture plates, therapy was stopped 72 hours before 
sacrificing the mice. The lungs and spleens were removed aseptically and homogenized in 
the M-tubes using the gentleMACS Octo Dissociator (Miltenyi Biotec BV, Leiden, the Neth-
erlands) in 2 mL Phosphate Buffered Saline (PBS). Tissue homogenates were centrifuged at 
14,000xg for 10 min, again to prevent carry–over of TB-drugs. Pellets were re-suspended 
in PBS. From each tissue homogenate 10-fold serial dilutions were performed and samples 
of 200 µL were cultured on drug-free solid media.
assessment of relapse of TB infection
The number of viable Mycobacterium tuberculosis counts in lung and spleen of mice 
(n=12) was assessed 13 weeks after termination of TB treatment. Relapse was defined as 
Mycobacterium tuberculosis-positive cultures of infected organs, while immediately after 
termination of treatment organs were Mycobacterium tuberculosis culture-negative.
resulTs
In vitro activity, mic
The MICs of SILA-421 for BE-1585 and BE-1585-H526Y were similar, being 8 mg/L SILA-
421.
In vitro time-kill kinetics towards Be-1585
In figure 1, the activity of SILA-421 as single drug exposure against BE-1585 is presented. 
SILA-421 showed a strong concentration- and time-dependent activity in the concentra-
tion range tested (0.5 – 64 mg/L). After 6 days of exposure to 8 mg/L SILA-421, all Myco-
bacterium tuberculosis cultures became sterile, whereas 16-64 mg/L resulted in complete 
Mycobacterium tuberculosis elimination already after 1 day of exposure.
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The activity of SILA-421 in combination with the TB-drugs against BE-1585 is shown in 
table 1. In the unexposed Mycobacterium tuberculosis cultures, CFU counts increased from 
(median + range) 5.8 (5.6 – 5.9) to 7.2 (7.1 – aggregation) within 6 days. Changes in 
CFU count of the Mycobacterium tuberculosis cultures after 6 days SILA-421 single drug 
exposure were (median + range) 5.8 (5.6 – 5.8) to 7.4 (7.2 – 7.5), to 6.8 (6.5- 7.0) and to 
4.2 (3.9 – 4.4) for 1, 2 and 4 mg/L SILA-421 respectively.
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figure 1. Concentration- and time-dependent bactericidal effect of SILA-421 against Mycobacterium tuberculosis BE-1585. 
Cultures of actively replicating Mycobacterium tuberculosis (starting at 5.8 x 105 CFU/mL) were exposed to SILA-421 at 2-fold 
increasing concentrations for 6 days at 37°C under shaking conditions. After 1, 3 and 6 days of drug exposure, samples 
were taken and quantitative cultures were performed. The dotted horizontal line is the lower limit of quantification of log 
CFU/ml.
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Addition of 2 mg/L SILA-421 to isoniazid 0.063 mg/L resulted in enhanced mycobacterial 
killing and a synergistic effect was obtained when 4 mg/L SILA-421 was added to isoniazid 
0.063 mg/L. When the BE-1585 was exposed to isoniazid as single drug, isoniazid resistant 
mutants were obtained from drug-containing plates, whereas the combination of 4 mg/L 
SILA-421 with 0.063 mg/L isoniazid resulted in prevention of emergence of resistance. 
Furthermore, addition of 2 and 4 mg/L SILA-421 to rifampicin (0.015 mg/L) resulted in 
enhanced mycobacterial killing. No effect was observed when SILA-421 was added to 
moxifloxacin (0.031), however, when 1 and 2 mg/L SILA-421 were added to amikacin 
Table 1. Effect of SILA-421 on the bactericidal activity of isoniazid, rifampicin, moxifloxacin or amikacin against BE-1585.
TB-drugs tested (mg/L) Log10 CFU/mL at day 0
LLQ = 0.7
Log 10CFU/mL at day 6
LLQ = 0.7
TB-drug resistant 
mutants
Δ Log10 CFU/
mL between drug 
combination and most 
active single drug at 
day 6
Control 5.8 (5.6 - 5.9) 7.2 (7.1 – aggregation) -
INH 0.063 5.8 5.1 [1:6.2 x 103]
RIF 0.015 5.6 5.3 0 
MXF 0.031 5.8 4.9 0 
AMK 0.25 5.9 4.7 0 
SILA 1 5.8 (5.6 - 5.9) 7.4 (7.2 – 7.5) ND
SILA 2 5.8 (5.6 - 5.9) 6.8 (6.5 – 7.0) ND 
SILA 4 5.8 (5.6 - 5.9) 4.2 (3.9 – 4.4) ND 
INH 0.063 + SILA 1 5.8 5.0 [1:5.0 x 103] -0.1
INH 0.063 + SILA 2 5.8 3.6 [1:5.4 x 102] -1.5 
INH 0.063 + SILA 4 5.8 2.0 0 -2.4* 
RIF 0.015 + SILA 1 5.6 5.1 0 -0.2
RIF 0.015 + SILA 2 5.6 4.6 0 -0.7 
RIF 0.015 + SILA 4 5.6 2.5 0 -1.7 
MXF 0.031 + SILA 1 5.8 5.2 0 +0.3
MXF 0.031 + SILA 2 5.8 4.7 0 -0,2 
MXF 0.031 + SILA 4 5.8 3.6 0 -0.3 
AMK 0.25 + SILA 1 5.9 6.7 0 +2.0
AMK 0.25 + SILA 2 5.9 5.8 0 +1.1 
AMK 0.25 + SILA 4 5.9 4.0 0 -0.1 
Cultures of BE-1585 were exposed to SILA-421 for 6 days at 37°C under shaking conditions At day 6, samples were taken 
and quantitative cultures were performed on drug free and drug containing solid media.
Δ Log10 CFU/mL is determined as: Log10 CFU/mL of a combination minus the Log10 CFU/mL of the most active single 
drug of the combination.
Resistant mutants are presented as the mutation rate, determined as: the amount of resistant mutants divided by the total 
amount of bacteria cultured on day 6.
* Synergy, ND = Not determined, LLQ = Lower Limit of Quantification, INH = isoniazid, RIF = rifampicin, MXF = moxi-
floxacin, AMK = amikacin
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(0.25 mg/L) an antagonistic effect (∆log 2 increase in mycobacterial load) between the 
compounds was observed.
In vitro, time-kill kinetics towards Be-1585-h526Y
The activity of SILA-421 in combination with 128 and 256 mg/L rifampicin against the 
rifampicin resistant isogenic BE-1585-H526Y, is presented in table 2 and figure 2. The com-
bination of rifampicin 64 mg/L and SILA-421 is presented in table 1 of the supplementary 
Table 2. Effect of SILA-421 on the bactericidal activity of rifampicin against BE-1585-H526Y
TB-drugs tested (mg/L) Log10 CFU/mL at day 0
LLQ = 0.7
Log 10CFU/mL at day 6
LLQ = 0.7
Δ Log10 CFU/mL between 
drug combination and most 
active single drug at day 6
Control 5.6 7.1
RIF 128 5.6 4.2
RIF 256 5.6 3.4 
SILA 2 5.6 5.8
SILA 4 5.6 3.6 
RIF 128 + SILA 2 5.6 3.1 -1.1
RIF 128 + SILA 4 5.6 1.5 -2.1* 
RIF 256 + SILA 2 5.6 3.3 -0.1
RIF 256 + SILA 4 5.6 <LLQ -3.4* 
Cultures of BE-1585-H526Y (rifampicin-resistant) were exposed to SILA-421 and RIF for 6 days at 37°C under shaking 
conditions. At day 6, samples were taken and quantitative cultures were performed on solid media.
Δ Log10 CFU/mL is determined as: Log10 CFU/mL of a combination minus the Log10 CFU/mL of the most active single 
drug of the combination.
* Synergy, LLQ = Lower Limit of Quantification, RIF = rifampicin
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figure 2. Concentration- and time-dependent bactericidal effect of SILA-421 against Mycobacterium tuberculosis BE-1585-
H526Y (rifampicin-resistant). Cultures of actively replicating Mycobacterium tuberculosis (starting at 5.6 x 105 CFU/mL) were 
exposed to 4 mg/L SILA-421 and to 256 mg/L rifampicin as single drug or in combination for 6 days at 37°C under shaking 
conditions. After 3 and 6 days of drug exposure, samples were taken and quantitative cultures were performed. The dotted 
horizontal line is the lower limit of quantification of log CFU/ml.
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data. The addition of SILA-421 to rifampicin 64 mg/L resulted in enhanced mycobacterial 
killing, where the addition of 4 mg/L SILA-421 to 128 and 256 mg/L rifampicin resulted in 
enhanced mycobacterial killing and a synergistic effect was obtained with both rifampicin 
concentrations. Even complete elimination of rifampicin-resistant Mycobacterium tubercu-
losis could be achieved after exposure to a combination of SILA-421 with rifampicin.
In vivo therapeutic efficacy
Zalatnai et al., showed that mice could tolerate 10 mg/kg SILA-409 for 34 days, SILA-409 
and SILA-421 are closely related compounds and very similar to each other 10, 21. Based on 
this study we started a small experiment to assess a maximum tolerated dose (MTD), in 
order to evaluate the novel combination of SILA-421 and a standard TB regimen in our 
mouse TB model. We observed that our mice when treated with SILA-421 (5 mg/kg or 
10 mg/kg) in combination with HRZ did not show toxic side effects, although some mice 
receiving 10 mg/kg appeared agitated the first 2 weeks of treatment. Based upon these 
observations on the behavior and survival of the mice we used 10 mg/kg SILA-421 for 
further experiments.
At two weeks after inoculation with the BE-1585 strain, mice had developed a TB 
infection including extra-pulmonary dissemination. Untreated control animals became 
moribund by three weeks after infection and were euthanized. To assess the therapeutic 
efficacy of the combination SILA-421 (10 mg/kg) and HRZ, mice were treated for 13 weeks 
(figure 3). After 13 weeks of treatment all lungs were culture-positive in the group of mice 
receiving HRZ only, whereas in the group of mice receiving HRZ + SILA-421 lungs of 2 out 
of 4 mice were culture-positive with very small numbers of Mycobacterium tuberculosis, 
showing no significant difference at this time point. After 13 weeks post-treatment all 
mice showed relapse/regrowth of Mycobacterium tuberculosis. From the spleen (data not 
shown), Mycobacterium tuberculosis was never cultured after 13 weeks treatment in both 
groups of mice. At 13-weeks post-treatment, 10 out of 12 mice in the HRZ only group 
were culture-positive, whereas 11 out of 12 mice in the HRZ+SILA-421 group were culture-
positive.
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discussiOn
The aim of this study was to evaluate whether SILA-421 had activity in itself and addition-
ally could improve the activity and efficacy of currently used TB-drugs. By using time-kill 
kinetics, we were able to show the time- and/or concentration-dependent activity of 
SILA-421 as single drug, as well as in combination with isoniazid, rifampicin, moxifloxacin 
or amikacin. We found for SILA-421 as single drug exposure a time- and concentration-
dependent effect on Mycobacterium tuberculosis of the Beijing genotype. An important 
observation was that SILA-421 is bactericidal, after 6 days exposure to 8 mg/L SILA-421 
Mycobacterium tuberculosis cultures were negative, whereas by increasing the concen-
tration to 16 mg/L complete mycobacterial elimination after just 1 day of exposure was 
achieved. SILA-421 at 4 mg/L resulted in inhibition of mycobacterial growth after 6 days 
of exposure. This observation expands upon prior studies of Martins et al. and Simons et 
al.11, 12, in which they present MIC values of SILA-421 in a range of 2 to 16 mg/L. Resistance 
of Mycobacterium tuberculosis against SILA-421 was not assessed, because no clinical 
breakpoints are available for SILA-421 to define resistance. Further research is necessary to 
investigate whether mycobacteria can be selected which are able to grow in the presence 
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figure 3. Mycobacterial load in infected lungs after treatment with HRZ (open bars) or a combination of HRZ and 
SILA-421 (chequered bars) of mice with TB caused by BE-1585. Treatment was started 2 weeks after infection (grey bars). 
Results are expressed as median ± range (error bars) of the colony forming units (CFU) per total lung. Numbers above bars 
are the numbers of culture-positive mice out of total number mice.
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of high concentrations SILA-421 and characterize them for example with whole genome 
sequencing.
To our knowledge this is the first study providing evidence that SILA-421 can potenti-
ate the activity of isoniazid in vitro. Furthermore, the emergence of isoniazid-resistance 
after exposure to isoniazid as single drug can be prevented by the addition SILA-421. 
When SILA-421 is combined with rifampicin we also observe substantial increased killing 
of Mycobacterium tuberculosis. Both these findings are important results in view of the 
urgent need of new drugs, that enhance the therapeutic efficacy of existing TB-drugs 
for the treatment of drug susceptible TB and prevention of MDR-TB. Given the fact that 
similar results are obtained when thioridazine was used as a compound to enhance the 
effect of TB-drugs 8, our results support the hypothesis that both isoniazid and rifampicin 
can be enhanced by adding an EPI such as SILA-421 9, 10 used in the present study. Also the 
antagonistic effect of SILA-421 on amikacin is interesting. A possible explanation for this 
observation can be the binding of SILA-421 to amikacin which may result in diminished 
binding of amikacin to the 30S ribosome, or limited influx of amikacin into the cell. Nor-
mally, amikacin binds to the 30S ribosome and as such interferes with the protein synthesis 
22, however, the mechanism resulting in antagonism between amikacin and SILA-421 is 
unclear.
We could not demonstrate enhancement of the therapeutic efficacy of the HRZ regimen 
when combined with SILA-421 in the treatment of TB in mice. After 13 weeks of HRZ 
treatment all mice were Mycobacterium tuberculosis culture positive whereas 2 out of 4 
mice were Mycobacterium tuberculosis culture negative after HRZ + SILA-421 combination 
treatment. However, all mice exhibited regrowth/relapse of TB infection after a 13 weeks 
post-treatment period. Possibly the relatively short treatment period of 13 weeks only is 
too ambitious for achieving superior therapeutic efficacy. Further research is needed to 
investigate the additional value of SILA-421 in long-lasting treatment periods. A limitation 
of the present study is the relatively low number of animals, which does not allow us to 
investigate the efficacy of more treatment schedules or do a proper study to determine the 
MTD. Another limitation is that we could not perform a pharmacokinetic study, due to the 
lack of a proper bio-analytical methods. In addition, a bio-analytical detection method such 
as a HPLC-MS should be developed and a pharmacokinetic study should be performed to 
assess the actual plasma and tissue concentrations of SILA-421 that are achieved after 
a dose of 10 mg/kg in mice, and to compare the (active, i.e. protein-unbound) in vivo 
concentrations to those studied in our in vitro time-kill kinetics experiments. In 2009, 
Martins et al. already demonstrated that SILA-421 at a concentration of 0.1 mg/L is able to 
kill intracellular Mycobacterium tuberculosis12. However, the translational value of this in 
vitro observation to the in vivo TB infection is difficult as data on the availability of SILA-421 
in mice at the site of infection is currently not available.
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Our in vitro time-kill kinetics assays and in vivo therapeutic efficacy experiments with 
SILA-421 largely focused on drug susceptible TB strains, but we also assessed the time-
kill kinetics of SILA-421 in combination with rifampicin against the rifampicin-resistant 
BE-1585-H526Y strain. In a previous study, we performed a genome-wide transcriptional 
profile analysis with micro-array, and showed that rifampicin-resistant Mycobacterium 
tuberculosis exposed to 256 mg/L still exhibited a response. Several genes involved in efflux 
and transport appeared up-regulated in the rifampicin-resistant mutants compared to the 
rifampicin-susceptible strain 14. We therefore hypothesized that by inhibiting the efflux 
of rifampicin following addition of SILA-421, we might be able to kill rifampicin-resistant 
Mycobacterium tuberculosis. In the present study we show that exposure of a rifampicin-
resistant Mycobacterium tuberculosis isolate to SILA-421 and high concentrations of 
rifampicin results in synergy and complete elimination of the culture is achieved. With the 
currently used rifampicin doses, an active (i.e. protein-unbound) rifampicin concentration 
of 256 mg/L seems clinically not achievable. Nevertheless, de Steenwinkel et al. showed in 
the same mouse TB model that high doses of rifampicin up to 160 mg/kg/day in combina-
tion with isoniazid and pyrazinamide during a 2 months treatment period were tolerated, 
and the application of these high rifampicin dosage schedules allowed reduction of the 
treatment period from 6 months to 2 months, without relapse of infection 20. Boeree et al. 
showed in TB patients that rifampicin doses up to 35 mg/kg were well tolerated 23. These 
combined results in TB infected mice and TB patients open new possibilities for studies 
investigating the capacity of high doses of rifampicin in combination with an EPI such as 
SILA-421 in the treatment of MDR-TB. To support clinical studies in this respect, a mouse 
MDR-TB model should be developed and the therapeutic efficacy of combinations of SILA-
421, or other EPIs and higher doses of rifampicin should be further evaluated.
Summarizing, we demonstrated in vitro that SILA-421 in itself has bactericidal activ-
ity towards rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis 
strains of the Beijing genotype. We show that SILA-421 enhanced the mycobacterial killing 
capacity of isoniazid and rifampicin, even in the rifampicin-resistant strain. Unfortunately, 
enhanced therapeutic efficacy following addition of SILA-421 to the currently used HRZ 
treatment schedule in our mouse TB model was not demonstrated.
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suPPlemenTarY daTa
Table s1. Effect of SILA-421 on the bactericidal activity of RIF against BE-1585-H526Y.
TB-drugs tested (mg/L) Log10 CFU/mL at day 0
LLQ = 0.7
Log 10CFU/mL at day 6
LLQ = 0.7
Δ Log10 CFU/mL between 
drug combination and most 
active single drug at day 6
Control 5.6 6.8
RIF 64 5.6 5.0
SILA 2 5.6 5.8
SILA 4 5.6 3.6 
RIF 64 + SILA 2 5.6 3.5 -1.5
RIF 64 + SILA 4 5.6 2.2 -1.4 
Cultures of BE-1585-H526Y (RIF-resistant) were exposed to SILA-421 and RIF for 6 days at 37°C under shaking conditions. 
At day 6, samples were taken and quantitative cultures were performed on solid media.
Δ Log10 CFU/mL is determined as: Log10 CFU/mL of a combination minus the Log10 CFU/mL of the most active single 
drug of the combination.
* Synergy, RIF = rifampicin
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aBsTracT
The current treatment of tuberculosis (TB) is complicated by the emergence of multi-drug 
resistant TB (MDR-TB). As a result, there is an urgent need for new powerful TB regimens 
and novel strategies. In this study we aim to potentiate a moxifloxacin – linezolid backbone 
as treatment for MRD-TB with efflux pump inhibitors verapamil and timcodar as well as 
with drugs that act on the mycobacterial cell wall stability like colistin and SQ109.
Using a time kill kinetics assay the activity of moxifloxacin, linezolid, verapamil, timcodar, 
colistin and SQ109 as single drugs against Mycobacterium tuberculosis was evaluated. In 
addition the activity of the moxifloxacin + linezolid backbone in combination with one of 
the potentiator drugs was assessed.
As little as 0.125 mg/L moxifloxacin achieved 99% killing of Mycobacterium tuber-
culosis after 6 days of exposure. Linezolid showed moderate killing but 99% killing was 
not achieved. Verapamil, timcodar and colistin only resulted in killing with the highest 
concentrations tested but 99% killing was not achieved. SQ109 resulted in complete 
elimination after 1 day of exposure to 256 mg/L and in 99% elimination after 6 days of 
exposure to 1 mg/L SQ109. Furthermore, we found that colistin added to the backbone 
resulted in increased elimination. Verapamil, timcodar and SQ109 showed no added value 
to the moxifloxacin + linezolid backbone. Our finding that colistin potentiates the activity 
of the moxifloxacin + linezolid backbone against Mycobacterium tuberculosis suggests its 
potential role in further studies on the applicability of a moxifloxacin + linezolid treatment 
of MDR-TB.
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inTrOducTiOn
Tuberculosis (TB) is the leading cause of death due to an infectious disease worldwide 1, 2. 
Treatment of this dreadful disease is complicated by the emergence of multi-drug resistant 
TB (MDR-TB), occurring in about half a million new TB cases annually 2. The current treat-
ment of MDR-TB is long and complex, with several drugs to be used in combination, result-
ing in patient non-compliance, inadequate response in 50% of patients and emergence 
of further drug resistance 2. Therefore, every effort should be made to improve MDR-TB 
treatment.
Moxifloxacin, one of the most potent fluoroquinolones, is the cornerstone of MDR-TB 
treatment in many countries, together with levofloxacin in others. In addition linezolid, 
one of the oxazolidinones, shows excellent efficacy but also toxicity in MDR-TB treatment 
3. The potential of oxazolidinones is underlined by the ongoing development of structural 
analogues to linezolid as TB drugs 4, 5.
As to adjuvant strategies in MDR-TB treatment, accumulating evidence shows that 
there is a significant role for mycobacterial efflux pumps in the extrusion of TB drugs and 
emergence of resistance towards different TB-drugs 6, including fluoroquinolones and oxa-
zolidinones 7. Inactivation of these mycobacterial efflux pumps with efflux pump inhibitors 
(EPI) may increase the intrabacterial concentration of TB-drugs, thereby increasing efficacy 
while avoiding high systemic exposures associated with adverse effects. This concept may 
even prevent or reverse resistance 8, 9. Recently, a combination of moxifloxacin, linezolid 
and the EPI thioridazine resulted in a favourable response in patients with extensively-drug 
resistant TB (XDR-TB), suggesting the potential of EPIs as treatment adjuncts for the treat-
ment of Mycobacterium tuberculosis infections 10.
Verapamil is a calcium channel antagonist, recognized to inhibit bacterial efflux pumps 
and has been shown to accelerate mycobacterial killing in mice infected with Mycobacte-
rium tuberculosis and it decreased relapse rates with shortened treatment regimens 11-13. It 
also reduced the mycobacterial drug tolerance induced in the intracellular department in 
macrophages as well as in zebrafish granuloma-like lesions 14.
Timcodar has also been described as a bacterial efflux pump inhibitor 15. Timcodar, used 
as a single agent, has in vitro a moderate effect against Mycobacterium tuberculosis in 
liquid cultures 16. However, this effect is more pronounced in a Mycobacterium tuberculo-
sis-infected macrophage assay 16. Additionally, timcodar added to rifampicin consistently 
improved the clearance of Mycobacterium tuberculosis in infected mice 16.
A different strategy to increase intrabacterial drug concentrations and improve the 
effect of TB drugs is to target the stability of the mycobacterial cell wall. Colistin is an 
old antimicrobial and part of the polymyxin family acting primarily on the cell wall by 
causing changes in the permeability of the plasma membrane of gram-negative bacteria 17. 
Recently, it has been shown that colistin potentiates the activity of isoniazid and amikacin 
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against Mycobacterium tuberculosisinvitro and also prevented the emergence of isoniazid 
resistance 18.
SQ109 is a TB drug candidate that was identified by creating more potent analogues 
of ethambutol, but it demonstrated a different mode of action compared to ethambutol 
19. SQ109 decreases the incorporation of mycolic acids into the mycobacterial cell wall, 
thereby targeting the mycobacterial cell wall 20. SQ109 is also an EPI at least to human 
efflux pumps 21. It demonstrated synergistic interaction with isoniazid and rifampicin as 
well as with moxifloxacin 20.
In this study we focus on combining moxifloxacin and linezolid as a proposed fluoro-
quinolone-oxazolidinone backbone for the treatment of MDR-TB. We aimed to further 
potentiate the anti-mycobacterial effect of this backbone by using potentiator drugs 
verapamil and timcodar as EPIs, and by colistin and SQ109, drugs that target the stability 
of the mycobacterial cell wall.
maTerials and meThOds
materials
Moxifloxacin, linezolid and verapamil were all purchased from Sigma Chemical Co, St. 
Louis, MO, USA, and were dissolved in water. Colistin sulphate (Hospital Pharmacy; 
Rotterdam, The Netherlands) was dissolved in water, Timcodar (Vertex Pharmaceuticals 
Incorporated, Boston, MA, USA) was dissolved in DMSO. SQ109 (Sequella Inc., Rockville, 
MD, USA) was dissolved in water.
Mycobacterium tuberculosis suspensions for the in vitro assays were cultured in 
Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI, USA), supplemented with 10% 
oleic acid-albumin-dextrose-catalase enrichment (OADC, Baltimore Biological Laboratories, 
Baltimore, MD, USA), 0.5% glycerol (Scharlau Chemie S.A, Sentmenat, Spain) and 0.02% 
Tween 20 (Sigma Chemical Co, St. Louis, MO, USA), under shaking conditions at 96 rpm at 
370C. All cultures on solid media were grown on Middlebrook 7H10 agar (Difco), supple-
mented with 10% OADC and 0.5% glycerol for 28 days at 37°C with 5% CO2.
Bacterial strain
The Mycobacterium tuberculosis genotype strain Beijing VN 2002-1585 (BE-1585) with a 
MIC of 0.25 mg/L moxifloxacin and 1 mg/L of linezolid was used 22, 23. MICs were deter-
mined using CLSI standards 24.
In vitro time-kill kinetics
The activities of moxifloxacin, linezolid, verapamil, timcodar, colistin and SQ109 were 
first determined as single compounds in liquid media, as described previously 25. In short, 
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cultures of actively replicating (exponential-phase) BE-1585 were exposed to increasing 
concentrations of the drugs at 370C and 96 rpm. Concentrations of moxifloxacin and 
linezolid tested were based on the maximum concentration of unbound drugs which can 
be achieved in patients (fCmax). Ranges were 4x to 1/256x the fCmax. Samples (200 µL) were 
taken on day 1, 2, 3 and 6, provided that the mycobacterial suspension did not show 
visible aggregation. Samples were centrifuged at 14.000xg, washed with PBS to avoid drug 
carry-over and sub-cultured on drug-free solid media. After 28 days of incubation at 370C 
with 5% CO2 the number of CFU was counted. To assess selection of moxifloxacin-resistant 
or linezolid-resistant bacteria, samples were sub-cultured on drug-containing solid media. 
The drug concentrations in the subculture plates were 4-fold the critical concentrations, 
i.e. 2 mg/L of moxifloxacin or 8 mg/L of linezolid as reported by the CLSI 24.
Next, the time-kill kinetics of drug combinations with exponential-phase BE-1585 were 
determined for both moxifloxacin and linezolid as single drugs in combination with the po-
tentiator drugs verapamil, timcodar, colistin or SQ109 and for the moxifloxacin + linezolid 
backbone in combination with the potentiator drugs. A concentration of moxifloxacin of 
0.031 mg/L (1/64 x fCmax) and a linezolid concentration of 0.069 mg/L (1/16 x fCmax) were 
selected based on results in the single drug experiments. These concentrations resulted 
in a mycobacterial load on day 6 that deviated no more than 1.5 log compared to day 0. 
Similarly, the concentrations of potentiator drugs selected for these experiments resulted 
a limited change in a mycobacterial load on day 6 compared to day 0 in the single drug 
experiments. Verapamil concentrations of 16, 64 and 256 mg/L; timcodar concentrations 
of 4, 16 and 64 mg/L; colistin concentrations of 16, 64 and 256 mg/L and SQ109 concen-
trations of 0.063, 0.25 and 1 mg/L were added to the moxifloxacin + linezolid backbone.
All time-kill kinetic assays were performed in duplicate. The lower limit of quantification 
(LLQ) was 5 CFU (Log 0.7). Emergence of resistance to moxifloxacin or linezolid was tested 
by sub-culturing of samples on drug-containing solid media.
endpoints for assessment of anti-TB drug combinations
The two endpoints of this experiment were drug synergy and the prevention of the emer-
gence of drug resistance. Synergistic activity of a 2 or 3-drug combination was determined 
after 6 days of exposure and was defined as ≥ 100-fold (∆log 2) decrease in mycobacterial 
load in the 2 or 3-drug combination compared to the mycobacterial load achieved with 
the potentiator drug as single agent and moxifloxacin or linezolid as single agent and in 
case of a 3-drug combination the backbone of moxifloxacin and linezolid. The definition of 
synergy was also met when a 2 or 3-drug combination achieved mycobacterial elimination 
which was not achieved during exposure to moxifloxacin or linezolid as single agents or the 
backbone of moxifloxacin and linezolid 8, 18, 26.
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resulTs
single-drug exposure of moxifloxacin and linezolid
The bactericidal activity of moxifloxacin as single-drug exposure is illustrated in figure 1A. 
Moxifloxacin showed a concentration dependent killing against BE-1585. A concentration 
of 0.125 mg/L moxifloxacin was needed to achieve 99% killing. However, there seemed 
to be an optimum concentration (0.5 mg/L) beyond which an increase in concentration 
does not result in more efficient killing of Mycobacterium tuberculosis. A concentration of 
8 mg/L of moxifloxacin even resulted in a 1.5 Log less effective killing of Mycobacterium 
tuberculosis after 6 days of exposure. The concentration of the fCmax (2 mg/L) resulted in an 
almost 3.5 Log decrease compared to the control after 6 day of exposure.
In figure 1B the bactericidal activity of linezolid as single-drug exposure is illustrated. 
Linezolid showed a moderate activity against Mycobacterium tuberculosis, as the concen-
tration of the fCmax (11 mg/L) resulted in a 1.5 Log decrease after 6 days of exposure. With 
the concentrations tested, 99% killing was not achieved with linezolid.
Both moxifloxacin as well as linezolid resistant Mycobacterium tuberculosis were not 
found in these experiments.
single-drug exposure of the potentiator drugs verapamil, timcodar, 
colistin and sQ109
The activity of verapamil (2A), timcodar (2B), colistin (2C) and SQ109 (2D) as single-drug 
exposures is presented in figure 2. Exposure to verapamil or colistin only resulted in kill-
ing of Mycobacterium tuberculosis with the highest concentrations tested, 99% killing of 
Mycobacterium tuberculosis was not achieved. Timcodar showed almost no bactericidal 
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figure 1. Bactericidal activity of moxifloxacin and linezolid as single drug against BE-1585. Cultures were exposed to 
2-fold increasing drug concentrations based on the fCmax for 6 days. On days 1, 2, 3 and 6, samples were collected for cfu 
counting. Data are presented as median with ranges (n=2). Dashed line represents the drug concentration used in the 
combination experiments.
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activity. Due to precipitation of timcodar in the broth, 64 mg/L was the highest concentra-
tion possible to test. SQ109 showed a clear concentration-dependent anti-mycobacterial 
activity. Exposure to 64 mg/L SQ109 resulted in 99% killing within one day and 256 mg/L 
resulted even in complete elimination of Mycobacterium tuberculosis. After 6 days of 
exposure, 1mg/L of SQ109 was needed to achieve 99% killing.
combined exposure of the moxifloxacin or linezolid with the potentiator 
drugs
Data obtained combining either moxifloxacin or linezolid with the potentiator drugs is 
presented in the supplementary data, table S1. Addition of verapamil or timcodar to moxi-
floxacin or linezolid does not result in an improved or decreased activity of moxifloxacin 
of linezolid. The addition of colistin to moxifloxacin or linezolid resulted in some improved 
activity of both moxifloxacin as well as linezolid, however, the results does not met the 
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figure 2. Bactericidal activity of the 4 potentiator drugs (verapamil, timcodar, colistin and SQ109) against BE-1585. 
Cultures were exposed to 2-fold increasing drug concentrations for 6 days. On days 1, 2, 3 and 6, samples were collected 
for cfu counting. Data are presented as median with ranges (n=2).
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synergy criteria. The results of the addition of SQ109 to both moxifloxacin and linezolid 
are diverse, in the lowest concentration SQ109 the combination is more active against My-
cobacterium tuberculosis compared to moxifloxacin and linezolid as single drug. Whereas 
by increasing the SQ109 concentration this effect is no longer observed in combination 
with moxifloxacin, furthermore, in combination with linezolid these higher concentrations 
of SQ109 resulted in a decreased activity of the combination compared to the most active 
single drug.
combined exposure of the moxifloxacin + linezolid backbone with the 
potentiator drugs
As shown in table 1, addition of verapamil to the backbone showed no improved or 
decreased bactericidal activity. Addition of timcodar to the backbone resulted in limited 
improvement of the bactericidal activity. However, synergy, defined as ≥ 100-fold (∆log 2) 
decrease in mycobacterial load in the 3-drug combination compared to the mycobacterial 
load achieved with the potentiator drug as single agent or the backbone of moxifloxacin 
and linezolid, was not achieved. Similarly, addition of colistin to the backbone resulted in 
increased mycobacterial killing; addition of 256 mg/L colistin showed a 2.6 Log difference 
compared to the moxifloxacin + linezolid backbone. However, only a 1.4 Log difference 
was observed when the 3-drug combination was compared to colistin as single drug. As 
a result, the 3 drug combination did not reach the synergy criteria. The combination of 
SQ109 with the backbone did not improve bactericidal activity either and it even resulted 
Table 1. The anti-mycobacterial effect of the moxifloxacin + linezolid backbone in combination with a potentiator drug. 
Abbreviations: MXF: moxifloxacin, LZD: linezolid, VP: verapamil, TIM: timcodar, CST: colistin
TB-drugs tested (mg/L) Log10 CFU/mL at day 0
LLQ = 0,7
Log10 CFU/mL at day 6
LLQ = 0,7
ΔLog10 CFU/mL between 
drug combination and 
most active single drug/
combination at day 6
Control 5.4 (5.1 - 5.6) 7.1 (7.0 - 7.5) -
MXF+LZD 5.5 (5.5 - 5.6) 5.1 (5.0 - 5.2) -
VP 16 7.3 (7.2 - 7.4) - 
VP 64 6.0 (5.9 - 6.0) - 
VP 256 4.0 (3.9 - 4.1) - 
MXF + LZD + VP 16 5.4 (5.3 - 5.5) 0.3 
MXF + LZD + VP 64 5.2 (5.2 - 5.2) 0.1 
MXF + LZD + VP 256 4.1 (4.0 - 4.2) 0.1 
MXF+LZD 5.2 (5.1 - 5.3) 5.5 (5.1 - 5.8) -
TIM 4 7.4 (7.2 - 7.5) - 
TIM 16 6.4 (6.4 - 6.4) - 
TIM 64 5.6 (5.1 - 6.1) - 
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in decreased activity. Addition of 0.25 mg/L SQ109 resulted in a 0.8 Log higher mycobacte-
rial load compared to 0.25 mg/L SQ109 as single drug after 6 days of exposure. Neither 
moxifloxacin nor linezolid resistant Mycobacterium tuberculosis were not found in these 
experiments.
discussiOn
To treat MDR-TB, options are limited with isoniazid and rifampicin no longer available 
2. Therefore other, less effective, more toxic and more costly second-line TB drugs are 
combined, leading to a prolonged treatment time and successful treatment in only 50% 
of patients 2, 27.
Fluoroquinolones and especially moxifloxacin have proven to be highly effective in the 
treatment of susceptible TB (although they did not achieve treatment shortening 28), and 
they are of great value in the treatment of MDR-TB 29. In the present study we show using 
time-kill kinetics that 99% killing of Mycobacterium tuberculosis can be achieved with a 
moxifloxacin concentration below the fCmax, thereby confirming its potential. However, 
Table 1. The anti-mycobacterial effect of the moxifloxacin + linezolid backbone in combination with a potentiator drug. 
Abbreviations: MXF: moxifloxacin, LZD: linezolid, VP: verapamil, TIM: timcodar, CST: colistin (continued)
TB-drugs tested (mg/L) Log10 CFU/mL at day 0
LLQ = 0,7
Log10 CFU/mL at day 6
LLQ = 0,7
ΔLog10 CFU/mL between 
drug combination and 
most active single drug/
combination at day 6
MXF + LZD + TIM 4 5.1 (5.0 - 5.2) -0.4 
MXF + LZD + TIM 16 5.1 (4.9 - 5.2) -0.4 
MXF + LZD + TIM 64 4.9 (4.6 - 5.2) -0.6 
MXF+LZD 5.2 (5.1 - 5.3) 5.5 (5.1 - 5.8) -
CST 16 7.3 (7.2 - 7.4) - 
CST 64 5.2 (4.8 - 5.6) - 
CST 256 4.3 (3.8 - 4.8) - 
MXF + LZD + CST 16 4.8 (5.4 - 4.1) -0.7 
MXF + LZD + CST 64 4.3 (4.0 - 4.6) -0.9 
MXF + LZD + CST 256 2.9 (2.2 - 3.6) -1.4 
MXF+LZD 5.5 (5.5 - 5.6) 5.1 (5.0 - 5.2) -
SQ109 0.063 7.3 (7.3 - 7.3) - 
SQ109 0.25 3.6 (3.5 - 3.7) - 
SQ109 1 2.3 (2.1 - 2.4) - 
MXF + LZD + SQ109 0.063 4.7 (4.5 - 4.8) 0.4 
MXF + LZD + SQ109 0.25 4.4 (4.1 - 4.7) 0.8 
MXF + LZD + SQ109 1 3.0 (2.8 - 3.1) 0.7 
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using moxifloxacin we repeatedly found that increasing the concentration leads to an 
optimum effect reached at 0.5 mg/L, whereas higher concentrations up to 64 mg/L where 
less bactericidal, but by increasing concentrations up to 128 and 256 mg/L complete 
elimination can be achieved in vitro (data no shown). This phenomenon was first described 
by Eagle et al. in 1948 for penicillin against various types of bacteria and is called the 
paradoxical effect, also known as the “Eagle effect” 30. This paradoxical effect is also 
described for several fluoroquinoles 31, and later by Drlica et al. using ciprofloxacin against 
Mycobacterium bovis in 1996 30, 32. This paradoxical effect is possibly explained by the 
observation that at high drug concentrations, synthesis of RNA and proteins, both of which 
are necessary for killing is inhibited 33, 34.
Linezolid is currently a group 5 anti-TB drug, i.e. not recommended for routine use in 
the treatment of MDR-TB. However, in vitro and in vivo studies with linezolid have shown 
good activity against Mycobacterium tuberculosis, and the current study showed moderate 
activity against this mycobacterium. Also off-label, clinical use as compassionate drug has 
shown that when linezolid is incorporated in the treatment of MDR-TB patients it might 
improve outcome 10, 35-38.
We aimed to combine moxifloxacin and linezolid with a companion drug to increase 
their efficacy. It appeared that the EPIs verapamil and timcodar did not improve the in vitro 
activity of moxifloxacin as single drug or the combination of moxifloxacin and linezolid. 
These results contrast with data presented by Adams et al. who showed a reduced mac-
rophage induced tolerance of moxifloxacin when verapamil was added 14. This effect was 
also observed when isoniazid, rifampicin and bedaquiline were combined with verapamil. 
A reduced tolerance of linezolid when combined with verapamil was not observed, which 
is in line with results in the current study. Gupta et al. showed using a murine TB model, 
acceleration of bacterial elimination when verapamil was added to the standard regimen 
of isoniazid, rifampicin and pyrazinamide 12. Addition of verapamil also resulted in signifi-
cantly decreased relapse rates. Furthermore, verapamil increased the bactericidal efficacy 
of sub inhibitory doses of bedaquiline in TB infected BALB/c mice 13. In a different study 
Gupta et al. showed that the MIC of clofazamine and bedaquiline against Mycobacterium 
tuberculosis decreases by 8-fold when verapamil was added. However, verapamil did 
not contribute to a MIC reduction of moxifloxacin 11, which is comparable with the data 
presented in this study.
Our data of timcodar are approximately similar to that of Grossman et al., who also 
found no additive effect of timcodar in combination with moxifloxacin and linezolid 
when used in broth cultures 16. In an acute, high-dose TB infection model they found 
a statistically significant reduction of the mycobacterial load when mice where treated 
with a combination of bedaquiline and timcodar compared to bedaquiline as single drug. 
However, this effect was not observed when moxifloxacin and sutezolid where combined 
with timcodar 16.
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A possible explanation for the lack of improvement of the activity of the moxifloxacin + 
linezolid backbone when verapamil or timcodar were added in vitro, is that verapamil and 
timcodar do not inhibit the mycobacterial transporters that are accountable for the trans-
port of moxifloxacin or linezolid through the bacterial cell. However, in macrophages and 
mice, verapamil can reduce the transmembrane potential and thereby inhibit eukaryotic 
transporters 13, 14, possibly leading to an increased moxifloxacin or linezolid concentration 
inside the macrophages. Therefore an in vivo study using a murine TB model studying the 
role of verapamil in combination with the moxifloxacin + linezolid backbone is warranted.
The most striking result of this study was the effect of colistin on the moxifloxacin + 
linezolid backbone. As single drug, colistin displayed limited activity, as also shown by 
Bax et al. 18, but it enhanced the activity of both moxifloxacin and linezolid as single 
drug as well as the activity of the moxifloxacin + linezolid backbone. Although synergy 
criteria were not met, with the 3 concentrations tested we showed 1.4-2.6 log CFU/mL 
increased killing when colistin was added to the moxifloxacin + linezolid backbone. A 
drawback of the effect observed with colistin is that only high concentrations of colistin 
can potentiate the moxifloxacin + linezolid backbone, i.e. concentrations systemically not 
achievable in patients. However, administration of colistin via inhalation deserves attention 
as several (pre-)clinical studies have shown dramatically increased colistin concentrations in 
pulmonary epithelial lining fluid and in sputum 39, 40.
Also, the observation that SQ109 in combination with moxifloxacin plus linezolid does 
not increase the efficacy of the backbone is very interesting, it even limited the activity 
of the backbone. The same is observed in the combination of linezolid with SQ109, the 
higher the concentration of SQ109, the less active the combination is. A possible expla-
nation could be that SQ109 exerts its effect against actively replicating Mycobacterium 
tuberculosis, whereas linezolid as a protein-synthesis inhibitor might growth arrest the 
bacteria and thereby preclude the effect of SQ109. As single drug we showed that SQ109 
is very active against Mycobacterium tuberculosis, with concentrations far below the Cmax 
observed in TB-patients treated with SQ109 41. Heinrich et al. recently showed that SQ109 
is safe to use for at least 14 days in TB patients, but it was not active as single drug or 
in combination with rifampicin in these patients over the first 14 days of treatment 41. In 
addition, in a clinical study recruitment of patients was stopped in the SQ109 containing 
treatment arms because the pre-specified efficacy thresholds were not met 42. Both the 
SQ109 containing arms also contained rifampicin and one also moxifloxacin, indicating 
that further research is needed to study the role of SQ109 as anti-TB drug.
In summary, we showed the strong bactericidal activity of moxifloxacin and SQ109 
as single drugs against Mycobacterium tuberculosis as well as the ability of colistin to 
potentiate the moxifloxacin + linezolid combination.
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Table s1. The anti-mycobacterial effect of moxifloxacin or linezolid in combination with a potentiator drug.
TB drugs tested (mg/L) Log10 CFU/mL at day 0
LLQ = 0,7
Log10 CFU/mL at day 6
LLQ = 0,7
ΔLog10 CFU/mL between 
drug combination and most 
active drug at day 6
Control 5.4 (5.2 - 5.5) 7.5 (7.4 - 7.6) -
MXF 0.031  6.7 (6.7 - 6.7) - 
LZD 0.69  5.6 (5.4 - 5.7) - 
VP 16 7.4 (7.3 - 7.4) -
VP 64 6.7 (6.6 - 6.7) - 
VP 256 4.3 (4.2 - 4.3) - 
MXF + VP 16 6.5 (6.5 - 6.5) -0.2
MXF + VP 64 5.9 (5.6 - 6.1) -0.6 
MXF + VP 256 4.6 (4.5 - 4.6) 0.3 
LZD + VP 16 5.8 (5.6 - 5.9) 0.2
LZD + VP 64 5.6 (5.5 - 5.6) 0.0 
LZD + VP 256 4.8 (4.5 - 5.0) 0.5 
Control 5.4 (5.2 - 5.5) 7.5 (7.4 - 7.6) -
MXF 0.031 6.7 (6.7 - 6.7) - 
LZD 0.69 5.6 (5.4 - 5.7) - 
TIM 4 7.5 (7.4 - 7.6) -
TIM 16 7.6 (7.4 - 7.7) - 
TIM 64 7.5 (7.4 - 7.5) - 
MXF + TIM 4 7.0 (6.8 - 7.1) 0.3
MXF + TIM 16 6.5 (6.4 - 6.6) -0.2 
MXF + TIM 64 6.3 (6.1 - 6.4) -0.4 
LZD + TIM 4 5.7 (5.4 - 5.9) 0.1
LZD + TIM 16 5.6 (5.4 - 5.8) 0.0 
LZD + TIM 64 5.5 (5.3 - 5.6) -0.1 
Control 5.2 (5.2 - 5.2) 7.4 (7.2 - 7.5) -
MXF 0.031  6.1 (5.8 - 6.4) - 
LZD 0.69  5.5 (5.4 - 5.5) - 
CST 16 6.9 (6.8 - 7.0) -
CST 64 5.2 (4.7 - 5.6) - 
CST 256 4.0 (3.5 - 4.5) - 
MXF + CST 16 5.7 (5.4 - 5.9) -0.4
MXF + CST 64 4.3 (4.1 - 4.4) -0.9 
MXF + CST 256 3.8 (3.4 - 4.1) -0.2 
LZD + CST 16 5.0 (5.0 - 5.0) -0.5
LZD + CST 64 4.4 (4.3 - 4.4) -0.8 
LZD + CST 256 4.2 (4.1 - 4.2) 0.2 
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Control 5.2 (5.2 - 5.2) 7.4 (7.2 - 7.5) -
MXF 0.031  6.1 (5.8 - 6.4) - 
LZD 0.69  5.5 (5.4 - 5.5) - 
SQ109 0.063 6.6 (6.4 - 6.8) -
SQ109 0.25 3.1 (3.1 - 3.1) - 
SQ109 1 2.3 (2.2 - 2.3) - 
MXF + SQ109 0.063 5.0 (4.1 - 5.8) -1.1
MXF + SQ109 0.25 3.0 (2.9 - 3.0) -0.1 
MXF + SQ109 1 2.7 (2.4 - 2.9) 0.4 
LZD + SQ109 0.063 4.5 (4.3 - 4.7) -1.0
LZD + SQ109 0.25 4.3 (4.2 - 4.3) 1.2 
LZD + SQ109 1 3.9 (3.7 - 4.0) 1.6 
Abbreviations: MXF: moxifloxacin, LZD: linezolid, VP: verapamil, TIM: timcodar, CST: colistin
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aBsTracT
The use of dried blood spot (DBS) analysis for the quantification of drug concentrations can 
reduce the number of animals used in pre-clinical drug development. In order to evaluate 
the use of DBS analysis we conducted a pharmacokinetic study in healthy mice to compare 
moxifloxacin concentrations in plasma with murine blood spots. We also determined 
the pharmacokinetic parameters to define a human equivalent dose of moxifloxacin. A 
Passing-Bablok plot showed a small positive bias for DBS versus plasma measurements and 
Bland-Altman analysis showed a small range around the mean DBS/plasma moxifloxacin 
concentration ratio. This indicates that DBS concentrations can predict plasma concentra-
tions with acceptable precision. Analyses of pharmacokinetic parameters showed that a 
200mg/kg dose of moxifloxacin in mice would approximate a human equivalent exposure, 
based on AUC values. These results suggests that DBS analysis can be used to predict 
moxifloxacin concentrations in plasma in pre-clinical murine models.
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inTrOducTiOn
Despite the recent failure of moxifloxacin to effectively shorten treatment duration of drug 
susceptible tuberculosis (TB) in recent trials 1, it remains a strong companion drug within 
novel TB drug combinations for susceptible TB 2. In addition, it is still of great value for 
multidrug-resistant TB (MDR-TB) treatment. MDR-TB requires a prolonged treatment time, 
drug treatment is expensive and yields successful response in only 50% of MDR-TB patients 
3. Preclinical studies presented promising results of moxifloxacin as part of novel regimens 
against drug resistant Mycobacterium tuberculosis 4, 5, and (as a result of such preclinical 
studies) moxifloxacin is being evaluated as part of a universal regimen for susceptible and 
MDR-TB 6.
The use of moxifloxacin in pre-clinical studies as well as its subsequent evaluation in 
novel treatment regimens in TB patients requires a clear understanding of its dose-response 
relationships. Pharmacokinetic confirmation and optimum dose finding in preclinical mod-
els may prevent suboptimal exposures in efficacy studies and avoid inaccurate comparisons 
between regimen potencies 7.
In these preclinical studies, moxifloxacin is ideally measured in small sample volumes 
allowing repeated sampling within one animal. These small blood samples can be collected 
via the tail vein with limited animal discomfort and can possibly replace blood collection via 
cardiac puncture. This would allow for a significant decrease in the number of animals used 
for pre-clinical pharmacokinetic studies, which is of ethical importance. Also more than one 
blood sample can be taken from the animals via the tail vein, this will increase the accuracy 
in PK studies. Dried blood spots (DBS) analysis in combination with high-performance 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis may permit these 
novel sampling strategies, which could possibly replace conventional sampling.
The objectives of our study were to evaluate the use of DBS analysis for measuring moxi-
floxacin concentrations in murine blood spots, as well as to identify the human equivalent 
dose (HED) of moxifloxacin.
maTerials and meThOds
animals
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les On-
cins, France). At the day of the experiments, animals were 13-15 weeks old and weighed 
20-25 gram. Experimental protocols adhered to the rules specified in the Dutch Animal 
Experimentation Act and are in concordance with the EU animal directive 2010/63/EU. The 
Institutional Animal Care and Use Committee of the Erasmus MC approved the present 
protocols (117-12-14).
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experimental set-up
A single-dose pharmacokinetic study was performed in healthy mice given oral doses of 
moxifloxacin (Sigma-Aldrich, Zwijndrecht, the Netherlands) dissolved in sterile water (50, 
100, 200 and 400 mg/kg). Mice were sacrificed by CO2 exposure and blood samples, ap-
proximately 700µl were obtained via cardiac punction (n=2 mice/dose/timepoint) at 0.25, 
0.50, 0.75, 1, 1.5, 3, 5 and 10 h after dosing. Samples were collected in microcentrifuge 
tubes with EDTA. To compare plasma analysis with DBS 40µl of blood was spotted onto 
Whatman FTA/DMPK-C cards (Whatman, Kent, UK). Cards were allowed to dry for 3 hours. 
Remaining blood was centrifuged at 10.000xg for 5 min to obtain plasma. Cards and 
plasma were frozen at -80°C.
analysis of plasma and dBs moxifloxacin concentrations
Moxifloxacin concentrations in plasma were analyzed with a LC-MS/MS assay, validated for 
human plasma, at the University Medical Center Groningen, the Netherlands 8.
Cross-validation of the assay for human plasma to murine plasma was performed by 
comparing responses of fivefold measurements of three Quality Control (QC) moxifloxacin 
samples (concentrations 0.5, 2.5 and 5.0 mg/L) in human plasma with those in murine 
plasma after analysis of all samples with the LC-MS/MS assay for human plasma. The ac-
curacy of measurement of murine samples with the assay for human samples was between 
88-97%, the within-run CV amounted to 4.0-6.2% and the LLOQ was 0.05 mg/L.
Protein-unbound (free, active) concentrations of moxifloxacin were measured in all 
samples and were obtained following ultrafiltration of plasma, to separate unbound from 
bound moxifloxacin, using Centrifree YM-T 30 kDa ultrafiltration tubes (Merck-Millipore, 
Amsterdam, the Netherlands). Clear ultrafiltrate was analyzed via LC-MS/MS.
To quantify DBS samples, a validated extraction method was used 9, 10. Extracts were 
analyzed using the same LC-MS/MS analysis method as for plasma. Cross-validation of 
the assay for human to murine DBS samples was performed by comparing responses of 
fivefold measurements of three QC moxifloxacin DBS samples (concentrations 0.5, 2.5 and 
5 mg/L) in human blood with those in murine blood (40 µL blood spots) after analysis of 
all samples with the LC-MS/MS assay for human DBS samples. Accuracy of measurement 
of murine DBS samples with the assay for human DBS samples was between 123-125%, 
the within-run CV amounted to 2.0-3.6% and the LLOQ was 0.05 mg/L. The positive bias 
of 23-25% may be explained by differences in hematocrit concentrations in humans and 
mice, i.e circa 35% versus measured hematocrit of 55% (95% CI 44-67%), respectively. 
DBS sampling is known to be hampered by variation in hematocrit, resulting in differ-
ences in blood viscosity values and sample volumes, yielding a proportional analytical bias. 
Therefore, we corrected all murine DBS concentrations with a factor 0.82 (1/mean bias).
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agreement analysis of moxifloxacin concentrations in plasma and dBs
The level of agreement between the DBS method and the plasma method was analyzed 
by comparing the moxifloxacin concentrations in DBS samples with the concentrations in 
plasma using Passing-Bablok regression and Bland-Altman analysis with Analyze-it version 
2.20 (Analyze-it Software, Ltd.) 11. Only DBS concentrations were included that were below 
the highest QC that was cross-validated, namely 5 mg/L.
Pharmacokinetic evaluation
PK parameters were assessed using standard noncompartmental methods in Phoenix 
WinNonlin version 6.4 (Pharsight Corporation), as described previously 12. To determine 
exposure equivalence with human moxifloxacin exposures, areas under the plasma 
concentration-time curve up to infinity (AUC0-∞) and peak (Cmax) values after a single dose 
in mice were compared to clinically relevant AUC0-t and Cmax steady state moxifloxacin 
exposures in humans, considering that AUC0-∞ after a single dose is equivalent to AUC0-t in 
a dosing interval t at steady-state.
resulTs
comparison of moxifloxacin concentrations in plasma and dBs
The level of agreement between moxifloxacin measured in murine plasma and with DBS 
was determined using Passing-Bablok regression and Bland-Altman analysis and is shown 
in figure 1. The Passing-Bablok analysis (1A) showed a high level of similarity between both 
methods with an intercept of 0.02155 (95% CI -0.01765 – 0.04669) mg/L and a slope of 
1.07 (95% CI 1.03 – 1.14), indicating an average 7% positive proportional bias for DBS 
versus plasma measurements of moxifloxacin in mice.
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figure 1. Assessment of the level of agreement between moxifl oxacin concentrations measured in plasma and in DBS 
using Passing-Bablok regression (A) and Bland-Altman analysis (B).In the scatter plot with Passing-Bablok fi t (A), moxi-
fl oxacin concentrations in DBS are plotted against their concentration in plasma. The line of identity is presented in solid 
grey and in black the Passing-Bablok regression line, y=0.02155+1.072x. Bland-Altman analysis plots (B) the moxifl oxacin 
DBS/plasma concentration ratio versus the average concentration in DBS and plasma. The line representing the mean ratio 
is solid, while the lines depicting the 95% Limits of Agreement (LoA), containing 95% of the data points, are dashed.
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Bland-Altman analysis (1B) showed a mean DBS/plasma concentration ratio of 1.13 with a 
95% CI of 1.09 – 1.16, with a lower limit of agreement (LoA) of 0.89 (95% CI 0.83-0.96) 
and an upper LoA of 1.36 (95% CI 1.29-1.42), which means that 95% of the data points 
is within 0.89 and 1.36 concentration ratios.
Pharmacokinetic evaluation
Figure 2 displays the concentration-time profiles as measured in plasma and table 1 the 
main pharmacokinetic parameters of single doses of moxifloxacin in uninfected mice. 
After oral administration of moxifloxacin in mice the AUC0-∞ values were 4.5, 11, 24 and 
76 mg/L/h for 50, 100, 200 and 400 mg/kg, respectively. Pharmacokinetics appeared to 
be dose linear with increasing concentrations, except for the increase from the 200 to 
400 mg/kg dose, where multiplying the dose by two resulted in a threefold increase in 
exposure. The Cmax values were 2.8, 6.7, 12 and 18 mg/L for 50, 100, 200 and 400 mg/
kg, respectively. The mean percentage unbound moxifloxacin in all 64 samples was 55% 
(42–76%) and seems comparable, but somewhat higher compared to the unbound frac-
tion in humans (39-50%) 13, 14.
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figure 2. Moxifloxacin profiles in plasma of healthy BALB/c mice following single oral doses of 50 mg/kg (circles), 100 
mg/kg (squares), 200 mg/kg (triangles) and 400 mg/kg (crosses) of moxifloxacin.
Plasma concentrations are plotted as median with ranges of two mice per dosage and time point.
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discussiOn
Moxifloxacin is a promising building block in novel TB regimens for drug susceptible and re-
sistant TB and remains an essential drug in the battle against MDR-TB. Therefore a clear un-
derstanding of its pharmacokinetics and pharmacodynamics in preclinical models is pivotal. 
In the present study we validate the use of DBS sampling by comparing concentrations in 
whole blood with concentrations in plasma, obtained from uninfected female BALB/c mice. 
When comparing DBS with plasma, the Passing-Bablok plot showed a positive bias with an 
acceptable level, demonstrating that data obtained with both methods are in concordance. 
Bland-Altman analysis showed a lower (0.89) and upper (1.36) 95% LoA indicating that 
DBS values can predict plasma concentrations with acceptable precision. Vu et al. found 
significantly higher moxifloxacin concentrations in DBS compared to plasma samples from 
actual TB-patients 10. This discrepancy between DBS and plasma concentrations is higher 
than found in the current study in mice. This might be explained by interspecies differences 
in the distribution of moxifloxacin between plasma and blood cells caused by a difference 
in binding capacity to plasma proteins and blood cells 15.
Based on these results we conclude that DBS can be used in preclinical drug develop-
ment models to assess moxifloxacin pharmacokinetics. Multiple blood sampling via the tail 
vein is possible up to 20% of the circulatory blood volume in 24h, this allow up to four 
samples from a single animal 16. In addition in PK/PD studies, mice can be used for a PK 
study and remain in the study for PD assessment. This significantly decrease the number 
of mice necessary as well as the costs of the experiments. A limitation of the study is 
the validated range of concentrations (0.5 – 5 mg/L) when cross-validating human DBS 
with murine DBS samples, in some samples the moxifloxacin concentrations in blood were 
higher than the upper limit and were excluded in the comparison.
Before performing efficacy studies with moxifloxacin in mice it is of great importance 
to use a HED. In the present study, the pharmacokinetics of moxifloxacin were studied to 
determine the HED in mice that can be used for further drug efficacy testing in TB infected 
mice. The AUC relative to the minimal inhibitory concentration has been suggested as the 
Table 1. Pharmacokinetic parameters of moxifloxacin in plasma following single dose of 50, 100, 200 and 400 mg/kg 
in BALB/c mice.
Dose
(mg/kg)
AUC0-∞
(mg/L.h)
Cmax
(mg/L)
Cl/F
(L/h)
Vd/F
(L)
T½
(h)
50 4.5 2.8 0.25 1.2 3.2
100 11 6.7 0.19 0.67 2.4
200 24 12 0.19 1.1 4.1
400 76 18 0.12 1.5 8.8
PK parameters are based on the average concentration of two sacrificed mice per dosage and time point (n=64)
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best parameter to predict in vivo efficacy against Mycobacterium tuberculosis17. Based on 
the protein binding which seems slightly lower in mice compared to humans and the AUC0-
∞ calculated in the current study, a single dose of 200 mg/kg moxifloxacin in mice would 
approximate a human equivalent free drug exposure (AUC0-24 24.8 mg*h/L / fAUC0-24 17.3 
mg*h/L 18), which can be used in efficacy studies. This suggested 200 mg/kg dose comple-
ments the data from Poissy et al. who found AUC values close to those found in humans 
when a similar dose was used as well as the highest decline in CFU with this dose 19.
The Cmax of moxifloxacin in humans after the standard dose of 400mg is 2.5 - 3.3 mg/L 
18, 20. The Cmax in mice obtained with the 100, 200 and 400 mg/kg dose was higher, where 
50 mg/kg resulted in a Cmax of 2.8 mg/L which is in the Cmax range found in TB-patients 
18, 20. However, the suggested 200 mg/kg dose yields an increased Cmax compared to those 
in humans, therefore an additional study must be performed to determine whether a 
fractionated dose over the day will minimize the Cmax and maintain the AUC. The median 
half-life of moxifloxacin in mice is 3.65 h compared to 8.3 – 15.6 in humans 13, 20.
Our results are in contrast with AUC0-∞ and Cmax data presented by Rosenthal et al. who 
found higher AUC0-∞ and Cmax values in mice after a single dose of moxifloxacin (100, 200 
and 400 mg/kg), except for the AUC0-∞ after a 400 mg/kg dose which is higher in the 
current study 21.
In summary, we showed that DBS can be used to perform further moxifloxacin stud-
ies in murine models to study pharmacokinetics and pharmacokinetic-pharmacodynamic 
relationships. Furthermore, we identified that 200 mg/kg moxifloxacin is an appropriate 
dose to perform efficacy studies in a murine TB model.
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aBsTracT
Linezolid is a promising agent for future multidrug-resistant TB (MDR-TB) regimens, to be 
evaluated in the TB mouse model. To improve clinical predictability from animal efficacy 
studies, it is important to test a linezolid dose that is pharmacokinetically equivalent to 
the dose used in MDR-TB patients. Furthermore, pharmacokinetic analyses in mice would 
benefit from measurement of analytes in small blood volumes using the ‘dried blood spot’ 
(DBS) technique, because it allows for the assessment of drug concentrations over time 
within a single mouse. This study aimed to identify the human pharmacokinetic equivalent 
dose of linezolid, as well as to evaluate DBS analysis for measuring linezolid concentrations 
in murine blood spots. We identified 50 mg/kg oral linezolid (AUC0-∞ 78 mg/L*h) in BALB/c 
mice as the pharmacokinetic equivalent of a dose between 300 and 600 mg in humans. 
We recommend this dose for future MDR-TB regimen efficacy testing. Nonlinear kinetics 
of linezolid were observed, which complicated deriving an exact human pharmacokinetic 
equivalent dose. Concentrations in murine blood spots were slightly lower than in plasma: 
Passing-Bablok regression demonstrated a significant proportional bias with a slope of 0.81 
(95% CI 0.79-0.84). To compensate for the differences in murine plasma and blood, we 
propose a conversion factor of 1.2 to predict plasma concentrations from DBS. Overall, we 
feel that the applied measurement of drug concentrations in murine DBS may significantly 
reduce the number of animals needed for future PK-PD assessments.
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inTrOducTiOn
Globally, an estimated 480,000 tuberculosis (TB) patients suffer from multi-drug resistant 
TB (MDR-TB), a level that has changed little in recent years 1. Only 50% of MDR-TB patients 
were successfully treated in 2014 1, indicating that MDR-TB treatment remains far from 
adequate. The oxazolidinone linezolid, a group 5 TB drug in the WHO treatment guideline, 
has shown good activity against drug resistant strains in preclinical studies 2, 3, with grow-
ing evidence for its efficacy in MDR-TB and XDR-TB patients 4, 5.
Before the contribution of linezolid to novel MDR-TB regimens can be investigated in 
patients, this first has to be tested in appropriate preclinical models, such as the TB mouse 
model. Pharmacokinetic data are indispensable in these studies, as linezolid exposure is 
considered predictive for treatment outcome and adverse effects such as hematologic 
toxicity and peripheral neuropathy 6-8. The linezolid pharmacokinetic-pharmacodynamic 
(PK-PD) parameters of interest are the (protein-unbound) area under the concentration 
versus time curve (AUC) to minimum inhibitory concentration (MIC) ratio, and time above 
MIC 7, 9 .
To improve clinical predictability from animal efficacy studies, it is important to test a 
linezolid dose that is pharmacokinetically equivalent to the dose used in MDR-TB patients. 
Furthermore, pharmacokinetics analyses in mice would benefit from measurement of 
analytes in small blood volumes using the ‘dried blood spot’ (DBS) technique 10, because 
it allows for the assessment of drug concentrations over time within a single mouse. This 
could significantly reduce the number of animals needed for pharmacokinetic assessment, 
as conventionally one animal is euthanized for collection of a single blood sample to ensure 
sufficient quantities of analytical sample.
To optimize linezolid efficacy testing in mice, the aim of this study was to identify the 
linezolid dose resulting in exposures equivalent to those found in humans, as well as to 
evaluate DBS analysis for measuring linezolid concentrations in murine blood spots.
meThOds
animals
Specified-pathogen-free female BALB/c mice were obtained from Charles River (Les Oncins, 
France). Experimental protocols adhered to the rules specified in the Dutch Animal Ex-
perimentation Act (1977) and the published Guidelines on the Protection of Experimental 
Animals by the Council of the EC (1986). The Institutional Animal Care and Use Committee 
of the Erasmus MC Rotterdam approved the protocol [117-12-14, EMC2888].
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experimental set-up
Pharmacokinetic studies were performed in 64 mice after oral administration of single 
doses of linezolid (Sigma-Aldrich, Zwijndrecht, the Netherlands). Mice were treated with 
a linezolid dosage range (12.5, 25, 50 and 100 mg/kg dissolved in PBS) and samples were 
taken at 0.25, 0.5, 0.75, 1, 1.5, 3, 5 and 10 h after the dose. Two animals were euthanized 
for each dosage and sampling time point. Blood was collected via cardiac puncture, after 
which DBS samples were obtained by pipetting 40 µl of blood onto Whatman DMPK-C 
cards (Whatman, Kent, UK). The remaining blood was centrifuged to obtain plasma, which 
was stored at -80 °C until further analysis.
analysis of plasma and dBs linezolid concentrations
Linezolid concentrations in plasma were analysed by a validated high-performance liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) assay at the University Medical 
Center Groningen, the Netherlands 11. The assay accuracy was 96.3-108.5%, the within-
run CV ranged from 2.5-7.1% and the lower limit of quantitation (LLOQ) was 0.05 mg/L. 
Cross-validation between human and murine plasma matrices was performed by com-
paring responses of three Quality Control (QC) linezolid concentrations (0.5, 15 and 30 
mg/L in five-fold) in human plasma with those in murine plasma. The accuracy of murine 
relative to human plasma measurements was between 101-114%, with a within-run CV 
of 1.7-2.6%. Protein-unbound concentrations of linezolid were measured in all samples 
and were obtained following ultrafiltration of plasma, to separate bound from unbound 
linezolid, using Centrifree YM-T 30 kDa ultrafiltration tubes (Merck-Millipore, Amsterdam, 
the Netherlands). Clear ultrafiltrate was analysed via LC-MS/MS.
To quantify murine DBS samples a validated method for human samples was used 12. 
The DBS assay accuracy was within 98.7-106.3%, the overall precision (CV) ranged from 
5.3-17.2%, and the LLOQ was 0.05 mg/L. Cross-validation between human and murine 
DBS was performed by comparing responses of three QC linezolid concentrations (0.5, 
15 and 30 mg/L in five-fold) in human DBS with those in mouse DBS (40 µL blood spots). 
The accuracy of murine relative to human DBS measurements was between 111-140% 
(mean bias 123%), with a within-run CV of 2.1-2.7%. The bias may be explained by 
measured differences in hematocrit concentrations in human and mice, 35% versus 55% 
(95% CI 44-67%), respectively. DBS sampling is hampered by variation in hematocrit due 
to differences in blood viscosity values, yielding a proportional analytical bias. Therefore, 
we corrected all murine DBS concentrations with a factor 0.82 (1/mean bias).
Pharmacokinetic evaluation
Pharmacokinetic parameters were assessed using standard noncompartmental methods 
in Phoenix WinNonlin version 6.4 (Pharsight Corporation) 13. To determine the human 
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pharmacokinetic equivalent dose, AUC0-∞ single dose values in mice were compared to 
clinically relevant AUC0-t linezolid exposures in humans at steady state.
agreement analysis of plasma and dBs linezolid concentrations
The level of agreement between the DBS and the plasma method was analysed by compar-
ing linezolid concentrations in DBS samples with those in plasma using Passing-Bablok 
regression and Bland-Altman analysis with Analyze-it version 2.20 (Analyze-it Software, 
Ltd.) 14. Only DBS concentrations were included that were below the highest QC cross-
validated (<30 mg/L).
resulTs
Pharmacokinetic evaluation
Plasma concentration-time profiles and pharmacokinetic parameters of linezolid dosages 
are shown in Figure 1 and Table 1, respectively. Pharmacokinetics appeared to be nonlinear, 
as increases in exposure were not proportional to increases in dosage. The highest dose of 
100 mg/kg was an exception to this, probably because limited solubility resulted in deviant 
absorption characteristics. The mean percentage unbound linezolid across all samples was 
57 ± 9% (mean ± sd), which seems comparable, though somewhat lower, than the free 
fraction found in humans (70%) 9.
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figure 1. Linezolid plasma concentration-time profiles following single oral doses of 12.5 mg/kg (diamonds), 25 mg/kg 
(crosses), 50 mg/kg (circles) and 100 mg/kg (triangles) in BALB/c mice.
Plasma concentrations are plotted as mean and minimum-maximum of two mice per dosage and time point (n=64).
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In literature, median AUC0-12h in TB patients taking 300 mg twice daily was 58 mg/L*h 15. 
For 600 mg twice daily, AUC0-12h amounted to 140-146 mg/L*h 15, 16. Single oral doses of 
375 and 625 mg in healthy adults resulted in an AUC0-∞ of 66 and 102 mg/L*h, respectively 
17. Considering these exposures and the relatively comparable protein binding in humans, 
50 mg/kg in BALB/c mice (AUC0-∞ of 78 mg/L*h) would approximate free linezolid expo-
sures of a dose between 300 and 600 mg in humans.
agreement between plasma and dBs concentrations
Figure 2 displays the assessment of the level of agreement between measurement of 
linezolid in murine plasma and DBS samples (n=46 data points <30 mg/L). A significant 
proportional bias was observed in the Passing-Bablok analysis with a slope of 0.81 (95% 
CI 0.79-0.84) (Figure 2A). The Bland-Altman analysis showed that the lower (0.71 (95% 
CI 0.69-0.73)) and upper (0.90 (95% CI 0.87-0.92)) 95% Limits of Agreement (LoA) were 
relatively narrow around the mean DBS/plasma linezolid concentration ratio of 0.80 (95% 
CI 0.79-0.82)) (Figure 2B). From a linear regression analysis with plasma concentration as 
dependent and DBS concentrations as independent variable, we derived a conversion fac-
tor of 1.23 to predict murine plasma concentrations from DBS levels (R2 = 0.995, p<0.001).
Table 1. Pharmacokinetic parameters of linezolid in plasma following single oral doses of 12.5 mg/kg, 25 mg/kg, 50 mg/
kg and 100 mg/kg in BALB/c mice.
dose
(mg/kg)
auc0-∞
(mg/l*h)
cmax
(mg/l)
cl/f
(l/h)
Vd/f
(l)
t½
(h)
12.5 8.3 6.3 0.033 0.054 1.1
25 28 18 0.020 0.038 1.3
50 78 40 0.014 0.030 1.4
100a 141 63 0.016 0.054 2.4
Pharmacokinetic parameters are based on the mean concentration of two sacrificed mice (n=64)
a Dosage was at the limit of solubility, homogeneity of suspension was strived for by vortexing just prior to administration
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figure 2. Assessment of the level of agreement between linezolid concentrations measured in plasma and in DBS using 
Passing-Bablok regression (A) and Bland-Altman analysis (B).
In the scatter plot with Passing-Bablok fi t, linezolid concentrations in DBS are plotted against their concentration in plasma 
(A). The line of identity is presented in solid grey and the Passing-Bablok regression line is dashed. The regression line has 
a slope of 0.81 (95% CI 0.79-0.84) and an intercept of -0.015 (95% CI -0.064-0.041). Bland-Altman analysis plots the 
linezolid DBS/plasma concentration ratio versus the average concentration in DBS and plasma (B). The line representing 
the mean ratio is solid, while the lines depicting the 95% Limits of Agreement (LoA), containing 95% of the data points, 
are dashed. The mean ratio is 0.90 (95% CI 0.79-0.82).
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discussiOn
In this study, we found that a linezolid dose of 50 mg/kg resulted in an AUC0-∞ of 78 
mg/L*h in BALB/c mice, which approximates free linezolid exposures of a dose between 
300 and 600 mg in humans. We recommend this dose for future MDR-TB regimen efficacy 
testing. In literature there has been an ongoing debate on the optimal linezolid dose or 
concentrations associated with treatment efficacy in humans. Initial treatment of MDR-TB 
with 600 mg of linezolid twice daily has been limited by adverse effects 15, 18. Lower doses 
mostly seemed to retain effectiveness and limit toxicity 7, 15, 18. Therefore, linezolid doses 
≥100 mg/kg tested in mice previously, probably by far exceed clinically useable doses and 
exposures 19, 20.
Nonlinear kinetics of linezolid were observed. Clearance decreased 30% after a 2-fold 
increase in dose, which complicated deriving an exact human pharmacokinetic equivalent 
dose. Nonlinearity has been demonstrated in mice previously at lower oral linezolid doses 
(0.625-40 mg/kg) 21, but not after intraperitoneal or subcutaneous administration 22, 23. 
This underlines the importance of route of administration as well as pharmacokinetic 
confirmation of drug exposures in drug efficacy studies. Nonlinearity has also been shown 
before in humans, but to different extends 9, 15, 17, 24. In a population pharmacokinetic 
analysis linezolid nonlinearity could not be explained by enzyme kinetics and was thought 
to be related to mitochondrial function 24.
With respect to the analysis of linezolid in murine DBS, we showed that concentrations 
in blood are slightly lower than in plasma, as we found a significant proportional bias with 
a slope of 0.81 (95% CI 0.79-0.84). To compensate for the differences in murine plasma 
and blood, we propose a conversion factor of 1.2 to predict plasma concentrations from 
DBS levels. Bland-Altman analysis showed that the lower and upper 95% LoA are relatively 
narrow around the average linezolid DBS/plasma concentration ratio, namely 0.71-0.90, 
meaning that the DBS/plasma ratio can be estimated with rather good precision.
Current findings are in contrast with the higher linezolid levels found in human DBS 
compared to human plasma previously 12, which may be explained by interspecies dif-
ferences in (binding to) blood components. Furthermore, less spread is observed in mice 
plasma/DBS ratios compared to human ratios 12, probably due to the larger heterogeneity 
in human blood/hematocrit composition. To our knowledge, no studies measuring line-
zolid (or any other TB drug) in murine DBS have been reported, even though the general 
feasibility of serial sampling in mice with the DBS technique has been published before 
25, 26. Compound specific validation in DBS matrix is indispensible, as factors such as blood/
plasma partition ratios and the impact of hematocrit may be very drug specific, and can 
complicate the comparison with plasma samples 27.
Overall, this study provides very practical considerations and techniques for linezolid 
drug efficacy studies in mice, with linezolid as part of a future MDR-TB regimen. Further-
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more, the applied measurement of drug concentrations in murine DBS may significantly 
reduce the number of animals needed for these future PK-PD assessments.
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aBsTracT
Tuberculosis (TB) is still a major life-threatening infectious disease, within which especially 
the rise of multidrug resistant TB (MDR-TB) is currently worrying. This study focuses on 
mechanisms of development of rifampicin resistance, since rifampicin seems to play an 
important role in the development of MDR-TB.
To provide further insight in rifampicin resistance, we performed a genome-wide tran-
scriptional profile analysis for Mycobacterium tuberculosis using microarray technology 
and qRT-PCR analysis. We exposed a rifampicin-susceptible H37Rv wild type (H37Rv-WT) 
and a rifampicin-resistant progeny H37Rv strain with a H526Y mutation in the rpoB gene 
(H37Rv-H526Y) to several concentrations of rifampicin, to define the effect of rifampicin 
on the transcription profile.
Our study showed that there are resistance-dependant differences in response between 
both Mycobacterium tuberculosis strains. Gene clusters associated with efflux, transport 
and virulence were altered in the rifampicin-resistant H37Rv mutant compared to the 
rifampicin-susceptible H37Rv-WT strain after exposure to rifampicin.
We conclude that the small gene cluster Rv0559c-Rv0560c in the H37Rv-H526Y strain 
was remarkably up-regulated in the microarray analysis and qRT-PCR results and appeared 
to be dependent on rifampicin concentration and time of exposure. Therefore this study 
suggests that Rv0559c and Rv0560c play a pivotal role in rifampicin resistance of Myco-
bacterium tuberculosis. Further investigation of Rv0559c and Rv0560c is needed to reveal 
function and mechanism of both genes that were triggered upon rifampicin exposure.
Chapter 7
101
7
inTrOducTiOn
Tuberculosis (TB) is one of the major life-threatening infectious diseases. In 2011, with 8.8 
million new cases reported, TB was responsible for the death of 1.5 million people, equal 
to 4100 deaths a day 1. Due to a considerable increasing rate of isoniazid and rifampicin 
resistance among strains of Mycobacterium tuberculosis and the poor treatment outcome 
of multidrug resistant (MDR)-TB treatment 1, more insight in the development of MDR-TB 
is needed. The World Health Organization estimated that worldwide 3.3% of all new TB 
cases in 2009 were MDR-TB 2 and over 85% of rifampicin-resistant clinical isolates are also 
resistant to isoniazid 3. Our study focused on rifampicin-induced transcriptome responses 
in rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis strains, since 
rifampicin seems to play a driving role in the development of MDR-TB.
Resistance can either be intrinsic or acquired via genotypic changes. Mycobacterium 
tuberculosis is intrinsically resistant to a wide ranges of antimicrobial compounds due to 
the unusually low permeability of the bacterial outer membrane 4. Additionally, Myco-
bacterium tuberculosis can become resistant to rifampicin via various routes. Genotypic 
resistance towards rifampicin is caused for almost 95% by target alteration due to non-
synonymous single nucleotide polymorphisms (nsSNP) 5. The nsSNP, which primarily occurs 
in an 81 base pair region in the rpoB gene, known as the rifampicin resistance-determining 
region (RRDR), results in several changes in the β-subunit of RNA polymerase. Due to 
these changes, rifampicin is less competent to bind to the β-subunit of RNA polymerase 
5, 6, resulting in Mycobacterium tuberculosis mutants that are less susceptible or resistant 
to rifampicin. Recently, Siu et al. showed two new mutations in the rpoB gene outside the 
RRDR that also resulted in rifampicin resistance 7. Another form of genotypic resistance is 
for example porin loss by mutations in genes encoding porin proteins leading to decreased 
cell wall permeability 8. Resistance can also be caused by efflux pump activity. Efflux pump-
induced drug extrusion will result in suboptimal intracellular drug concentrations 9-11. The 
activity of efflux pumps genes and transporter genes can be actively induced by rifampicin 
at the level of gene expression 12.
To define the effect of rifampicin on the transcription profile, we performed a genome-
wide transcriptional profile analysis for Mycobacterium tuberculosis exposed to rifampicin 
using microarray technology. We compared the transcription profiles of an isogenic pair 
of rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis strains, to 
provide further insight in the influence rifampicin resistance on overall gene expression 
upon rifampicin exposure.
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maTerials and meThOds
Bacterial culture and drug exposure
The two Mycobacterium tuberculosis strains used were: a H37Rv wild type (H37Rv-WT) 
strain and a progeny H37Rv strain with a H526Y mutation in the rpoB gene (H37Rv-H526Y). 
The minimum inhibitory concentration (MIC) for rifampicin (Rifadin®, Aventis Pharma B.V, 
Hoevelaken, the Netherlands) was determined to be 0.25 mg/L for the H37Rv-WT strain 
and 512 mg/L for the H37Rv-H526Y strain, using CLSI guidelines.
Mycobacterium tuberculosis suspensions were taken from a frozen stock, thawed and 
cultured in Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI, USA), supplemented 
with 10% oleic acid-albumin-dextrose-catalase enrichment (OADC, Baltimore Biological 
Laboratories, Baltimore, MD, USA), 0.5% glycerol (Scharlau Chemie S.A, Sentmenat, Spain) 
and 0.05% Tween 20 (Sigma-Aldrich, St. Louis, MO, USA), under shaking conditions at 96 
rpm at 37°C. After 6 days of growth Mycobacterium tuberculosis cultures were exposed 
to 0.063 mg/L and 0.25 mg/L rifampicin for the H37Rv-WT, and 128 mg/L and 512 mg/L 
rifampicin for the H37Rv-H526Y. These rifampicin concentrations represent ¼x the MIC 
and 1x the MIC of rifampicin for both strains, in the controls solvent was added.
Mycobacterium tuberculosis was cultured to late log-phase, prior to addition of rifam-
picin. Samples were collected 30 minutes and 12 hours after exposure to rifampicin, or 
solvent.
rna extraction
RNA was isolated using a FastPrep-24 with a FastRNA® Pro Blue Kit (MP Biomedicals, 
Irvine, CA, USA). To remove residual DNA, RNA samples were treated with RNase-free 
DNase (Ambion, Austin, TX, USA) and were purified using the RNeasy MiniElute Clean-up 
Kit (Qiagen Benelux, Venlo, the Netherlands), all according to the manufacturers protocol. 
The amount of RNA was measured using the NanoDrop ND-1000 (Thermo Scientific, Wilm-
ington, DE, USA) and the integrity was investigated with the 2100 BioAnalyzer (Agilent 
Technologies Inc., Santa Clara, CA, USA) using a RNA Nano 6000 kit (Agilent Technologies) 
yielding RIN-values ≥ 8.9.
labeling protocol
Per test sample, 5 µg total RNA together with 1 µg random octamers (Biolegio, Nijmegen, 
the Netherlands) in 4.5 µl was heated to 65°C for 10 min to denature the RNA and was 
allowed to cool in an ice-water bath for 10 min. This 4.5 µl was supplemented to 10 µl with 
a first strand mastermix. The mastermix contained final concentrations of 50 mM Tris-Cl 
(pH 8.3), 3 mM MgCl2, 75 mM KCl, 200 mM Raffinose (Sigma-Aldrich), 0.015% Triton 
X-100, 30 ng Actinomycin-D (Sigma-Aldrich), 0.01M DTT, 0.5 mM dGAC, 0.35 mM dUTP, 
0.15 mM dUTP-Cy3 (test) or dUTP-Cy5 (common reference) (GE Healthcare, Hoevelaken, 
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the Netherlands) and 200U SuperScript-II (Life Technologies, Bleiswijk, the Netherlands). 
The mixture was incubated for 2 min at 25°C, 120 min at 42°C and 15 min at 70°C. Finally, 
1.5 µl of 2.5M NaOH was added to hydrolyze the remaining RNA upon heating for 10 min 
at 70°C. 8.5 µl 2M MOPS was added for neutralization and the labeled cDNA was purified 
with the E.Z.N.A. MicroElute RNA Clean-up Kit (Omega Biotek, Norcross, GA, USA). Dye 
incorporation and cDNA yield was measured on the NanoDrop ND-1000 yielding 2-2.5 µg 
per sample and a FOI >8 pmol/µg. The common reference was made by an equimolar pool 
of the test samples (5 µg per sample) and subsequently labeled as the test samples with 
Cy5 incorporation.
microarray hybridization and scanning
Each hybridization mixture was made up from 500 ng test (Cy3) and 500 ng common 
reference (Cy5) material. Hybridization mixtures were prepared as described in the Agilent 
Two-Color Microarray-Based Gene Expression Analysis guide version 5.5 (G4140-90050, 
Agilent technologies) without the inclusion of the RNA fragmentation mixture. Mycobacte-
rium tuberculosis whole genome arrays were supplied by the Bacterial Microarray Group at 
St. George’s Hospital, University of London. Hybridization samples were loaded onto 8x15k 
Mycobacterium tuberculosis microarrays (Design ID: 027543, Agilent Technologies) and 
hybridized for 17 hours at 65°C. Afterwards the slides were washed and scanned (20 bit, 
5 µm resolution) in an ozone-free room with the Agilent G2505C scanner as described in 
the Agilent G4140-90050 guide. Data were extracted with Feature Extraction (v10.7.3.1, 
Agilent Technologies) with the GE2_107_Sep09 protocol for two-color Agilent microarrays.
microarray data processing
The raw data from all arrays were subjected to multiple quality control checks, i.e. visual 
inspection of the microarray scans, testing against criteria for foreground and background 
signals, testing for consistent performance of the labeling dyes, checking for spatial effects 
through pseudo-color plots, and inspection of pre- and post-normalized data with box 
plots, ratio-intensity (RI) plots and PCA plots. These checks revealed significant position 
effects on a slide. Subsequently, within-array normalization was performed using LOESS. 
Between-array normalization was run on the Cy3-channel by summarizing the intensity 
values of the probes in a probe set using the robust multi-array average (RMA) algorithm. 
The study (basically a three-factorial design) was subjected to 2 types of contrast analyses 
using mixed linear models with coefficients for slide-position and sample isolation day 
(both random) and each experimental group (fixed), to determine differential gene expres-
sion between ¼x MIC, 1x the MIC of rifampicin and non-exposure, per genotype and 
time-point and also to determine differential gene expression between the H37Rv-H526Y 
and H37Rv-WT per MIC treatment and time-point 13, 14. For hypothesis testing, a Fs test 
was used and correction of the resulting P-values for false discoveries was done according 
104
to Storey and Tibshirani 15, 16. All data handling was performed using R-2.11.1 (http://
www.R-project.org) and Bioconductor (www.bioconductor.org) software. The array design 
is available in BµG@Sbase (Accession No. A-BUGS-41; http://bugs.sgul.ac.uk/A-BUGS-41) 
and also ArrayExpress (Accession No. A-BUGS-41). Fully annotated microarray data have 
been deposited in BµG@Sbase (accession number E-BUGS-139; http://bugs.sgul.ac.uk/E-
BUGS-139) and also ArrayExpress (accession number E-BUGS-139).
qrT-Pcr analysis
Reverse transcriptase was performed with 50 ng of total RNA of each sample using a 
Reverse Transcriptase Core kit (Eurogentec, Seraing, Belgium). Primers were designed using 
Primer-BLAST (NCBI) and primer sequences are shown in Table 3. Quantitative Real-Time 
PCR (qRT-PCR) was performed with a 7500 Fast Real-Time PCR System (Applied Biosystems, 
Bleiswijk, the Netherlands) using a MESA FAST qRT-PCR MasterMix Plus for SYBR® Assay 
Low ROX (Eurogentec). The relative fold induction level of each transcript was obtained 
by ∆∆Ct analysis and was performed on duplicate biological samples that were assayed in 
duplicate. For quantitative results sigA was used for normalization.
resulTs
Mycobacterium tuberculosis growth
H37Rv-WT and H37Rv-H526Y at a density of 7.4 x 105 [4.3 – 9.9 x 105] CFU/mL were cul-
tured and after 6 days had increased up to 3.1 x 107 [2.1 – 4.0 x 107] CFU/mL. Both strains 
showed identical growth patterns. At day 6, rifampicin was added and quadruple cultures 
were exposed to either solvent or rifampicin concentrations at ¼x the MIC or 1x the MIC. 
After 30 minutes and 12 hours exposure the control curves of both strains reached 3.9 x 
107 [3.0 – 5.0 x107] CFU/mL and 2.5 x 107 [1.9 – 2.8 x 107] CFU/mL respectively. Exposure to 
¼x the MIC of rifampicin led in both strains to similar CFU counts being 3.0 x 107 [2.1 – 4.1 
x 107] after 30 minutes and 2.1 x 107 [1.5 – 3.1 x 107] after 12 hours exposure. Exposure 
to 1x the MIC of rifampicin led in both strains to CFU counts of 3.1 x 107 [2.8 – 3.4 x 107] 
after 30 minutes and 2.3 x 107 [1.2 – 3.1 x 107] after 12 hours exposure.
microarray analysis
After microarray analysis, all genes that responded to rifampicin (FDR p-values ≤ 0.05), at 
each time point were categorized and the associated distribution between functional cat-
egories is displayed in Table 1. Of the total number of up-regulated genes upon rifampicin 
exposure, 4 genes were up-regulated in both strains and 2 genes were down-regulated in 
both strains upon rifampicin exposure of the total number of down-regulated genes.
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In H37Rv-WT no genes were induced after 30 minutes exposure to ¼x the MIC and 1x the 
MIC of rifampicin. After 12 hours exposure to ¼x the MIC of rifampicin, Rv1397c (vapC10) 
encoding a possible toxin was found down-regulated, a 12 hour exposure to 1x the MIC 
of rifampicin resulted in 104 up-regulated genes and 149 down-regulated genes. After 12 
hours exposure to 1x the MIC of rifampicin vapC10 was also down-regulated which was a 
little bit stronger compared to exposure to ¼x the MIC.
The H37Rv-H526Y showed more response upon rifampicin exposure compared to the 
H37Rv-WT. Exposure to ¼x the MIC of rifampicin resulted in 10 up-regulated genes and 1 
down-regulated gene after 30 minutes, and 13 up-regulated genes and 6 down-regulated 
genes after 12 hours. Exposure to 1x the MIC of rifampicin resulted in 18 up-regulated and 
5 down-regulated genes after 30 minutes and 75 up-regulated and 39 down-regulated 
genes after 12 hours. Under all conditions in the H37Rv-H526Y strain nine genes were 
found up-regulated.
Twenty genes were selected that showed in at least 2 conditions differential expression 
≥ 4 (14 genes) or ≤ ¼ (6 genes) in H37Rv-H526Y and not in H37Rv-WT upon exposure 
to rifampicin (Table 2). From the 14 up-regulated genes, 8 appeared to be involved in 
cell wall and cell processes (Rv0450c, Rv0451c, Rv0559c, Rv0676c, Rv0677c, Rv1216c, 
Rv1217c and Rv1218c), 2 encode proteins involved in intermediary metabolism and 
respiration (Rv0560c and Rv0711), 1 encode regulatory proteins (Rv0452), 1 is associ-
ated with virulence, detoxification and adaption (Rv0251c), and 1 encodes a conserved 
hypothetical protein (Rv0678). Of the 6 down-regulated genes, 3 encode proteins that are 
involved in lipid metabolism (Rv0098, Rv0099 and Rv0101), 1 belongs to the PPE family 
proteins (Rv0096), 1 encodes a protein involved in intermediary metabolism and respiration 
(Rv0097), and 1 encodes a conserved hypothetical protein (Rv0100).
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qrT-Pcr confirmation
Aliquots of the RNA from rifampicin-treated and control samples were also used for qRT-
PCR analysis. The samples obtained after 12 hours 1x the MIC of rifampicin exposure, were 
compared with the 12 hours control samples; sigA was used for normalization. Results of 
the ∆∆Ct analysis are in agreement with the microarray data. The direction of change was 
in concurrence by both qRT-PCR and microarray analysis for all samples. However, the fold 
change determined by qRT-PCR is different from that determined by the microarray analysis 
as shown in Table 2 and Figure 1. Another ∆∆Ct analysis of independent RNA samples 
showed that the direction of change was in agreement by both qRT-PCR and microarray 
analysis for 70% of the samples. However, in general gene-expression levels are lower 
compared to the microarray analysis and to the expression levels obtained from the first 
qRT-PCR experiment.
Table 3. Primers used for the qRT-PCR
gene annotation forward primer reverse primer
Rv0096 PPE1 CAGCAGCTGGCAGGGAACCG AGCTCTGCTGGGGTGGGCAT
Rv0097 TCCGTCTCCGCGGGAGTTCA ATGCCAGAACGCGCCGGTTT
Rv0098 fcoT ACACCGACTTGACGCCCTGC TGGCGCTGTACTGTGCGTCG
Rv0099 faD10 GATGGCATCGGCCCTACCGC CCGGTGTTCACCCAGCCGTC
Rv0100 CGCCGTCTGCGACGTGTTGTA GGCCAATCGGGACGGCAGTT
Rv0101 nrp ATTCCTGGCCGCTCTGCACG GCACCGTATGCCGCACCAGT
Rv0251c hsp GCTGCGCCTGAGTTTCGGCT TCATTCCGCCGCTCGTTCCG
Rv0450c MmpL4 GTCGCTGCTCATCGCCAAGGG CGCCATCCATCGCCGCACTA
Rv0451c MmpS4 CACGGTAGCACCGCTCCATCG GATCCGCGGCTTCTTCGGCTC
Rv0452 AACGGCTGTCGCAGGTCGTG AGCTGCTCGCATACCGTGCC
Rv0559c CGCCCACATGCTCAGGGCAG GGCGTTGACGGCGATGCGTA
Rv0560c GTGTCCCCGTTCGGCCAGTG GGAGGGAGTCCGACCGCCAT
Rv0676c MmpL5 CCAACGGCACACCGAGGGTC CAGGACCGGGAGTCGGCGTA
Rv0677c MmpS5 GCCATCGACGGTGATTCGGCA GACCTCGACGCCAAGCCACAG
Rv0678 TCCGGGCAATGGCCGAACTG GTCCTCTCCGGTTCGCTGGC
Rv0711 atsA GCCCGACAAGCCGTGGTTCA TGTCGGGTGGCACGATCCCT
Rv1216c GCACGCGCTCAGCACCATCA AGCACCACGATTGGCCCCAC
Rv1217c CGAACGTCACGCCGTCGGAA CGCTGTACCTGCTCGGCTCG
Rv1218c TCGCACAGCGCTTCGGTCTC GCGCGCACCTACTCCAAGGG
Rv1219c CGGCGCGTACTCCTTCGTCC AACGACCCGACCACCTGGCT
Rv2703 sigA* GTCGGAGGCCCTGCGTCAAG AGGCCAGCCTCGATCCGCTT
* SigA was used for normalization
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Of the 20 genes that were up-regulated in at least two conditions in the microarray analy-
sis, only Rv0559c and Rv0560c were found strongly and constantly up-regulated in both 
qRT-PCR experiments in H37Rv-H526Y compared with H37Rv-WT.
discussiOn
We have investigated differences in rifampicin-induced gene responses between rifampicin-
susceptible and rifampicin-resistant Mycobacterium tuberculosis strains using microarray 
analysis and qRT-PCR. At ¼x the MIC of rifampicin exposure more genes are differentially 
expressed in H37Rv-H526Y than H37Rv-WT, whereas at 1x the MIC of rifampicin and long 
exposure this is reversed. This shows that the rifampicin-susceptible and rifampicin-resistant 
Mycobacterium tuberculosis strain have an altered response upon rifampicin exposure.
Using qRT-PCR we assessed if biological duplicates showed similar up-regulation. This 
revealed that one cluster of genes (Rv0559c-Rv0560c) was strongly up-regulated in all 
experiments after exposure to rifampicin in the H37Rv-H526Y. These results were con-
firmed in a second qRT-PCR experiment in which expression of Rv0559c and Rv0560c was 
also highly up-regulated in the H37Rv-H526Y strain compared to the H37Rv-WT strain 
(data not shown). Therefore Rv0559c and Rv0560c are potential candidates for further 
investigation in rifampicin resistance.
The Rv0559c gene encodes a protein with an unknown function. However, a previous 
study of Denkin et al. showed that Rv0559c is also induced upon salicylate exposure 17. 
Rv0560c is also induced by salicylate and probably encodes a benzoquinone methyltrans-
ferase 17, 18. Schuessler et al. showed that Rv0559c and Rv0560c have slow induction 
kinetics after exposure to salicylate and that gene expression is increasing over time 19. Our 
results are in agreement with these findings, since our microarray data also revealed that 
up-regulation of Rv0559c and Rv0560c is time dependent and rifampicin concentration 
dependent. The data showed an increase in expression of Rv0560c between 30 minutes 
and 12 hours of rifampicin exposure. An increased expression was also measured for 
both genes comparing exposure to rifampicin at ¼x the MIC and 1x the MIC. Sun et al. 
suggested that Rv0559c, Rv0560c and Rv0561c are located within the same operon 18, 
and Schuessler et al. showed that only Rv0559c and Rv0560c are regulated by the same 
promoter. In our microarray analysis we did not find a significant up-regulation of Rv0561c 
after rifampicin exposure in the H37Rv-H526Y strain, which is in concordance with earlier 
observations by Schuessler et al.
We have found 4 other distinct clusters of genes and 2 different genes differently ex-
pressed between both strains after 12 hours of exposure to 1x the MIC of rifampicin. The 
first cluster of Rv0096 to Rv0101 is strongly down-regulated in the H37Rv-H526Y strain 
upon 12 hours of rifampicin exposure. The other clusters, Rv0450c to Rv452, Rv0676c to 
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Rv678 and Rv1216c to Rv1219c are strongly up-regulated in the H37Rv-H526Y. None of 
these clusters are induced in the H37Rv-WT in response to rifampicin exposure.
Genes of the Rv0096-Rv0101 operon encode a PPE protein family member (Rv0096), 
a putative oxidoreductase of the tfdA dioxygenase family (Rv0097), a type III thioester-
ase (Rv0098), a fatty acid AMP ligase (Rv0099), an acyl carrier protein (Rv0100) and a 
nonribosomal peptide synthase (Rv0101). These genes seem to be co-regulated by a 
two-component regulatory system (senX3-regX3) 20 and are involved in biosynthesis of 
Phthiocerol Dimycocerosate (PDIM) 21. PDIM is part of the lipid-rich content of the my-
cobacterial cell envelop and is associated with an increased Mycobacterium tuberculosis 
virulence 22, 23. Interestingly, no down-regulation was found after microarray analysis for 
Rv2942 (MmpL7), which is also involved in the transport of PDIMs 24. So, down-regulation 
of this operon in the H37Rv-H526Y may result in decreased Mycobacterium tuberculosis 
virulence and may be due to a fitness loss as a result of mutations in the RRDR region.
Rv0251c is found up-regulated after 12 hours of exposure to 1x the MIC of rifampicin in 
the H37Rv-H526Y and is associated with stress response 25. Furthermore, two up-regulated 
gene clusters being Rv0450c to Rv452 and Rv0676c to Rv678 were found. Both clusters 
consist of genes of the MmpL (Mycobacterial membrane protein Large) family, of the 
MmpS (Mycobacterial membrane protein Small) family and a gene with unknown function. 
The MmpL proteins belong to the group of resistance, nodulation and cell division proteins 
(RND) and are associated with drug efflux 26. The RND family is a group of multidrug resis-
tance pumps that recognize and mediate the transport of a great diversity of compounds 
and has been well-documented in Gram-negative bacteria. However these MmpL genes 
does not seem to play a critical role in anti-TB drug resistance in Mycobacterium tuberculo-
sis26MmpL4 (Rv0450c) and MmpL5 (Rv0676c) are transcriptional coupled with MmpS4 and 
MmpS5, these smaller genes are predicted to encode proteins with one transmembrane 
domain. Little is known about the MmpS family. In Mycobacterium smegmatis MmpS4 
(Rv0451c) is associated with glycopeptidolipid biosynthesis and export cell surface glycolip-
ids 27. The up-regulation of Rv0450c to Rv0452 is almost constant in all conditions tested.
Our data showed that the response of Rv0676c to Rv0678 is higher after 30 minutes of 
exposure to both rifampicin concentrations compared to 12 hours of rifampicin exposure. 
This suggests that Rv0676c to Rv0678 are early response genes. MmpL5 and MmpS5 
(Rv0677c) are associated with efflux pump-related azole resistance in Mycobacterium 
tuberculosis and are regulated by Rv0678 28. Milano et al. showed that Rv0678 has almost 
50% homology with the well-characterized MarR of E. coli 28, this family of regulatory 
proteins plays an important role in of the development of antibiotic resistance 29. Based on 
the already known function of MmpL and MmpS genes and the up-regulation found in the 
microarray analysis it is likely that in Mycobacterium tuberculosis MmpL4, MmpS4, MmpL5 
and MmpS5 are involved in rifampicin efflux out of the cell.
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Rv0711 (atsA) encodes for a possible arylsulfatase but knowledge about atsA is very 
limited in Mycobacterium tuberculosis.
The knowledge about the up-regulated gene cluster Rv1216c-Rv1219c in the H37Rv-
H526Y is also very limited. Rv1216c and Rv1217c encode for probable integral membrane 
proteins. Rv1218c encodes an ABC transporter and previous studies suggest an important 
role for this gene product in mediating efflux to a wide variety of compounds 30, 31. How-
ever Balganesh et al. showed that the MIC of rifampicin is not influenced in Rv1218c 
knock-out mutants 30. This suggests that Rv1218c is not primarily involved in regulation 
of the intracellular concentration of rifampicin. In our rifampicin-resistant H37Rv-H526Y 
mutant however, Rv1218c is strongly up-regulated, which implies an association between 
up-regulation of Rv1218c and rifampicin resistance. Rv1219c probably encodes for a tran-
scriptional regulatory protein but further function and regulation is unknown.
To conclude, our results show that several interesting gene clusters associated with 
efflux, transport and virulence show an altered response in the rifampicin-resistant H37Rv 
mutant compared to the rifampicin-susceptible H37Rv wild type strain upon exposure to 
rifampicin. Not all genes could be completely confirmed with qRT-PCR. Although the direc-
tions of change were identical, fold changes appeared in general to be lower in qRT-PCR. 
This lack of concurrence between methods for genes exhibiting low levels of change has 
been reported by several others 32-35. Here we show by microarrays and qRT-PCR experi-
ments that Rv0559c and Rv0560c are strongly rifampicin-inducible. This indicates that the 
induction of both genes is dependent on concentration of rifampicin and exposure time. 
Therefore this study suggests that Rv0559c and Rv0560c play a pivotal role in rifampicin 
resistance of Mycobacterium tuberculosis. Further investigation on the exact function and 
regulation of Rv0559c and Rv0560c is needed to understand the mycobacterial mecha-
nisms that are triggered upon rifampicin exposure.
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aBsTracT
The increasing emerging Mycobacterium tuberculosis Beijing genotype is associated with 
lower treatment success rates in tuberculosis patients and resistance. Therefore, we ex-
plored the impact of using a Beijing strain instead of H37Rv on treatment outcome in our 
mouse tuberculosis model. Additionally, we assessed the predictive value of bactericidal 
activity on treatment outcome.
We observed that the treatment success rates of conventional anti-TB regimens ranged 
between 80-95% in Beijing-infected animals opposed to 100% treatment success ob-
served in previous studies using H37Rv-infected mice. The bactericidal activity was only 
predictive for treatment outcome after at least 3 months of treatment.
Our data advocate the use of Beijing strains to increase the translational value of mouse 
TB models. Additionally, our findings support the notion that bactericidal activity in the 
first 2 months of treatment as measured in clinical phase IIa/b trials, has limited predictive 
value for TB treatment outcome, thus emphasizing the need for better parameters to guide 
future phase III trials.
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inTrOducTiOn
With 1.8 million deaths in 2015, tuberculosis (TB) surpassed HIV as leading cause of death 
amongst infectious diseases 1. One factor contributing to this ongoing burden of TB is the 
rapid emergence of Mycobacterium tuberculosis strains of the Beijing genotype 2, 3. These 
strains specifically contribute to the spread of drug-resistant TB and are clinically associated 
with increased rates of treatment failure 3-8.
To overcome this new challenge in TB treatment, novel treatment strategies with 
increased efficacy are urgently needed. However, clinical trials evaluating TB treatment 
outcome are expensive, involve large numbers of patients, and may take up to 10 years 
from drug design to clinical use 9. Moreover, phase IIa trials, measuring early bactericidal 
activity (EBA), and phase IIb trials, based on surrogate endpoints such as two month spu-
tum culture status, cannot predict treatment outcome in phase III trials in TB to a satisfying 
degree 9-11.
Alternatively, phase III trials can be guided by preclinical testing of anti-TB drugs, which 
is often performed in mouse TB models 12-15. However, recent disappointing results of 
phase III clinical trials on moxifloxacin for anti-TB treatment, which were partly based 
on promising results from mouse experiments, have also raised skepticism regarding the 
predictive value of preclinical TB models and the need for their improvement 9. This has led 
to the formation of multiple international consortia, such as PreDiCT-TB and CPTR, aimed 
at improving the translational value of preclinical TB models 12.
Approaches that are currently being evaluated include the development of specific in 
vitro models that allow drug activity assessment against Mycobacterium tuberculosis in 
different metabolic states 14, increased appreciation of the pharmacokinetic aspects of 
treatment 9 and mouse models that develop cavitating lesions, thus better representing 
human pathology 12.
Currently, most mouse TB models that evaluate treatment outcomes use Mycobacte-
rium tuberculosis strains such as H37Rv, which originally derived from a clinical isolate in 
1905, but is no longer found in patients 12, 14. Given the significant clinical impact of Beijing 
strain infections on treatment outcome, the main outcome parameter of phase clinical 
III trials, use of Beijing should increase the translational value of preclinical TB models. 
Therefore, the primary aim of this study was to assess treatment outcomes in mice infected 
with an Mycobacterium tuberculosis-Beijing genotype strain 16-18. Additionally, since phase 
IIa/b trials depend on early or late bactericidal activity, we evaluated the predictive value 
of bactericidal activity on treatment outcome at multiple time points throughout the full 
6-months treatment course.
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maTerials and meThOds
Bacterial strain
For all experiments, the previously described Beijing VN 2002-1585 (BE-1585) Mycobac-
terium tuberculosis genotype strain was used 18. This strain was isolated from a patient 
in Vietnam in 2002 and was verified as a typical Beijing strain based on single nucleotide 
polymorphism analysis 19. Susceptibility assays performed according to CLSI guidelines 
showed minimal inhibitory concentrations for rifampicin of 0.25 mg/L, for isoniazid of 
0.125 mg/L, for ethambutol of 5 mg/L and for streptomycin of 2 mg/L 20.
mice
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les Oncins, 
France) and acclimatized at least 7 days prior to starting experiments. Mice received food 
and water ad libitum. At the day of infection, animals were 13-15 weeks old and weighed 
20-25 grams. Experimental protocols adhered to the rules specified in the Dutch Animal 
Experimentation Act and were in concordance with the EU animal directive 2010/63/EU. 
The Institutional Animal Care and Use Committee of the Erasmus MC approved the present 
protocols (117-12-08 and 117-12-13).
infection
A suspension of Mycobacterium tuberculosis stored at -80°C was thawed at room tempera-
ture for 30 min and centrifuged for 10 min at 14.000xg. The Mycobacterium tuberculosis 
pellet was resuspended and diluted in fresh phosphate buffered saline (PBS). Mice were 
infected under general anesthesia using a mixture of medetomidine (Sedator®, 0.5 mg/kg; 
Eurovet Animal Health, Bladel, the Netherlands), midazolam (Midazolam, 5 mg/kg; Actavis, 
Baarn, the Netherlands) and fentanyl (Fentanyl, 0.05 mg/kg; Hameln Pharmaceuticals, 
Hameln, Germany), by intratracheal installation of a 40 µl suspension containing 1.4 x 
105 (0.3 – 2.0 x 105) CFU of BE-1585, using a repeating dispenser (Hamilton company; 
Bonaduz, Switzerland), a 1 mL syringe and a 22-Gauge mouse gavage feeding needle (Fine 
Science Tools; Heidelberg, Germany), followed by proper inhalation. Mice were antago-
nized using a mixture of atipamezole (Antisedan®, 2.5 mg/kg; Orion Corporation, Espoo, 
Finland), flumazenil (Flumazenil, 0.5 mg/kg; Pharmachemie, Haarlem, the Netherlands) and 
naloxon (Naloxon, 1.2 mg/kg; Orpha-Devel Handels und Vertriebs, Purkersdorf, Germany). 
Anesthetic and antagonistic agents were administered intraperitoneally, in a total volume 
of 175 µL and 250 µL, respectively.
antibiotic treatment
All treatment schedules started 14 days after infection. In the experiments assessing 
bactericidal activity of single anti-TB drugs, mice received 0.5x, 1x or 2x the human phar-
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macokinetic equivalent dose (HED) with rifampicin (R) (5, 10 or 20 mg/kg), isoniazid (H) 
(12.5, 25 or 50 mg/kg), streptomycin (S) (100, 200 or 400 mg/kg), ethambutol (E) (50, 100 
or 200 mg/kg) or pyrazinamide (Z) (75, 150 or 300 mg/kg), for 5 days a week, up to 28 
days 21. In the experiments assessing bactericidal activity and treatment outcome of the 
different anti-TB drug regimens, mice received treatment up to 6 months with different 
regimens of 1x the HED of each antibiotic 5 days a week. All drugs were administered via 
oral gavage except streptomycin, which was administered via subcutaneous injections. The 
different drug regimens are shown in Table 1.
assessment of mycobacterial load in the lungs
In order to assess the mycobacterial load in the lungs, mice were sacrificed by CO2 expo-
sure. To prevent carry-over of anti-TB drugs on subculture plates, treatment was stopped 
72 hours before sacrificing the mice. In addition, activated charcoal (0.4%) was added 
to the agar to inhibit the antibiotic residue from the tissue samples 22. The lungs were 
removed aseptically and homogenized according to protocol using the gentleMACS Octo 
Dissociator (Miltenyi Biotec BV, Leiden, the Netherlands) in 2 mL PBS. From each tissue 
homogenate 10-fold serial dilutions were made. Next, 200 µL per dilution was cultured 
on drug-free 7H10 Middlebrook agar and incubated for 28 days at 370C with 5% CO2 
Table 1: schematic overview of the experiments
D0 a D7 D14 D28 M2b M3 M6 M6+3c
R 3 d 3 3 3
H 3 3 3 3
Z 3 3 3 3
S 3 3 3 3
E 3 3 3 3
RE (6 RE) 3 3 3 3 3 3 3 20
RZ (2 RZ / 4 R) e 3 3 3 3 3 3 3 15
RH (6 RH) 3 3 3 3 3 3 3 15
RHZ (2 RHZ / 4 RH) 3 3 3 3 3 3 3 21
RHZE (2 RHZE / 4 RH) 3 3 3 3 3 3 3 21
RHZS (2 RHZE / 4 RH) 3 3 3 3 3 3 3 21
HS (2 HS / 4 H) 3 3 3 3 3 3 3 9
HZ (2 HZ / 4 H) 3 3 3 3 3 3 3 20
HE (6 HE) 3 3 3 3 3 3 3 18
ZES (2 ZES / 4 E) 3 3 3 3 3 3 3 20
a D0= day 0 (start of treatment), b M2= 2 months after start of treatment, c M6+3= 3 months after stop of a 6-months 
treatment course, d number of mice used for determination of Mtb-loads in the lungs,e 2 RZ / 4 R= two months of RZ 
treatment followed by 4 months of R treatment. Drugs were administered in their human pharmacokinetic equivalent dose, 
mice were infected at day -14.
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followed by colony enumeration. The time points at which mycobacterial loads were evalu-
ated are shown in the schematic overview of the experiments in Table 1.
data analysis and statistics
Analyses were performed and graphs were made using PRISM Graphpad 6 (Graphpad 
software, La Jolla, CA). All data are expressed as median ± range. Student’s t-test was used 
to calculate significance in figure 1. Two-way ANOVA followed by Bonferroni correction 
was used to calculate significance in table 3. P-values less than 0.05 were considered 
statistically significant.
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figure 1. Bactericidal activity after single drug exposure
Mycobacterial loads in the lungs after single drug exposure over a 28-days treatment course, using 0.5x (dots), 1x (squares) 
and 2x (triangles) the human pharmaco equivalent dose (HED) of the selected drugs. Data are shown as median with 
ranges with n=3 mice per time point. a) Rifampicin showed significant dose responses after 28 days of treatment between 
0.5x, 1x HED and 2x HED (*) B) Isoniazid showed significant dose responses after 7 days of treatment between 0.5x and 
2x HED (**) and between 1x and 2x HED (*). c) Streptomycin showed limited bactericidal activity, but prevented mortality 
d) Ethambutol showed no dose responses and could not prevent mortality. e) Pyrazinamide showed a significant dose-
response between 0.5x and 2x HED after 7 days (**), but none of the administered dosages could prevent mortality. f) 
Comparison of 1x HED treatment with rifampicin, isoniazid and streptomycin shows significantly stronger bactericidal 
activity of rifampicin compared to the other two drugs after 28 days (****), * p< 0.05, ** p< 0.01, **** p<0.0001.
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resulTs
mortality and bactericidal activity after single drug exposure
Mice infected with the Beijing strain were treated with isoniazid, rifampicin, ethambutol, 
pyrazinamide, or streptomycin in 3 different doses. Figure 1 shows mortality and bacteri-
cidal activity after 7, 14 and 28 days of single drug exposure. Earlier observations in our 
model have shown that untreated Beijing-infected mice all become moribund after 3-4 
weeks of infection 16. Treatment with rifampicin, isoniazid and streptomycin was able to 
prevent mortality, whereas mice treated with pyrazinamide or ethambutol showed similar 
mortality as untreated mice.
Rifampicin effectively reduced the mycobacterial loads in the lungs and showed a sig-
nificant dose-dependent bactericidal effect after 28 days (Fig. 1A). Isoniazid also showed 
bactericidal activity, but significant dose-dependent effects were only observed at day 7 
(Fig. 1B). Streptomycin reduced mycobacterial loads, but did not show dose-dependent 
effects (Fig. 1C). Ethambutol showed bactericidal activity after 7 days that was comparable 
to rifampicin or isoniazid, but failed to prevent mortality (Fig. 1D). Pyrazinamide did not 
display bactericidal activity in any of the dosages tested and did not prevent mortality (Fig. 
1E).
Comparison of the bactericidal activity of rifampicin, isoniazid and streptomycin over 
the 28-days exposure window showed no significant differences between the different 
drugs after 7 and 14 days of treatment (Fig. 1F). After 28 days rifampicin showed markedly 
stronger bactericidal activity than the other two drugs.
Treatment outcome and bactericidal activity after treatment with different 
anti-TB drug regimens
Treatment outcome after a 6-months treatment course for 10 different anti-TB drug regi-
mens is shown in Table 2. Unexpectedly, none of the regimens achieved 100% treatment 
success.
We also found that treatment success depended critically on rifampicin. Rifampicin-
containing-regimens showed treatment success rates between 80-95%, compared to 0% 
treatment success of all non-rifampicin containing regimens (Table 2). Among the different 
rifampicin-containing regimens themselves, no significant differences in treatment success 
could be detected. This indicates limited contribution of anti-TB drugs other than rifampi-
cin on treatment outcome. Notably, the rifampicin-pyrazinamide regimens even appeared 
to perform better than the rifampicin-isoniazid-pyrazinamide regimen.
Next, we determined whether the degree of bactericidal activity after any given treat-
ment duration could predict the impact of rifampicin on treatment outcome as observed 
in Table 2. To this aim, we ranked the bactericidal activity of the different rifampicin-
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containing regimens and non-rifampicin-containing regimens after 7, 14 and 28 days and 
after 2, 3 and 6 months are shown in Table 3.
After 7 and 14 days, no significant differences in the mycobacterial load could be found 
between rifampicin-containing regimens and non-rifampicin-containing regimens. After 
28 days, the rifampicin-containing regimens started to show a trend towards stronger 
bactericidal activity compared to non-rifampicin-containing regimens. At this time point, 
two out of six rifampicin-containing regimens showed significantly lower mycobacterial 
loads in the lungs compared to all non-rifampicin-containing regimens tested. After 2 
months of treatment, four out of six rifampicin-containing regimens showed significant 
lower mycobacterial loads compared to all non-rifampicin-containing regimens. However, 
a clear distinction in bactericidal activity between all rifampicin-containing regimens and 
all non-rifampicin-regimens to similar extent as observed for treatment outcome in Table 
2, could only be made after 3 months of treatment (Table 3).
Lastly, at the end of the 6-months treatment course no mycobacteria could be cultured 
from the lungs of nearly all mice treated with rifampicin-containing regimens. Of the non-
rifampicin-containing regimens, all mice treated with H in the continuous phase (HE, HZ 
and HS) showed reductions in mycobacterial load, but mycobacteria could still be cultured 
from the lungs. Two exceptions were the RZ and the HS group, which both contained 1 
out of 3 mice with culture-positive lungs. Mice of the ZES group, which were treated with 
E in the continuous phase actually showed an increase in mycobacterial loads compared to 
Table 2: Treatment outcome against a Beijing strain
drug regimen Treatment successa
rZ (2 RZ / 4R)b 95% (20/21)c
rhZs (2 RHZS / 4 RH) 95% (20/21)
rhZe (2 RHZE / 4 RH) 90% (19/21)
rh (6 RH) 87% (13/15)
re (6 RE) 85% (17/20)
rhZ (2 RHZ / 4 RH) 80% (17/21)
hs (2 HS / 4 H) 0% (0/9)
hZ (2 HZ / 4 H) 0% (0/20)
he (6 HE) 0% (0/18)
Zes (2 ZES / 4 E) 0% (0/20)
a percentage of mice with culture-negative lungs 3 months after stop of a 6-months treatment course, b (2 RZ / 4 R) = 2 
months RZ treatment followed by 4 months treatment with R only, c (20/21) = 20 mice with culture-negative lungs out of 
21 mice assessed. All rifampicin-containing regimens are marked grey. R = rifampicin, H = isoniazid, Z = pyrazinamide, S 
= streptomycin and E = ethambutol.
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3 months of treatment. Thus, bactericidal activity only correlated with treatment outcome 
after 3 months of treatment.
discussiOn
Two important findings in this study were that infection with an Mycobacterium tuber-
culosis-Beijing genotype strain in mice is associated with lower treatment success rates 
compared to other strains in literature 13, 17, 23, 24 and that bactericidal activity is an unreliable 
predictor for treatment outcome in TB when assessed in the first 2 months of treatment.
Infections with Beijing strains are associated with treatment failure in TB patients 3, 5-8. 
The data obtained in our mouse TB model reflect these clinical findings. None of the 
regimens tested, including the standard of care regimen 2RZH/4RH, achieved 100% treat-
ment success. In contrast, at least four different studies using Mycobacterium tuberculosis-
H37Rv genotype strains, including one previous study in our own model, showed 100% 
treatment success of the 2RHZ/4RH regimen in BALB/c mice 13, 17, 23, 24. In TB patients, 
treatment success rates with 2RHZE/4RH in controlled trial settings are 92% or less 25. This 
indicates that the repeatedly found 100% treatment success rates in preclinical mouse TB 
models using H37Rv might overestimate clinical treatment success rates. The 90% treat-
ment success rate for 2RHZE/4RH observed in our model using a Beijing strain might better 
represent the clinical situation.
The difference in treatment outcome between Beijing and H37Rv strains might be 
explained by the observation that only Beijing strains constitutively express proteins be-
longing to the DosR dormancy regulon 26, 27. These proteins regulate the mycobacterial 
metabolic state in response to stressors induced by the host-response. This could result in 
a more rapid or more profound conversion by Beijing genotype strains to a metabolic state 
in which the mycobacteria are less susceptible to anti-TB drugs. Other possibilities include 
the ability of Beijing strains to circumvent and manipulate host-responses more effectively 
than H37Rv 28, 29, resulting in better localization in (intracellular) niches, shielded from 
anti-TB drugs 30.
In TB, clinical phase IIa trials were found to be a poor predictor for treatment outcome 9, 31. 
These studies measure early bactericidal activity (EBA) in patient sputum samples between 
2-7 days or between 2-14 days in case of the extended EBA 11. Our mouse TB model clearly 
supports this clinical finding, as it is impossible to distinguish the rifampicin-containing 
regimens from the non-rifampicin-containing regimens after 7 or 14 days of treatment, 
despite their markedly different treatment outcome after 6 months of treatment.
Our single-drug exposure experiments showed that rifampicin only starts to show sig-
nificantly stronger bactericidal activity compared to other anti-TB drugs after a minimum of 
28 days of treatment. Two clinical studies that continued EBA measurements up to 28 days 
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indeed found a markedly stronger association between bactericidal activity and treatment 
outcome for anti-TB drug regimens containing pyrazinamide and rifampicin 32, 33. These 
studies indicate that extending EBA to 28 days might be a better predictor for treatment 
outcome. In our regimen-experiments we found that after 28 days the rifampicin-contain-
ing regimens showed a trend towards lower mycobacterial loads in the lungs compared to 
the non-rifampicin-containing regimens. However, a significant distinction in bactericidal 
activity between all rifampicin-containing regimens and all non-rifampicin-containing regi-
mens could still not be made. Moreover, after 28 days the standard of care RHZE-regimen 
showed similar mycobacterial loads in the lungs as the non-rifampicin-containing ZES-
regimen, while having markedly different treatment outcomes. Thus, based on our data we 
conclude that extending EBA for up to 28 days is more informative compared to 7 or 14 
days, but remains an unreliable parameter for predicting treatment outcome.
Clinical phase IIb trials measure bactericidal activity over a 2-months period with sputum 
culture status as surrogate endpoint for treatment outcome 31. These studies were initially 
thought indicative for phase III trial outcomes in TB 31, but the disappointing results of the 
recent phase III REMox trials show otherwise 9, 25. Our study shows that after 2 months of 
treatment, the rifampicin-containing regimens RH and RHZ still do not show significant 
differences in lung mycobacterial loads compared to the non-rifampicin-containing regi-
mens. The inability at this time point to significantly distinguish between regimens with a 
markedly different treatment outcome after 6 months supports the limited predictive value 
of measuring bactericidal activity during longer treatment durations in TB.
Our mouse TB model did show a clear distinction in lung mycobacterial loads between 
rifampicin-containing regimens and non-rifampicin-containing regimens after 3 months of 
treatment. However, the value of such a late time point in clinical studies is highly question-
able, especially when phase III trials strive to shorten treatment duration to 4 months 25.
In conclusion, multiple approaches are currently evaluated for their potential to further 
increase the translational value of preclinical TB models. Implementation of mouse strains 
that better mimic human disease are likely to improve future anti-TB drug research. Fur-
thermore, integration of advanced biostatistics to generate more informative models and 
increased appreciation for pharmacokinetics,- and dynamic aspects of treatment are also 
necessary to optimize anti-TB drug research. Our data complement these developments by 
advocating the use of Mycobacterium tuberculosis-Beijing genotype strains to increase the 
translational value of preclinical models assessing treatment outcomes. Also, our data in 
this mouse TB model support the notion that bactericidal activity in the first 2 months of 
treatment as measured in clinical phase IIa/b trials has limited predictive value for treatment 
outcome, which emphasizes the need for better biomarker to guide future phase III trials.
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aBsTracT
The aim of the study is to compare counting of colony forming units (CFU), the time to 
positivity (TTP) assay and the molecular bacterial load (MBL) assay, and explore whether 
the last assays can detect a subpopulation which is unable to grown on solid media. 
CFU counting, TTP and the MBL assay were used to determine the mycobacterial load in 
matched lung samples of a murine tuberculosis model. Mice were treated for 24 weeks 
with 4 treatment arms: isoniazid (H) - rifampicin (R) - pyrazinamide (Z), HRZ-Streptomycin 
(S), HRZ – ethambutol (E) or ZES.
Inverse relationships were observed when comparing TPP with CFU or MBL. Positive as-
sociations were observed when comparing CFU with MBL. Description of the net elimina-
tion of bacteria was performed for CFU vs. time, MBL vs. time and 1/TTP vs. time and fitted 
by nonlinear regression. CFU vs. time and 1/TTP vs. time showed bi-phasic declines with the 
exception of HRZE. A similar rank order, based on the alpha slope, was found comparing 
CFU vs. time and TTP vs. time, respectively HRZE, HRZ, HRZS and ZES. In contrast, MBL vs. 
time showed a mono-phasic decline with a flat gradient of elimination and a different rank 
order respectively, ZES, HRZ, HRZE and HRZS. The correlations found between methods 
reflects the ability of each to discern the general mycobacterial load. Based on the descrip-
tion of net elimination, we conclude that the MBL assay can detect a subpopulation of 
Mycobacterium tuberculosis which is not detected by the CFU or TTP assays.
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inTrOducTiOn
Tuberculosis (TB) is a bacterial infection that affects more than ten million people globally 
every year, with 1.8 million deaths recorded in 2015 and is ranked as a leading cause of 
death from infectious diseases worldwide 1.
Mycobacterial populations in TB patients are heterogeneous; several subpopulations of 
bacteria have been identified in the lungs, in different microenvironments 2. Environmental 
stress and antibiotic pressure can drive Mycobacterium tuberculosis into a non-replicating 
state 3, 4. As a consequence, extensive and long-term treatment is required to eradicate all 
these subpopulations of Mycobacterium tuberculosis5. In order to shorten the treatment 
duration, new drugs and novel combinations are essential and provide the best opportunity 
to eliminate all mycobacterial subpopulations.
For the development of new drugs and regimens, it is important at an early stage to 
determine a drug’s and regimen’s potency to prevent relapse, which will determine the 
required treatment duration with this regimen 6.
Monitoring treatment response provides information that can be used to make infer-
ences regarding treatment success. Current methods to monitor treatment response such 
as sputum smear or sputum serial colony counting have their drawbacks including loss of 
sensitivity, being laboratory intensive 7, or being sensitive to contamination 8. As a result, 
these methods do not predict individual success with enough certainty, but also seem 
to lack precision in predicting the important long-term clinical outcome of a regimen 
9. Furthermore, it is rather unlikely that all different subpopulations of Mycobacterium 
tuberculosis are detected using these methods 10.
In vitro experiments and animal models often use counting of colony forming units 
(CFU) as a parameter to determine the total bacterial load. It has been shown by Hu et al. 
that CFU counts are not always representative for the total population present in an in vitro 
system, as well as in the lungs of TB infected mice 11. Besides the CFU counts found, there 
was also a population of Mycobacterium tuberculosis present that could only be detected 
when they were resuscitated using resuscitation promoting factors (RPFs), indicating that 
basic CFU counting is maybe not the most optimal parameter to determine the total bacte-
rial load. Therefore new techniques, which are less dependent on culture viability, are 
necessary to provide this information.
In the present study, we used matched lung samples of our murine TB model to com-
pare CFU counting, liquid culture/time to positivity (TTP) and the molecular bacterial load 
(MBL) assay 12. This MBL assay detects Mycobacterium tuberculosis 16S ribosomal RNA 
with a robust internal control (IC) which normalizes for RNA loss during extraction and the 
presence of sample inhibitors. By measuring 16S ribosomal RNA the MBL assay is therefore 
not depending on actively growing mycobacteria.
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The aim of the study is to compare CFU counting, TTP and the MBL assay, and explore 
whether the last assays can detect a mycobacterial subpopulation which is unable to 
grown on solid media.
maTerials and meThOds
mouse TB model
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les Oncins, 
France). At the day of infection, animals were 13-15 weeks old and weighed 20-25 g.
Four groups of mice were infected with Mycobacterium tuberculosis as described previ-
ously 13. In short, mice under anesthesia were infected by intra-tracheal instillation of a 
suspension (40 µL) containing 1.3 x 105 CFU (0.7 – 1.7 x 105) of the Beijing VN 2002-1585 
genotype strain 14, followed by proper inhalation to ensure the formation of a bilateral TB 
infection.
antibiotic therapy
Four treatment arms, each with a total length of 6 months (24 weeks) were designed, as 
part of the research conducted within the PreDiCT-TB consortium: HRZ (2HRZ / 4HR), ZES 
(2ZES / 4E), HRZE (2HRZE / 4HR) and HRZS (2HRZS / 4HR). All treatment arms started 2 
weeks after infection.
Human equivalent doses of antibiotics were used: isoniazid (H) 25 mg/kg, rifampicin (R) 
10 mg/kg, pyrazinamide (Z) 150 mg/kg, streptomycin (S) 200 mg/kg and ethambutol (E) 
100 mg/kg 15. All drugs were dissolved in water and given orally (0.2 mL) as a bolus, 5x/
week, except for S, which was administered subcutaneously.
determination of the mycobacterial load in infected lungs
To determine the mycobacterial load in infected lungs, mice were sacrificed by CO2 ex-
posure at the start of therapy and after 1, 2, 4, 8, 12 and 24 weeks of therapy (n=3). To 
prevent carry-over of TB-drugs, therapy was stopped 72 hours before sacrificing the mice.
The lungs were removed aseptically and homogenized within 5 minutes in M-tubes with 
the gentleMACS Octo Dissociator using the RNA program (Miltenyi Biotec BV, Leiden, the 
Netherlands) in 2 mL Phosphate Buffered Saline (PBS).
colony forming units counts
From each tissue homogenate 10-fold serial dilutions were performed and samples of 
200 µL were cultured on drug-free 7H10 Middlebrook agar containing activated charcoal 
(0.4%) , and incubated for 28 days at 370C with 5% CO2 to perform colony counting. 
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Activated charcoal was added to the agar to inhibit the antibiotic residue from the tissue 
samples and prevent carry-over 16. Lower limit of quantification is 10 CFU per lung.
Time to Positivity
From each tissue homogenate 200 µL was added to a mycobacterial growth indicator 
tube (BBL MGIT; Becton, Dickinson and Company, MD, USA) in combination with 800 µL 
OADC enrichment. Tubes were incubated in the Bactec MGIT 960 (Becton, Dickinson and 
Company, MD, USA) and TTP was automatically recorded.
mBl assay
From each tissue homogenate 300 µl was directly preserved in guanidine thiocyanate 
(GTC) containing 1% ß-mercaptoethanol and stored at -80°C. MBL assay was performed 
as previously described by Honeyborne et al.12. In short, following thawing, 50 ng of the 
internal control (IC), a 1,957-bp RNA molecule that contain parts of the sol gene from 
potato tuber (Solanum tuberosum) 12, was spiked into each tissue sample. The IC normal-
izes for RNA loss during extraction and the presence of sample inhibitors. To assign cycle 
threshold values to bacterial loads, a standard curve was prepared. Naïve lung homogenate 
in GTC was spiked with serial diluted concentrations of a Mycobacterium tuberculosis 
stock ranging from 1.3 x 107 down to 1 CFU/mL, including the IC (table 1).
Lung homogenate in GTC plus IC was centrifuged (14,000 x g;20 minutes) at room 
temperature, supernatant was discarded and 1 mL of RNApro (FastRNA pro Blue kit; MP 
Biomedicals) was added to the pellet. RNA extraction was performed according to the 
manufacturer’s instructions. DNase I (Turbo DNA-fee kit; Ambion) was used to remove 
contaminating DNA.
Expression of 16S-ROX and IC-JOE was measured using multiplex reverse transcriptase-
quantitative PCR (RT-qPCR). RT-qPCR was performed on a 7500 Fast Real-Time PCR System 
(Applied Biosystems, Bleiswijk, the Netherlands) using a one-step qRT-PCR MasterMix for 
probe Assay Low ROX (Eurogentec, Maastricht, the Netherlands). Primers and dual-labelled 
probes were also purchased from Eurogentec.
Table 1. Standard curve of CFU and CT values obtained from a serially diluted Mycobacterium tuberculosis stock spiked in 
naïve lung homogenate.
cfu Mycobacterium tuberculosis / 1ml lunghomogenate
cfu 1,3E+07 1,3E+06 1,3E+05 1,3E+04 1,3E+03 1,3E+02 1,3E+01 0,0E+00
mean cT 11,99 13,26 19,05 24,17 31,02 35,23 >40 -
sd 0,77 0,71 0,78 0,78 1,82 1,71 - -
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data analysis
Data 0-24 weeks of treatment (2-26 weeks following infection) were used to investigate 
elimination of bacteria under the four therapeutic conditions (HRZ, ZES, HRZE, HRZS). 
Contaminated CFU (n=2) and TTP (n=11) samples were excluded. Correlations between 
measurements obtained by CFU, TTP and MBL assay over time collectively were evaluated 
by Spearman’s Rank (p <0.017 was considered statistically significant at the 5% level incor-
porating a Bonferroni correction for 3 pairwise comparisons for each treatment). Given that 
data from 3 distinct mice were available at each time point, naïve pooling was undertaken 
for analysis 17. Mathematical models to describe the profiles of elimination of bacteria 
under treatment were fitted by nonlinear regression to the observed profiles of bacterial 
load vs. time as measured by CFU, 1/TTP, and MBL (TTP in broad terms being inversely 
proportional to the number of bacteria in the system). Parameter estimates for this mod-
elling analysis were determined using the nonlinear least squares optimization function 
“lsqnonlin” as part of the “pracma” package in R (www.r-project.org). Standard errors 
were calculated using previously described methods by Landaw et al. with the Jacobian 
of model parameter sensitivities estimated using a numerical central difference method 
18. Exponential growth and death of bacteria cannot be differentiated with this data (the 
growth and death processes may occur simultaneously across the bacterial population as a 
whole) therefore exponential rate constants describing the “net” rate of bacterial growth 
or death were estimated from the quantitative timecourse profiles of bacterial load as 
determined by the 3 assays. These net rate constants take a negative value corresponding 
to net elimination, and a positive one to describe net growth.
resulTs
The data of lung CFU, MBL and TTP (TTP data is converted to 1/TTP) over 24 weeks of treat-
ment are illustrated (Figure 1) and statistical relationships between assays are summarized 
(Table 2). Overall, inverse correlations were observed between TTP with CFU and MBL and 
positive associations between CFU and MBL with statistical significance for all regimens 
with the exception of TTP vs. MBL for ZES and HRZE and CFU vs. MBL for HRZS (Table 2). 
For HRZ, HRZE and HRZS, MBL consistently reported lower than CFU between 2-8 weeks 
post-infection and higher than CFU to 14 weeks and 26 weeks post-infection (Figure 1).
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figure 1. Mouse lung CFU, MBL and TTP over 24 weeks post-treatment (26 weeks post-Mycobacterium tuberculosis infec-
tion) with HRZ, ZES, HRZE and HRZS. Data are presented as mean value (n=3 mice per time point) ± SD with CFU and MBL 
on the left y-axis and 1/TTP on the right. The solid and dashed lines represent the modelled fit to the data.
Figure legend
♦ Observed CFU ------- Predicted CFU
■ Observed MBL ------- Predicted MBL
▲ Observed 1/TTP ------- Predicted 1/TTP
CFU: Colony Forming Units; MBL: Molecular Bacterial Load; TTP: Time To Positivity
H: isoniazid; R: rifampicin; Z: pyrazinamide; S: streptomycin; E: ethambutol
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modelling of cfu vs. time
For CFU profiles over time (t) from the lung while under therapy the best description was 
given by a bi-exponential decline of the form CFU(t) = A*10^(-α*t)+B*10^(-β*t) with the 
exception of HRZE for which a mono-phasic decline was supported [CFU(t) = A*10^(-α*t)] 
(Figure 1). The first order exponential rate constants alpha (α) and beta (β) (in broad terms 
the “slopes” of the phases of the profile vs. time when plotted on a semi-logarithmic scale) 
are summarized (Table 3). Based on the β exponential rate constant, governing the 2nd 
phase of a multiexponential profile (if 2 exponential phases are present, and governing 
the only phase if the profile is mono-phasic) a rank order HRZE > HRZ > HRZS > ZES was 
shown, i.e. HRZE produced the steepest gradient on a logarithmic scale corresponding to a 
more rapid rate of elimination of bacteria, in contrast to ZES which actually showed signs 
of regrowth of bacteria during the second phase of its profile, though at a slow rate close 
to stasis over the 12-24 week period of the study (β of -0.414 vs. +0.049; Table 3). The β 
exponential rate constant is potentially a more interesting parameter of comparison as it is 
likely to reflect more the activity of treatment against a slower dying, less drug susceptible 
mycobacterial subpopulation similarly though, based on α slope, rate of eliminations were 
in the order of HRZ > HRZS > ZES (Table 2) with HRZE for unknown reasons showing only 
a mono-phasic decline in this experiment.
Table 2. Summary of spearman rank correlation coefficients evaluating the relationships between assays for measure-
ment of Mycobacterium tuberculosis in mouse lung following 24 weeks treatment with HRZ, HRZE, HRZS, ZES (analyses from 
week 2-26 post- Mycobacterium tuberculosis infection). P values highlighted in bold type represent statistically significant 
correlations with Bonferroni correction of 3 per drug combination for multiple comparisons (p< 0.017)
Treatment comparison rho* (95% ci) P value
HRZ TTP vs. CFU -0.993 (-0.998 to -0.978) <0.0001
CFU vs. MBL 0.846 (0.529 to 0.956) 0.0008 
TTP vs. MBL -0.874 (-0.964 to -0.602) 0.0003 
HRZE TTP vs. CFU -0.766 (-0.911 to -0.452) 0.0005
CFU vs. MBL 0.797 (0.412 to 0.941) 0.0027 
TTP vs. MBL -0.382 (-0.799 to -0.283) 0.248 
HRZS TTP vs. CFU -0.965 (-0.989 to -0.890) <0.0001
CFU vs. MBL 0.507 (-0.0069 to 0.809) 0.054 
TTP vs. MBL -0.753 (-0.922 to -0.345) 0.0044 
ZES TTP vs. CFU -0.982 (-0.994 to -0.952) <0.0001
CFU vs. MBL 0.492 (0.0888 to 0.757) 0.010 
TTP vs. MBL -0.457 (-0.762 to 0.0120) 0.028 
* Spearman’s rank correlation co-efficient
CFU: Colony Forming Units; MBL: Molecular Bacterial Load; TTP: Time To Positivity; H: isoniazid; R: rifampicin; Z: pyrazin-
amide; S: streptomycin; E: ethambutol; CI: confidence interval
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modelling of mBl vs. time
Profiles of MBL over time during therapy were described by mono-phasic declines (Figure 
1). The gradients of the elimination slopes on the logarithmic scale for each combination 
therapy were relatively flat and similar numerically suggesting slow bacterial elimination 
for all therapies (Table 3).
modelling of TTP vs. time
Given the inverse relationships observed between TTP with CFU and MBL a bi-exponential 
elimination model was fitted to 1/TTP vs. time data in order to determine a comparable 
elimination rate for TTP (Figure 1) (1/TTP being a more directly comparable measure of 
bacterial load). Based on the β rate constant, rate of bacterial decline was of an identical 
order to that observed for CFU (HRZE > HRZ > HRZS > ZES) with ZES also showing potential 
regrowth (i.e. a positive β rate constant) in the 12-24 week period as it did in its CFU 
profile.
Table 3. Parameter estimates and associated percentage relative standard errors (%RSE) for α and β exponential rate 
constants describing net bacterial growth/elimination for each treatment regimen between weeks 2-24 of infection. Data 
analysed by fitting a bi or mono-exponential model as appropriate.
cfu vs time
Treatment α (wk-1) %rse β (wk-1) %rse
HRZE* - - -0.414 9.4
HRZ -1.127 30.4 -0.346 7.6
HRZS -0.971 11.2 -0.270 19.0
ZES -0.664 9.8 +0.049 25.6
mBl vs time
Treatment α (wk-1) %rse β (wk-1) %rse
ZES* - - -0.136 11.4
HRZ* - - -0.132 4.5
HRZE* - - -0.130 10.0
HRZS* - - -0.116 10.9
(1/TTP) vs time
Treatment α (wk-1) %rse β (wk-1) %rse
HRZE -0.605 19.7 -0.038 10.4
HRZ -0.718 14.2 -0.032 9.2
HRZS -0.526 12.6 -0.030 17.8
ZES -0.276 7.6 +0.008 18.6
* Mono-exponential fitting
CFU: Colony Forming Units; MBL: Molecular Bacterial Load; TTP: Time To Positivity; H: isoniazid; R: rifampicin; Z: pyrazin-
amide; S: streptomycin; E: ethambutol; %RSE: percentage Relative Standard Error of parameter estimate.
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discussiOn
Identification of subpopulations of Mycobacterium tuberculosis is important for drug de-
velopment, refinement of existing or novel drug combinations to ultimately achieve thera-
peutic success in a clinical setting. Animal models can be particularly useful to evaluate 
potential methods of quantifying different populations of Mycobacterium tuberculosis11, 19. 
One of the benefits of an animal model is the ability to study the total population of My-
cobacterium tuberculosis in the lung, including the more hidden bacteria in granuloma like 
formations, whereas in sputum from TB patient only the secreted bacteria can be studied 
20. However, animal studies from the past using CFU counts as a parameter are maybe 
not predictive enough because it has been shown by Hu et al. that CFU counts are not 
representative for the total population present in an in vitro systems as well as in the lungs 
of TB infected mice, using RPFs to resuscitate a persistent and non-growing population 11.
We have presented for the first time the comparison of CFU, MBL and TTP methods 
using matched lung samples from a mouse TB model and explored the use of mathemati-
cal modelling to further summarize and scrutinize the data, describing the elimination 
of Mycobacterium tuberculosis over time for each method under different therapeutic 
conditions.
The ability to detect different Mycobacterium tuberculosis populations in our mouse TB 
model using the three methods can be explained by the principles of the techniques. In 
contrast to DNA based assays like the GeneXpert® MTB/RIF assay, the MBL assay detects 
the presence and amount of 16S rRNA and is therefore less hampered by the presence of 
genomic material of already dead cells 21. The 16S rRNA is much more unstable compared 
to DNA and degrades much faster 22. It has been shown that RNA, in particular mRNA, 
correlated with solid culture but more closely with growth in liquid culture 23. However, for 
culture on solid media or in liquid media actual growth is still required, thereby presenting 
only the fittest mycobacteria which were capable of growing. In contrast, for the MBL 
assay a particular population of Mycobacterium tuberculosis should be alive, and have 
metabolic activity, but actual growth is not required.
Statistically significant correlations between assays were evident for the majority of 
regimens tested. Lack of association between TTP vs. MBL for ZES and HRZE and CFU vs. 
MBL for HRZS was possibly due to small sample size in these groups. Unsurprisingly, TTP 
was inversely related to CFU and MBL as a shorter time to positivity would be expected 
with high bacterial load measured with CFU as well as with the MBL assay. Conversely, if 
the viable mycobacterial count CFU was zero, the MGIT will not measure fluorescence as 
a result of oxygen consumption and time to positivity would be infinite, because there are 
no growing mycobacteria present.
Mathematical modelling allowed estimation of the elimination rate of bacteria under 
each of the four drug combinations. The rates of elimination of bacteria for HRZ, ZES, 
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HRZE and HRZS as measured by CFU and TTP were of a similar rank order and were both 
typically bi-exponential in this study. This suggests that CFU and TTP are measuring similar 
bacterial populations that show net elimination under chemotherapy. A study conducted 
by Diacon et al. showed that CFU can be substituted with TTP in early bactericidal activity 
(EBA) studies 7, but on the other hand, a sample taken at the end of treatment can take 
longer to signal positive in MGIT compared to a sample taken early with a similar CFU 
count as shown by Bowness and colleagues 24. They showed that the relationship between 
CFU and TTP changes over time in early response to treatment (14 days). These observa-
tions imply that MGIT detects an extra sub-population of Mycobacterium tuberculosis 
and that this sub-population decreases in number during drug exposure and treatment. A 
similar analysis to Bowness and colleagues was not feasible however with the data in our 
study due to the limited number of samples per time point (or groups of time-points). We 
therefore cannot conclude that CFU and TTP are detecting different sub-populations of 
Mycobacterium tuberculosis in our mouse model.
Compared to the bi-phasic decline of CFU and TTP over time (with the exception of 
HRZE), description of MBL was mono-phasic for all four treatments with gradients on the 
logarithmic scale close to zero, but MBL counts remained positive during treatment in all 
four treatment arms, suggesting the presence of a mycobacterial subpopulation which 
decreases slowly under treatment, but cannot be detected by TTP and CFU counting. How-
ever, elimination rate constants derived from MBL data cannot arms tested. All four treat-
ment arms have MBL elimination rate constants of similar magnitude, whose differences 
cannot be considered statistically significant. In contrast to the mono-phasic elimination in 
the present study, a bi-phasic decline with the MBL was observed by Honeyborne et al.12. 
However, the study reported an EBA measured over 14 days with the first 3 days showing 
a steeper gradient compared to EBA 3-14 days. The difference in observations between the 
Honeyborne study and the present study may be a result of the richer initial time course 
studied by Honeyborne et al. compared to sampling 1 week after start treatment in our 
study. Thereby potentially failing to capture a bi-phasic decline of the first 3 days, which is 
a limitation of the current study.
At week 12, MBL numbers were higher compared to CFU and TTP (with the exception 
of ZES) and at week 24 CFU counts were negative for HRZ, HRZE and HRZS but the MBL 
numbers were still positive. Because rRNA is downregulated in bacteria entering dormancy 
25, we could speculate this could infer that the MBL assay maybe even underestimates the 
mycobacterial load during the continuation phase of treatment. This could for instance 
explain the failure of the MBL assay to differentiate between the efficacy of ZES and the 
HRZ-based regimens at the end of treatment.
In the present study, MBL also measured lower than CFU in the early phase of treat-
ment, indicating a less sensitive assay to detect high numbers of actively replicating Myco-
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bacterium tuberculosis. This was also shown by van der Vliet et al. 26, demonstrating that 
conversion of 16S rRNA to CFU must be optimized.
Also notable, , is the disparity between CFU and MBL counts after 12 weeks with 
rifampicin and isoniazid containing regimens (HRZ, HRZE and HRZS), compared with the 
observation of CFU and MBL after 12 weeks of the ZES treatment where minimal differ-
ence is found between the two. This observation is in keeping with a pattern where during 
the early phase of treatment the metabolically active Mycobacterium tuberculosis are 
eliminated by isoniazid, while rifampicin is one of the drugs responsible for the elimination 
during the sterilizing phase 27. The positive MBL counts at later time points which are not 
counted by the CFU and TTP assay possibly represent a subpopulation of Mycobacterium 
tuberculosis, which are in a dormant state. To add on to this, Malherbe et al. recently 
showed that mRNA can still be found in a bronchoalveolar lavage samples at the end of 
treatment in cured patients, also indicating that there is a subpopulation of mycobacteria 
which cannot be detected on solid media but is still present in the lungs 28. This suggest 
an important complementary role for the hosts immune system to maintain a disease-free 
state and shows that sterilizing or host-directed therapies are needed for the development 
of shortened and improved treatment regimens 28.
A study by de Steenwinkel et al., aiming for a shortened treatment regimen found 
that increasing the rifampicin dose up to 80 mg/kg/day reduced the treatment duration 
by four months, without relapse of infection 29. To add on to this, Hu et al. recently found 
that increasing the rifampicin dose eventually also eliminate the non-culturable population 
in their model 11. However, Kayigire et al. showed that rifampicin significantly reduced 
the CFU counts, but also significantly changed the proportions of non-growing, lipid 
body-containing mycobacteria an viable mycobacteria, indicating that treatment can drive 
mycobacteria in a non-culturable state 30.
Therefore, additional investigation of the use of the MBL assay with high doses of 
rifampicin in combination with RPFs is warranted to further characterize the non-culturable 
subpopulation.
In conclusion, we show strong correlations between CFU, TTP, and the MBL assay reflect-
ing the ability of each to determine the mycobacterial load in our mouse TB model. The 
findings also show that the MBL assay tells “a different story” to that of CFU counts and 
TTP, by detecting a subpopulation of Mycobacterium tuberculosis which is not detected by 
CFU or TTP assays.
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summariZing discussiOn
The overarching aim of this thesis is to contribute to better tuberculosis (TB) therapy. TB 
therapy can be improved in many ways, this work focussed on the additional value of ef-
flux pump inhibition. Moreover, we set ourselves the goal to further optimize the predictive 
value of our preclinical mouse TB model.
The primary objectives were:
– To assess the therapeutic potential of co-administration of efflux pump inhibitors, i.e. 
thioridazine or SILA-421 with the standard treatment regimen
– To study a moxifloxacin and linezolid combination as a novel treatment regimen for 
MDR-TB and potentiate this combination with efflux pump inhibitors and cell wall 
destabilizing drugs
– To characterize the effect of rifampicin on the transcription profile of a rifampicin-
susceptible and a rifampicin-resistant Mycobacterium tuberculosis strain
– To study the added value of using a Mycobacterium tuberculosis strain of the clinical 
highly relevant Beijing genotype in our mouse TB model
– To compare colony forming units counting, the time to positivity assay and the molecu-
lar bacterial load assay, and explore whether the last assays can detect a mycobacterial 
subpopulation which is unable to grow on solid media
To attain these objectives we studied the in vitro and in vivo activity of ‘classic’ and novel 
TB drugs in combination with efflux pump inhibitors against Mycobacterium tuberculosis
Therapeutic potential of coadministration of efflux pump inhibitors with 
the standard TB regimen
Thioridazine is described in literature as a potent efflux pump inhibitor 1-9. Therefore, we 
set out to potentiate the standard isoniazid-rifampicin-pyrazinamide (HRZ) combination in 
vitro as well as in vivo (chapter 2). The addition of thioridazine as a companion drug, was 
prompted by promising results from other groups 5, 6, 8. Using thioridazine as a companion 
drug in our in vitro model we were able to potentiate the activity of both mono-exposure 
of isoniazid and rifampicin against Mycobacterium tuberculosis, and concluded that thio-
ridazine could work synergistically with both drugs. The synergy also was found on the 
prevention of selection of isoniazid resistance. In spite of the promising in vitro results, 
translation to our mouse TB model was less successful as the addition of thioridazine to 
the HRZ-regimen was not associated with shorter treatment duration. This was in contrast 
to a previous study where a significant reduction of the mycobacterial load was observed 
when the HRZ-regimen was combined with thioridazine at a dose of 32 mg/kg compared 
to HRZ only treatment 8. Also a study by Dutta et al. reported a trend towards enhanced 
clearance when thioridazine at a dose of 25 mg/kg was combined with the HRZ treatment 
5. Due to severe toxic events the maximum tolerated dose in our mice was much lower than 
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previously published thioridazine doses in mice 5, 8. However, our final dose of 18 mg/kg/
day is close to the 25 mg/kg/day dose used by others that yields exposures of thioridazine 
in mice similar to those in humans after a 25 mg/kg/day dose 6. In addition, over time 
thioridazine accumulates in lung tissue up to 30-fold relative to serum 6. But nevertheless, 
a 3-months HRZ-regimen in combination with thioridazine was not successful and relapse 
of infection occurred. Unfortunately, we did not assessed relapse of infection after four 
or five months treatment to study the possibility of shortening treatment duration by only 
one or two months.
In a guinea pig TB model exposure to thioridazine also causes severe toxic events and 
limited bactericidal activity was found against extracellular mycobacteria within granulo-
mas 10. No support could be found in our studies for the use of thioridazine in combination 
with the standard TB regimen. Our results and the literature on thioridazine use as a TB 
drug taken together, the question remains whether it is still worth to study thioridazine as 
a potential TB drug. Alternatively, we may focus on more promising and safer efflux pump 
inhibitors e.g. verapamil in combination with bedaquiline.
To potentiate the activity of TB drugs in vitro and the HRZ-regimen in vivo, we also used 
the organosilicon compound SILA-421 (chapter 3). Little is known about the mode of 
action of SILA-421, but it is associated with efflux pump inhibition 11-14. We found a clear 
antimycobacterial effect of SILA-421 as single drug and synergistic activity in combination 
with isoniazid against drug-sensitive Mycobacterium tuberculosis. SILA-421 as single drug 
is also active against rifampicin-resistant strains. In combination with high concentrations 
of rifampicin it works synergistically and can completely eliminate the rifampicin-resistant 
Mycobacterium tuberculosis. However, despite promising in vitro results, we found no 
added value of SILA-421 in our mouse TB model when it was used for three months in 
combination with the standard HRZ-regime. SILA-421 is a novel compound and there was 
no assay available to measure SILA-421 levels in murine plasma. A PK/PD study that might 
explain why SILA-421 failed to improve the HRZ-regimen was therefore not possible. A 
dose finding study in combination with a pharmacokinetic study is needed to define the 
optimal SILA-421 dose in mice. Similar to chapter 2, we did not study the relapse of infec-
tion after four or five months treatment with the HRZ-regimen together with SILA-421. To 
better assess the sterilizing capacity of this combination, assessment of relapse of infection 
after different treatment lengths should be included.
a novel treatment regimen for mdr-TB based on moxifloxacin and 
linezolid
Treatment options for multidrug-resistant TB (MDR-TB) are limited 15. Second-line treat-
ment usually consist of various TB drug combinations administered for many months and 
with success rates of only 50% 15, 16. We therefore explored the effectiveness of a novel 
regimen consisting of moxifloxacin and linezolid in different combinations with two efflux 
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pump inhibitors (verapamil and timcodar) and/or the cell wall destabilizers colistin and 
SQ109 (chapter 4).
These efflux pump inhibitors and cell wall destabilizers can potentially increase the intra 
mycobacterial concentrations of moxifloxacin and linezolid and possibly enhance the activ-
ity of the drugs. In vitro, both moxifloxacin and linezolid were effective as single drugs 
against Mycobacterium tuberculosis. While moxifloxacin was associated with 99% killing 
with as little as 1/16x the fCmax, exposure to 1x fCmax of linezolid resulted in 90% killing. 
There is every reason, therefore, to propose that moxifloxacin may serve as a key drug to 
treat MDR-TB 17, 18.
The WHO recently upgraded linezolid to group C, which includes ‘other core second-
line agents’ for the treatment of drug resistant TB, but warned that more (pre-) clinical 
data of linezolid is urgently needed 18. Our data shows indeed that linezolid acts against 
Mycobacterium tuberculosis at relative low concentrations. We also showed that the 
combination of moxifloxacin plus linezolid is active against Mycobacterium tuberculosis at 
concentrations that can be achieved in TB patients.
Nevertheless, administration of especially linezolid carries the risk of toxicity 19. Adding 
potentiator drugs, we thought, would optimize the activity of the moxifloxacin - linezolid 
regimen and avoid high systemic drug concentrations, which are associated with toxicity 20.
To this aim we used moxifloxacin and linezolid concentrations which in combination 
would only inhibit growth, and not result in killing. The addition of colistin to the moxi-
floxacin plus linezolid resulted in an increased elimination of Mycobacterium tuberculosis. 
This, however, did not meet our criterion of synergy of a 2 log difference between the 
combination and the most active single drug of the combination 21. Verapamil, timcodar 
and SQ109 did not increase the in vitro activity. We concluded that Mycobacterium tu-
berculosis could be effectively eliminated with the moxifloxacin – linezolid combination, 
and that colistin could act as potentiator compound. Our data support the usefulness of 
moxifloxacin and linezolid in the treatment of MDR-TB. To evaluate the bactericidal activity 
and sterilizing capacity of this combination, the results from our extracellular in vitro model 
must be translated to our in vivo mouse TB model.
To study the moxifloxacin and linezolid regimen in mice we needed to know what doses 
would achieve a human pharmacokinetic equivalent exposure (chapters 5 & 6). Using 
increasing dosages and a pharmacokinetic analysis we obtained different parameters upon 
which we could perform the comparisons of mouse and humane data. In this studies, we 
also assessed the usability of the Dried Blood Spot (DBS) analysis method for measuring 
moxifloxacin and linezolid concentrations in murine blood spots. DBS analysis can reduce 
the number of animals needed in preclinical drug development because it allows for the 
assessment of drug concentrations in small blood volumes over time within a single mouse. 
In addition it may serve as a method for therapeutic drug monitoring (TDM) during activ-
ity and efficacy experiments in mice. For instance, TDM can be used to study drug-drug 
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interactions for their impact on the drug exposure of drugs studied 22. We found that DBS 
concentrations of moxifloxacin and linezolid can predict plasma concentrations with good 
precision, so DBS analysis can be of use in preclinical murine models for its capacity of 
reducing the number of animals needed.
For moxifloxacin, the AUC relative to the minimal inhibitory concentration has been 
suggested as the best parameter to predict in vivo efficacy against Mycobacterium tuber-
culosis23. Based on the protein binding, which seems slightly lower in mice compared to 
humans and the AUC0-∞ calculated in the current study, we concluded that a single dose 
of 200 mg/kg moxifloxacin in mice would approximate a human equivalent free drug 
exposure (AUC0-24 24.8 mg*h/L / fAUC0-24 17.3 mg*h/L 24). In line with this, Poissy et al. 
reported AUC values close to those found in humans with the use of a similar dose as well 
as the highest decline in CFU with this dose 25.
For linezolid we found that a dose of 50 mg/kg resulted in an AUC0-∞ of 78 mg/L*h in 
BALB/c mice, which approximates free linezolid exposures of a dose between 300 and 600 
mg in humans. The literature is divided on the optimal linezolid dose associated with treat-
ment efficacy in humans. Initial treatment of MDR-TB with 600 mg of linezolid twice daily 
has been limited by adverse effects 26, 27. Lower doses mostly seemed to retain effectiveness 
and to limit toxicity 20, 26, 27. Therefore, the linezolid doses ≥100 mg/kg tested in mice by 
other groups probably by far exceed clinically useable doses and exposures 28, 29.
characterization of the transcription profile after rifampicin exposure
A small side-step in this thesis is presented in chapter 7. We studied the transcriptome re-
sponse following rifampicin exposure of an isogenic pair of strains, one rifampicin-sensitive 
and one rifampicin-resistant Mycobacterium tuberculosis strain. Rifampicin resistance in 
Mycobacterium tuberculosis is caused for almost 95% by non-synonymous single nucleo-
tide polymorphisms in the 81 base pair region in the rpoB gene 30. Still, rifampicin can 
actively induce the activity of efflux pump genes and transporters genes, at the level of 
gene expression 31.
With this study, we aimed to provide more insight in the influence of rifampicin 
resistance on the overall gene expression upon rifampicin exposure. We were particu-
larly interested in whether efflux pumps and transporter-associated genes were affected. 
Microarray analysis revealed resistance-dependent differences in response between the 
rifampicin-sensitive and the rifampicin-resistant strain. Gene clusters associated with ef-
flux, transport and virulence were altered in the rifampicin-resistant mutant compared to 
the rifampicin-susceptible wildtype strain after exposure to rifampicin. Two up-regulated 
gene clusters, that is Rv0450c to Rv452 and Rv0676c to Rv678, respectively, were found 
which both consist of genes of the MmpL (Mycobacterial membrane protein Large) family, 
and the MmpS (Mycobacterial membrane protein Small) family. Recently, mutations in the 
Rv0678 gene were shown to lead to subsequent transcriptional upregulation of all three 
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genes (rv0678, mmpS5, and mmpL5) of the locus. As a consequence, partial resistance 
to both clofazimine and bedaquiline was found 32. These data, together with the results 
of Milano et al.33 and the results presented in chapter 7, confirms the role of the gene 
cluster (rv0678, mmpS5, and mmpL5) that is involved in drug efflux. Functions of the 
other upregulated gene clusters are still unknown. RNA-sequencing, the new version of 
microarray analysis, would be an interesting option for further research.
evaluation and optimisation of our mouse TB model with a Beijing isolate 
as a preclinical model
Evidence continues to accumulate indicating that TB caused by strains of the Beijing geno-
type are clinically associated with treatment failure 34-37. However, the H37Rv laboratory 
strain is used in many preclinical TB models, which might not optimally represent the 
virulence of strains that cause TB in patients. Therefore, we aimed to assess the bactericidal 
activity and sterilizing capacity of TB drugs in our preclinical mouse TB model with a Beijing 
genotype strain (chapter 8).
We found that bactericidal activity after 2 and 4 weeks treatment was primarily driven 
by rifampicin, were in TB-patients isoniazid showed the best bactericidal activity after 2 
weeks treatment 38. In the sterilizing capacity experiments only the rifampicin-containing 
combinations reached culture-negativity of lungs after a 6-months treatment course. 
Based on this we concluded that rifampicin is essential in the treatment of drug-susceptible 
TB. Nevertheless, even these rifampicin-containing combinations failed to reach complete 
sterilizing capacity. The remarkable difference between the rifampicin-pyrazinamide (RZ) 
combination (5% relapse) and the rifampicin-isoniazid-pyrazinamide (RHZ) combination 
(20% relapse) is interesting. This difference was not significant, but our results are comple-
mentary to those of an earlier study assessing sterilizing activity after a 6-months treatment 
course with RZ or RHZ after intravenous infection of Swiss mice 39.
In line with clinical studies 40, bactericidal activity did not correlate with sterilizing capac-
ity in our model. This is particularly true for RHZ-treated mice, which showed the highest 
bactericidal activity between 0-14 days but also the highest relapse rate of 20%.
In our previous studies and in studies by other groups, the RHZ regimen against the 
H37Rv strain in BALB/c mice resulted in 100% sterilizing capacity, without relapse of infec-
tion 41-44. Moreover, other mouse TB models such as C3HeB/FeJ mice also show 100% 
sterilizing capacity using the RHZ regimen against infection with H37Rv 45, 46. In this study 
we clearly demonstrated that each of the studied combinations of conventional TB drugs, 
including the RHZ, regimen did not achieve 100% sterilizing capacity against a clinical 
Beijing isolate.
We concluded that testing sterilizing capacity of TB drugs against different mycobacterial 
strains is important to improve the predictive value of our mouse TB model. Furthermore, 
we concluded that bactericidal activity is not predictive for the sterilizing capacity.
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The method of colony forming units (CFU) counting is often used to monitor the my-
cobacterial load in preclinical models. Bowness et al. have suggested that liquid media is 
more suitable to detect a population of cells that are viable but non-culturable on solid 
agar 47. Also the Molecular Bacterial Load (MBL) assay is thought to be a good replacement 
of solid culture 48. We therefore optimized the MBL assay for use in our studies, together 
with the time to positivity (TTP) assay, and the standard CFU counting to monitor changes 
in the mycobacterial load and thereby the treatment response (chapter 9). Mice infected 
with Mycobacterium tuberculosis were treated with four different treatment arms i.e. HRZ, 
HRZS, HRZE and ZES. The obtained CFU counts at multiple time points during treatment 
were compared to the results obtained with the TTP assay and MBL assay.
We found significant correlations between the three methods, and concluded that all 
methods were able to discern a general mycobacterial load of Mycobacterium tuberculosis 
in our mouse TB model. However, when fitting the net elimination of mycobacteria with 
nonlinear regression, we found that both CFU counting and the TTP assay describe the 
data in a bi-phasic manner with a small but steep α-slope during the first phase of treat-
ment, followed by a β-slope during the rest of treatment. In contrast the MBL showed 
a mono-exponential decline with a flat gradient of elimination. This would explain why 
CFU counting and the TTP assay indicated culture negativity after three months treat-
ment whereas the MBL assay was still positive. Maybe the MBL assay is detecting a sub-
population of mycobacteria which is gone unnoticed by CFU counts or the TTP assay. This 
subpopulation is possibly in a dormant state and therefore not able to grow. Obviously, 
only drug combinations that can successfully eradicate this dormant population can reach 
true culture negativity and can prevent relapse of disease. Therefore it is pivotal to detect, 
visualize and closely monitor the dormant population of mycobacteria in preclinical models 
as well as in TB-patients. 
fuTure PersPecTiVes
The use of efflux pump inhibition
Regardless of the limited success of efflux pump inhibition described in this thesis, there is 
clearly a role of efflux pump inhibition in the treatment of TB, as shown by Gupta et al.49-51. 
They performed experiments in mice using verapamil in combination with the standard 
regimen as well as in combination with bedaquiline. Verapamil added as potentiator drug 
to the HRZ-regimen accelerated the mycobacterial killing, and addition of verapamil to 
bedaquiline increased the bactericidal activity of bedaquiline 49-51. Recent WHO guidelines 
recommend bedaquiline and delamanid separately as an ‘add on agent’ in the treat-
ment of MDR-TB and XDR-TB. So far, no clinical trials have studied the combination of 
bedaquiline and delamanid. However, two recent case reports describe good short-term 
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outcomes for this combination in XDR-TB patients, although side effects were seen 52, 53. 
Our mouse TB model is suitable to evaluate the bactericidal activity and sterilizing capacity 
of a bedaquiline and delamanid combination, and to provide preclinical data which can be 
used to design a clinical trial. This combination can be administered with the efflux pump 
inhibitor verapamil to increase the activity of bedaquiline. By optimizing the bedaquiline 
and verapamil combination, it might be possible to lower the bedaquiline dose without 
loss of activity and efficacy and avoid toxicity.
further optimize our mouse TB model
In an experimental setting the most important factor describing treatment success is the 
relapse rate. Therefore, relapse of infection was also a parameter in some of the studies 
included in this thesis. There is no standard method of performing relapse assessment stud-
ies, however, and many variations are possible, e.g. sample size, duration of the treatment 
free period and the use of Cornell model.
The current method of relapse assessment is not informative enough; it lacks dynamics. 
Describing the relapse in a more dynamic way could help improve the predictive value of 
our mouse TB model. For future studies it is essential that we optimize and standardize 
the way we do relapse studies. Continuous assessment of the relapse mycobacterial load 
after different durations might enable to characterize the dynamics of relapse and the 
underlying microbiological response.
evaluate the bactericidal activity and sterilizing capacity against non-
replicating Mycobacterium tuberculosis
Our findings that CFU counting might lead to underestimation of the total population 
of mycobacteria shows that better tools are needed to monitor treatment response. By 
using the MBL assay a population of bacteria was detected that was not able to grow on 
agar or in liquid media. It is thought that this persisting population is responsible for the 
relapse of TB and that prolonged treatment is needed to eliminate these persisting myco-
bacteria. Several recent clinical trials of shortened regimens containing fluoroquinolones 
failed to show non-inferiority mainly due to increased relapse rates, despite a more rapid 
clearance of mycobacteria in both mice and patients 17, 54-56. This highlights the important 
role of the hidden, non-culturable mycobacterial population. Great effort must be made 
to study this hidden population and its response to treatment. One way to character-
ize this population is by using resuscitation-promoting-factors (RPFs). RPFs are a family 
of secreted peptidoglycan-remodelling enzymes, which are required for the regrowth of 
dormant mycobacteria 57. RPF-dependent mycobacteria are highly abundant in sputum 
from TB-patients and can also be recovered from infected lungs 58, 59. These RPFs can drive 
Mycobacterium tuberculosis into an active state in which they can be cultured. The use of 
RPFs must be evaluated in the time-kill kinetic experiments in order to identify TB drugs 
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that are real sterilizing drugs instead of drugs that inhibit growth and drive Mycobacterium 
tuberculosis in a non-replicating state.
To prove that the subpopulation found using the MBL assay is an actual non-replicating 
subpopulation, we have to resuscitate the bacteria present in the lung homogenate of 
our mouse TB model using RPFs. If we can increase the CFU numbers identical to the 
MBL counts, we can combine CFU counts with RPFs as an optimized tool to monitor the 
mycobacterial load.
At the start of this thesis we referred to the ‘END TB STRATEGY’ of the WHO and the 
targets set in that document. We hope that this thesis forms a piece of the enormous 
TB eradication puzzle and contribute to a slightly better view and understanding of the 
challenges and putative solutions that will lead to the end of TB.
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samenVaTTing
Tuberculose (TBC) is een infectieziekten en door de geschiedenis heen heeft TBC wereld-
wijd de meeste doden op zijn naam staan ten opzichte van andere infectieziekten. Geschat 
wordt dat het er meer dan 1 miljard zijn in de afgelopen 200 jaar. Ook vandaag de dag is 
TBC de infectieziekte die de meeste doden tot gevolg heeft. De Wereldgezondheidsorgani-
satie (WHO) schat dat in 2015 1,8 miljoen mensen zijn overleden aan de gevolgen van TBC 
en dat er 10,4 mensen TBC hebben opgelopen, waaronder 1 miljoen kinderen. Om deze 
kille cijfers meer gevoel te geven; dit betekent dat er wereldwijd elke minuut drie mensen 
overlijden aan TBC. Om deze ziekte een halt toe te roepen, heeft de WHO in mei 2014 de 
‘END TB STRATEGY’ gelanceerd. Het doel is een wereld zonder TBC. Om dit te realiseren 
zijn ambitieuze doelen gesteld, zoals een 95% reductie van het aantal doden ten gevolge 
van TBC en een 90% reductie van de TBC-incidentie in 2035 ten opzichte van 2015. Het 
is bijzonder ambitieus, omdat de WHO ook inschat dat 2 tot 3 miljard mensen wereldwijd 
zijn besmet met de bacterie die TBC veroorzaakt. Deze mensen zijn latent geïnfecteerd, 
maar zijn niet ziek. Van deze groep ontwikkelt 5 tot 15% alsnog TBC gedurende zijn of 
haar leven. Uiteindelijk kan iedereen TBC krijgen, maar er zijn een aantal factoren bekend 
die het risico vergroten op het oplopen van TBC. Dit zijn diabetes, roken en het gebruik 
van verdovende middelen, maar ook problemen met de gezondheid waarbij het immuun-
systeem is aangetast, zoals HIV. Daarnaast is TBC een aan armoede gerelateerde ziekte.
De bacterie die al deze ellende veroorzaakt, is Mycobacterium tuberculosis. Het is een 
bacterie die al duizenden jaren deze ziekte veroorzaakt en zelfs al ver voor Christus is 
beschreven in bijvoorbeeld de Bijbel (Lev 26:16). De bacterie is voor het eerst ontdekt door 
Robert Koch in 1882, en is geclassificeerd als een gram positieve bacterie. De overdracht 
van mens naar mens gebeurt meestal via kleine waterdruppeltjes die worden uitgehoest 
door de patiënt. De klassieke symptomen van TBC zijn hoesten, significant gewichtsverlies, 
nachtzweten en koorts. Als de infectie niet wordt behandeld, overlijdt ongeveer 70% van 
de mensen binnen tien jaar na infectie.
Voor de Tweede Wereldoorlog waren er geen antibiotica beschikbaar om TBC te behan-
delen. In 1944 werd streptomycine ontdekt en in 1952 isoniazide. Door deze antibiotica 
te combineren was TBC te behandelen, maar de behandelduur was minstens achttien 
maanden. In 1967 werd rifampicine voor het eerst gebruikt ter bestrijding van TBC en 
dat is vandaag de dag nog steeds het middel om TBC mee te behandelen in combinatie 
met isoniazide, pyrazinamide en ethambutol. De totale behandelduur is nu zes maanden 
in het geval van een niet resistente Mycobacterium tuberculosis. De mycobacteriële bac-
teriepopulatie in een patiënt is gevarieerd en bestaat uit diverse subpopulaties, en al deze 
subpopulaties kunnen verschillend reageren op antibiotica. Voor een succesvolle behande-
ling van TBC is het extreem belangrijk dat de combinatie van antibiotica actief is tegen alle 
subpopulaties, om zo de kans op ‘relapse’ van TBC en resistentie te voorkomen.
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Resistentie maakt het moeilijk om de wereldwijde epidemie van TBC te stoppen. Op 
dit moment zijn er volgens de WHO per jaar bijna een half miljoen gevallen van multidrug 
resistente TBC. De behandeling van deze vorm van TBC is moeilijk, omdat de bacteriën 
resistent zijn voor de meest gebruikte antibiotica. Een alternatieve behandeling kan tot 
wel twintig maanden duren, is complex en bestaat uit veel verschillende pillen en injecties, 
samen dit kan oplopen tot wel 14.000 stuks over de gehele periode. En uiteindelijk is er 
slechts in 50% van de gevallen genezing mogelijk. Een groot probleem van deze tweede 
keus antibiotica zijn de vele bijwerkingen, zelfs zo erg dat patiënten de bijwerkingen van 
de antibiotica ervaren als erger dan de ziekte zelf. De extreem lange behandelduur en de 
vele serieuze bijwerkingen leiden ertoe dat patiënten tijdens de behandeling afhaken, met 
als resultaat dat de bacteriën alleen nog maar resistenter worden. Het is dan ook duidelijk 
dat de behandeling van TBC moet worden geoptimaliseerd.
het onderzoek
Voor de optimalisatie zijn er meerdere wegen die naar Rome kunnen leiden, meerdere 
strategieën zijn mogelijk. De eerste optie de we hebben bestudeerd om TBC efficiënter te 
bestrijden is de hoeveelheid van de antibiotica op de plaats van infectie te vergroten. De 
hoofdstukken 2, 3 en 4 beschrijven onderzoek naar hoe we door middel van effluxpomp-
remmers de activiteit en effectiviteit van verschillende antibiotica hebben geprobeerd te 
optimaliseren. Dit kan bijvoorbeeld bereikt worden door effluxpompen te blokkeren. Deze 
effluxpompen bestaan uit eiwitcomplexen in de celwand van bacteriën en kunnen allerlei 
stoffen, waaronder antibiotica, de bacterie uit pompen. Door deze effluxpompen te blok-
keren kunnen antibiotica niet meer, of in mindere mate, de bacterie of cel uit gepompt 
worden. Ook kan met antibiotica worden gezorgd dat de celwand van de bacterie wordt 
verzwakt, waardoor deze beter doorlaatbaar wordt en andere antibiotica makkelijker de 
bacterie in kunnen.
Een andere manier om de behandeling van TBC te optimaliseren is het gebruik van 
nieuwe antibiotica. Na decennia van relatieve stilte op het gebied van nieuwe antibio-
tica voor TBC, zijn er nu verschillende nieuwe antibiotica beschikbaar en zijn er aantal 
in ontwikkeling. Voordat deze nieuwe stoffen kunnen worden ingezet als antibiotica 
worden zeer uitgebreide testen gedaan, maar deze preklinische fase duurt jaren. Om dit 
proces te optimaliseren en te versnellen zijn wereldwijd verschillende onderzoek consortia, 
waaronder PreDiCT-TB, bezig om methoden te ontwikkelen om zo in een vroege fase 
van antibiotica-ontwikkeling de meest veelbelovende stoffen te identificeren en verder 
te ontwikkelen. Een deel van het werk beschreven in dit proefschrift (hoofdstuk 8 en 9) 
maakt deel uit van PreDiCT-TB. In hoofdstuk 8 hebben we in ons muis TBC-model met een 
klinische Mycobacterium tuberculosis stam van het Beijing genotype de bacteriële activiteit 
en steriliserende capaciteit van verschillende antibiotica tegen TB bepaald. De data als 
resultaat van deze experimenten wordt in wiskundige modellen gebruikt om de voorspel-
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lende waarde van de verschillende preklinische modellen te berekenen. In hoofdstuk 9 
hebben we drie verschillende methoden onderling vergeleken die kunnen worden gebruikt 
voor de monitoring van de hoeveelheid mycobacteriën in de long. Dit met als doel het 
onderzoeken of één van deze methoden in staat is een subpopulatie van mycobacteriën 
aan te tonen die niet groeit op vaste voedingsbodems. De drie gebruikte methoden zijn 
‘Colony Forming Units (CFU) counting’ in een longhomogenaat op vaste voedingsbodems, 
de ‘Time to Positivity’ (TTP) assay vanuit een longhomogenaat in vloeibaar medium en de 
‘Molecular Bacterial Load’ (MBL) assay voor het bepalen van de hoeveelheid mycobacterieel 
ribosomaal RNA in een longhomogenaat.
resultaten
het therapeutisch potentieel van het combineren van effluxpomp-
remmers met de standaard TB-behandeling
In hoofdstuk 2 hebben we de activiteit van thioridazine tegen Mycobacterium tuber-
culosis onderzocht, allereerst alleen en vervolgens samen met de isoniazide-rifampicine-
pyrazinamide (HRZ) combinatie in vitro. Vervolgens hebben we thioridazine ook toege-
voegd aan de HRZ-combinatie in ons muis TB-model. De rationale achter het gebruik van 
thioridazine is het feit dat thioridazine in verschillende literatuur is beschreven als potente 
effluxpomp-remmer, zowel in vitro als in vivo als daadwerkelijk in TB-patiënten. Onze 
resultaten van de in vitro experimenten zijn veelbelovend. Thioridazine heeft van zichzelf 
activiteit tegen Mycobacterium tuberculosis en de combinatie van isoniazide met thiorida-
zine werkt synergistisch ten opzichte van de activiteit van beide middelen los. Dit effect 
van thioridazine zagen we ook als het werd toegevoegd aan rifampicine. De combinatie 
van isoniazide met thioridazine zorgde ook voor de eliminatie van isoniazide-resistente 
mycobacteriën die worden gevonden na blootstelling aan isoniazide alleen. De toevoeging 
van thioridazine aan de HRZ-combinatie in het muis TB-model was minder succesvol, de 
beoogde therapieduur verkorting werd niet behaald, dit in contrast met sommige andere 
studies. Vanwege toxische bijwerking was de maximum toelaatbare dosis in onze muizen 
lager dan in eerdere publicaties waarbij thioridazine is gebruikt in muizen. Ook in een 
cavia TB-model was toxiciteit een probleem en is een zeer beperkte bactericide werking 
gerapporteerd. Concluderend zijn er dus tegenstrijdige resultaten gepubliceerd en moeten 
we ons afvragen of het nog steeds zinvol is om onderzoek te doen naar thioridazine als 
middel dat de activiteit en effectiviteit kan versterken van de HRZ-combinatie.
In hoofdstuk 3 hebben we SILA-421, een organosilicon, gebruikt om de activiteit en 
effectiviteit te versterken van isoniazide of rifampicine in vitro, of de HRZ-combinatie in 
vivo in een vergelijkbare opzet als beschreven in hoofdstuk 2. Ook SILA-421 heeft een 
anti-mycobacteriële werking en werkt synergistisch in combinatie met isoniazide. Daar-
naast is SILA-421 ook actief tegen rifampicine-resistente Mycobacterium tuberculosis, in 
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combinatie met hoge concentraties rifampicine is volledige eliminatie van deze rifampicine-
resistente mycobacteriën mogelijk. Vergelijkbaar met de resultaten met thioridazine, leidt 
ook toevoeging van SILA-421 aan de HRZ-combinatie in ons muis TB-model niet tot een 
succesvolle verkorting van de behandelduur tot drie maanden.
een nieuwe behandeling van multidrug-resistente tuberculose gebaseerd 
op moxifloxacin en linezolid
In hoofdstuk 4 hebben we, met als doel een nieuwe combinatie te maken van antibiotica 
voor de behandeling van MDR-TBC, eerst de activiteit van moxifloxacin en linezolid tegen 
Mycobacterium tuberculosis onderzocht. Vervolgens hebben we onderzocht of we met 
beide middelen ook een combinatie konden maken die effectief is tegen Mycobacterium 
tuberculosis. Daarnaast is van twee effluxpomp-remmers (verapamil en timcodar) en twee 
middelen die de mycobacteriële celwand destabiliseren (colistine en SQ109) de activiteit 
bepaald, om vervolgens deze middelen toe te voegen aan de moxifloxacin-linezolid combi-
natie met als doel deze combinatie te versterken door middel van remming van effluxpom-
pen of celwand destabilisatie. Zowel moxifloxacin als linezolid is in staat tot het afdoden 
van Mycobacterium tuberculosis in concentraties die ook haalbaar zijn in patiënten, en 
ook een combinatie van beide antibiotica is mogelijk. Zowel verapamil als timcodar als 
colistine heeft als middel op zichzelf weinig activiteit tegen Mycobacterium tuberculosis, 
dit in contrast met SQ109 wat een heel duidelijke dosis-respons laat zien en zeer effectief 
is in het afdoden van Mycobacterium tuberculosis. Als we vervolgens deze vier middelen 
één voor één toevoegen aan de moxifloxacin-linezolid combinatie, kunnen we concluderen 
dat zowel verapamil als timcodar geen toegevoegde waarde hebben in deze combinatie. 
De toevoeging van SQ109 leidt tot antagonisme en dus een verminderde werking van de 
combinatie. Toevoeging van colistine zorgt wel voor een verbetering van de activiteit, maar 
deze verbetering voldeed nog niet aan onze eisen om het daadwerkelijk synergistisch te 
noemen. Vervolgonderzoek zal moeten uitwijzen of de in vitro gevonden resultaten zijn te 
vertalen naar in vivo experimenten en mogelijk uiteindelijk ook naar patiënten.
Om in ons muis TB-model een humaan equivalente blootstelling van moxifloxacin en 
linezolid te gebruiken, hebben we in hoofdstuk 5 en 6 de farmacokinetiek bepaald van 
beide antibiotica om de dosis te bepalen die resulteert in de humaan equivalente blootstel-
ling. Ook is het gebruikt van ‘Dried Bloot Spot’ (DBS)-analyse gevalideerd voor het bepalen 
van moxifloxacin en linezolid concentraties in muizenbloed. De DBS methode wordt in de 
praktijk in patiënten gebruikt om in bijvoorbeeld een druppel bloed verkregen na een vin-
gerprik de concentraties van antibiotica te bepalen. In ons muismodel kan het gebruik van 
DBS-analyse het gebruik van muizen voor farmacokinetiek onderzoek reduceren, omdat 
we door middel van DBS-analyse de antibiotica concentraties kunnen bepalen in een klein 
sample volume. Hierdoor kunnen we meerdere monsters uit één muis nemen in plaats van 
één monster per muis per tijdsmoment. Op basis van de resultaten beschreven in hoofdstuk 
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5 en 6 kunnen we concluderen dat DBS-analyse geschikt is om moxifloxacin en linezolid 
concentraties te bepalen in bloed en te vertalen naar plasma concentraties, en dat we deze 
techniek kunnen gebruiken in ons muis TB-model. Voor gebruik van moxifloxacin in ons 
muis TB-model resulteert een dosis van 200 mg/kg in een blootstelling die de blootstelling 
in patiënten benadert. De daarbij behorende Cmax is wel hoger dan gevonden in patiënten, 
een aanvullende studie kan uitwijzen of een dosis van 200 mg/kg gesplitst in 2x 100 mg/
kg resulteert in een gelijke blootstelling met een lagere en humaan vergelijkbare Cmax. 
Een linezolid dosis van 50 mg/kg resulteert in een blootstelling die tussen de blootstelling 
ligt bij het gebruik van 300 mg/kg en 600 mg/kg dosis in patiënten en is geschikt om te 
gebruiken in ons muis TB-model.
karakterisatie van het transcriptieprofiel van Mycobacterium tuberculosis 
na rifampicine blootstelling
In hoofdstuk 7 hebben we geprobeerd meer inzicht te verkrijgen in de verandering in 
genexpressie nadat Mycobacterium tuberculosis is blootgesteld aan rifampicine. We heb-
ben onderzocht of er in het bijzonder verschillen in genexpressie zijn in aan efflux gerela-
teerde genen, na blootstelling aan rifampicine tussen een rifampicine-gevoelige stam en 
rifampicine-resistente stam. Dit onderzoek hebben we uitgevoerd met behulp van microar-
ray analyse. Op basis van de resultaten beschreven in hoofdstuk 7 kunnen we concluderen 
dat er verschil is in respons tussen de rifampicine-gevoelige stam en rifampicine-resistente 
stam. In de rifampicine-resistente stam is er bij een aantal genenclusters een significant ver-
hoogde expressie, waarbij twee genenclusters opvallen omdat ze coderen voor membraam 
eiwitten. Van één van deze clusters (rv0678, mmpS5 en mmpL5) is recent aangetoond dat 
een mutatie in rv0678 leidt tot een verhoogde expressie van mmpS5 en mmpL5 met als 
gevolg dat de stam deels ongevoelig werd voor clofazimine en bedaquiline. We kunnen op 
basis van de resultaten en de literatuur concluderen dat dit cluster van genen betrokken 
is bij efflux. De functie van de andere genen en clusters van genen met een verhoogde 
expressie is nog onduidelijk, hiervoor is meer onderzoek vereist.
evaluatie en optimalisatie van ons muis TBc model als preklinisch model
De resultaten beschreven in hoofdstuk 8 en 9 zijn onderdeel van het PreDiCT-TB project 
dat, zoals eerder beschreven, tot doel heeft om een de preklinische fase van antibiotica 
tegen TBC te optimaliseren. In dat kader hebben we in hoofdstuk 8 in ons muis TB-
model de activiteit bepaald van de conventionele TBC antibiotica tegen een Mycobacte-
rium tuberculosis stam behorend tot het Beijing genotype. Ook hebben we de activiteit 
en effectiviteit van tien combinaties van antibiotica onderzocht. De gegenereerde data 
wordt gebruikt in mathematische modellen die door middel van wiskundige formules 
de voorspellende waarde van de verschillende experimenten proberen te vergroten. Los 
van het bovenstaande vonden we dat van alle antibiotica rifampicine de sterkste anti-
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mycobacteriële activiteit heeft na vier weken blootstelling. In de effectiviteitsstudie vonden 
we dat alleen de antibioticacombinaties die rifampicine bevatten na 24 weken behandeling 
resulteerde in kweek-negatieve longen. In aanvulling daarop, deze rifampicine combinaties 
laten na een twaalf weken durende periode zonder behandeling veel minder gevallen van 
‘relapse’ van TBC zien vergeleken met de niet rifampicine combinaties. Op basis hiervan 
kunnen we concluderen dat rifampicine inderdaad, zoals al eerder was beschreven, het 
belangrijkste antibioticum is om TBC te behandelen. Verder kunnen we op basis van deze 
data concluderen dat de ‘early bactericidal activity’ (EBA 0-14) de uitkomst van de ef-
fectiviteitsexperimenten niet goed kan voorspellen en dat kweek-negatieve organen na 
behandeling niet genoeg voorspellende waarde hebben voor de incidentie van ‘relapse’ 
van TBC. Een mogelijke oorzaak hiervan kan zijn dat de methode waarmee we de daling 
van het aantal mycobacteriën monitoren in in vitro experimenten en in vivo experimen-
ten niet de meest optimale methode is. Het is eerder aangetoond in de literatuur dat 
vloeibaar groeimedium in staat is een populatie van mycobacteriën te detecteren die niet 
of nauwelijks groeien op de vaste groeimedia. PreDiCT-TB heeft als subdoel het ontwik-
kelen en testen van nieuwe technieken om de preklinische fase van TBC-antibiotica te 
optimaliseren. Als resultaat hiervan is de MBL assay ontwikkeld. Deze MBL assay detecteert 
de aanwezigheid van 16S ribosomaal RNA van Mycobacterium tuberculosis, deze assay is 
daarom niet afhankelijk van groeicapaciteit van de bacteriën. Dit in tegenstelling tot CFU 
counting -met andere woorden het tellen van kolonies op een vaste voedingsbodem- en 
de TTP assay waarbij de tijd tot groei in vloeibaar groeimedium een maat is voor de hoeveel 
aanwezige mycobacteriën. In hoofdstuk 9 hebben we deze drie methoden met elkaar 
vergeleken in ons muis TB-model. We hebben gevonden dat we met alle drie de methoden 
vrij vergelijkbaar de hoeveelheid mycobacteriën in de longen van muizen konden bepalen 
tijdens vier verschillende soorten therapieën. Maar aan het einde van de therapieduur 
waren CFU counting en de TTP assay negatief bij drie van de vier TBC-behandelingen 
terwijl de MBL assay nog steeds positief was. Op basis hiervan concluderen wij dat CFU 
counting en de TTP assay de hoeveelheid bacteriën onderschatten, en dat de MBL assay 
een populatie van bacteriën kan aantonen die niet meer in staat zijn om te groeien maar 
wel aanwezig zijn. En juist deze persisterende populatie van mycobacteriën is van groot 
belang, omdat deze voor een groot deel het succes bepalen van een behandeling van TBC.
We hebben eerder gerefereerd aan de ‘END TB STRATEGY’ van de WHO en de ambiti-
euze doelen die daarbij zijn gesteld. We hopen dan ook dat dit onderzoek een stukje is van 
de enorme TBC-puzzel en bijdraagt aan meer kennis van de uitdagingen en oplossingen 
die kunnen leiden tot het einde van TBC.
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